(12) STANDARD PATENT (11) Application No. **AU 2002228471 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
A virus causing respiratory tract illness in susceptible mammals

(51) International Patent Classification(s)
G01N 33/53 (2006.01)
A61K 31/7105 (2006.01)
A61K 35/64 (2006.01)
A61K 35/74 (2006.01)
A61K 35/76 (2006.01)
A61K 38/00 (2006.01)
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
A61K 48/00 (2006.01)
A61P 11/00 (2006.01)
A61P 31/14 (2006.01)
C07K 14/11 (2006.01)
C07K 14/115 (2006.01)
C07K 14/135 (2006.01)
C07K 16/10 (2006.01)
C12N 1/15 (2006.01)
C12N 1/19 (2006.01)
C12N 1/21 (2006.01)
C12N 5/10 (2006.01)
C12N 7/00 (2006.01)
C12N 7/01 (2006.01)
C12N 15/09 (2006.01)
C12N 15/86 (2006.01)
C12Q 1/68 (2006.01)
C12Q 1/70 (2006.01)
G01N 33/543 (2006.01)
G01N 33/569 (2006.01)

(21) Application No: **2002228471** (22) Date of Filing: **2002.01.18**

(87) WIPO No: **WO02/057302**

(30) Priority Data

(31) Number	(32) Date	(33) Country
01203985.5	**2001.10.18**	**EP**
01200213.5	**2001.01.19**	**EP**

(43) Publication Date: **2002.07.30**
(43) Publication Journal Date: **2003.02.13**
(44) Accepted Journal Date: **2008.02.14**

(71) Applicant(s)
Vironovative B.V.

(72) Inventor(s)
Van Den Hoogen, Bernadetta, Gerarda;De Jong, Jan, Cornelius;Fouchier, Ronaldus, Adrianus, Maria;Groen, Jan;Osterhaus, Albertus, Dominicus, Marcellinus, Erasmus

(74) Agent / Attorney
Phillips Ormonde & Fitzpatrick, Level 22 367 Collins Street, Melbourne, VIC, 3000

(56) Related Art
Accession number: Q9QF48
Accession number: Q9QF47
Accession number: Q9Q244
Accession number: Q9QDI1
Accession number: P87509
WO 2000/020600
Bayon-Auboyer M H et al., Archives of Virology, 1999, 144(6): 1091-1109
Bayon-Auboyer M H et al., Journal of General Virology, 2000, 81(11): 2723-2733
Randhawa J S et al., Journal of Virology, 1997, 71(2): 9849-9854

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057302 A3

(51) International Patent Classification^7: C07K 14/135

(21) International Application Number: PCT/NL02/00040

(22) International Filing Date: 18 January 2002 (18.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

01200213.5	19 January 2001 (19.01.2001)	EP
01203985.5	18 October 2001 (18.10.2001)	EP

(61) Related by addition to earlier applications or grants:

CU	Not furnished (ICA)
Filed on	Not furnished
KP	Not furnished (ICA)
Filed on	Not furnished

(71) Applicant *(for all designated States except US)*: **VIRONOVATIVE B.V.** [NL/NL]; Burgemeester Oudlaan 50, NL-3062 PA Rotterdam (NL).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **DE JONG, Jan, Cornelius** [NL/NL]; Krugerlaan 205, NL-2806 EH Gouda (NL). **FOUCHIER, Ronaldus, Adrianus, Maria** [NL/NL]; Essenburgsingel 44a, NL-3021 AR Rotterdam (NL). **VAN DEN HOOGEN, Bernadetta, Gerarda** [NL/NL]; Essenburgsingel 44a, NL-3021 AR Rotterdam (NL). **OSTERHAUS, Albertus, Dominicus, Marcellinus, Erasmus** [NL/NL]; Dr. Breveestraat 16, NL-3981 CH Bunnik (NL). **GROEN, Jan** [NL/NL]; Anholtkade 2, NL-3446 BM Woerden (NL).

(74) Agent: PRINS, A., W.; c/o Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).

(81) Designated States *(national)*: AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU (inventor's certificate), CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH (utility certificate), GM, HR (consensual patent), HU, ID, IL, IN, IS, JP, KE, KG, KP (inventor's certificate), KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT (utility certificate), TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report: 27 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALS



(57) Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) within the sub-family *Pneumovirinae* of the family *Paramyxoviridae* and identifiable as phylogenetically corresponding to the genus *Metapneumovirus*and components thereof.

WO 02/057302 A3

A virus causing respiratory tract illness in susceptible mammals.

The invention relates to the field of virology.

In the past decades several etiological agents of mammalian disease, in particular of respiratory tract illnesses (RTI), in particular of humans, have been identified[7]. Classical etiological agents of RTI with mammals are respiratory syncytial viruses belonging to the genus *Pneumovirus* found with humans (hRSV) and ruminants such as cattle or sheep (bRSV and/or oRSV). In human RSV differences in reciprocal cross neutralization assays, reactivity of the G proteins in immunological assays and nucleotide sequences of the G gene are used to define 2 hRSV antigenic subgroups. Within the subgroups the aa sequences show 94 % (subgroup A) or 98% (subgroup B) identity, while only 53% aa sequence identity is found between the subgroups. Additional variability is observed within subgroups based on monoclonal antibodies, RT-PCR assays and RNAse protection assays. Viruses from both subgroups have a worldwide distribution and may occur during a single season. Infection may occur in presence of pre-existing immunity and the antigenic variation is not strictly required to allow re-infection. See for example Sullender, W.M., *Respiratory Syncytial Virus Genetic and Antigenic Diversity.* Clinical Microbiology Reviews, 2000. 13(1): p. 1-15; Collins, P.L., McIntosh, K. and Chanock, R.M., *Respiratory syncytial virus.* Fields virology, ed. B.N. Knipe, Howley, P.M. 1996, Philadelphia: lippencott-raven. 1313-1351; Johnson, P.R., et al., *The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.* Proc Natl Acad Sci U S A, 1987. 84(16): p. 5625-9; Collins, P.L., *The molecular Biology of Human Respiratory Syncytial Virus (RSV) of the Genus Pneumovirus*, in *The Paramyxoviruses*, D.W. Kingsbury, Editor. 1991, Plenum Press: New York. p. 103-153.

Another classical *Pneumovirus* is the pneumonia virus of mice (PVM), in general only found with laboratory mice. However, a proportion of the illnesses observed among mammals can still not be attributed to known pathogens.

The invention provides an isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is capable of infecting mammalian cells. Said virus is identifiable as phylogentically corresponding to the genus *Metapneumovirus* by determining a nucleic acid sequence of said virus and testing it in phylogenetic analyses, for example wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogentically corresponding to a virus isolate deposited as **I-2614** with CNCM, Paris than it is corresponding to a essentially avian virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotrachetis. For said phylogenetic analyses it is more useful to obtain the nucleic acid sequence for a non-MPV as outgroup to be compared with, a very useful outgroup isolate can be obtained from avian pneumovirus serotype C (APV-C), as is for example demonstrated in figure 5 herein.

The present invention also provides an isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is phylogenetically more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

In addition, the present invention provides an isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae*of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is phylogenetically more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than related to APV type C.

The present invention also provides an isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneurnovirus, wherein the virus is phylogenetically more closely related to a virus isolate comprising the nucleotide sequence of HMPV as shown in Figure 6A, 6B, or 6C than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein

(i) the metapneumovirus belongs to the subfamily *Pneumovirinae* of the family *Paramyxoviridae;* and

(ii) the metapneumovirus is identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus corresponds phylogenetically to the genus Metapneumovirus if the nucleic acid sequence of the virus in a phylogenetic tree analysis using 100 bootstraps and 3 jumbles is more closely related to a virus isolate deposited as **I-2614** with

CNCM, Paris than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein

(i) the metapneumovinis belongs to the subfamily *Pneumovirinae* of the family *Paramyxoviridae;* and

(ii) the metapneumovirus is identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus corresponds phylogenetically to the genus Metapneumovirus if the nucleic acid sequence of the virus in a phylogenetic tree analysis using 100 bootstraps and 3 jumbles is more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than it is related to APV type C.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the N protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20, wherein sequence identity is determined over the entire length of the N protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the P protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21, wherein sequence identity is determined over the entire length of the P protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the M protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22, wherein sequence identity is determined over the entire length of the M protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the F protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23, wherein sequence identity is determined over the entire length of the F protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the M2-1 protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24, wherein sequence identity is determined over the entire length of the M2-1 protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the M2-2 protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 56% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25, wherein sequence identity is determined over the entire length of the M2-2 protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the L protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28, wherein sequence identity is determined over the entire length of the L protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the SH protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 29% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26, wherein sequence identity is determined over the entire length of the SH protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the amino acid sequence of the G protein of the isolated negative-sense single stranded RNA metapneumovirus is greater than 29% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27, wherein sequence identity is determined over the entire length of the G protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the negative-sense single stranded RNA metapneumovirus encodes at least two proteins of the following:

(i) a N protein with greater than 88% amino acid sequence identity to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) a P protein with greater than 68% amino acid sequence identity to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) a M protein with greater than 87% amino acid sequence identity to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) a F protein with greater than 81% amino acid sequence identity to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) a M2-1 protein with greater than 84% amino acid sequence identity to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24; or

(vi) a M2-2 protein with greater than 56% amino acid sequence identity to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25,

(vii) a L protein with greater than 90% amino acid sequence identity to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(viii) a SH protein with greater than 29% amino acid sequence identity to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(ix) a G protein with greater than 29% amino acid sequence identity to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27,

wherein sequence identity is determined over the entire length of the respective protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the negative-sense single stranded RNA metapneumovirus encodes:

(i) a N protein with greater than 88% amino acid sequence identity to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) a P protein with greater than 68% amino acid sequence identity to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) a M protein with greater than 87% amino acid sequence identity to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) a F protein with greater than 81% amino acid sequence identity to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) a M2-1 protein with greater than 84% amino acid sequence identity to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24; or

(vi) a M2-2 protein with greater than 56% amino acid sequence identity to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25,

(vii) a L protein with greater than 90% amino acid sequence identity to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28,

(viii) a SH protein with greater than 29% amino acid sequence identity to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26, or

(ix) a G protein with greater than 29% amino acid sequence identity to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27,

wherein sequence identity is determined over the entire length of the respective protein.

Further, the present invention also provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the genome of the virus comprises a nucleotide sequence of HMPV as shown in Figure 6A, 6B, or 6C.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 56% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 29% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26.

Further, the present invention also provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising an amino acid sequence that is greater than 29% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 56% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 29% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26.

Further, the present invention also provides an isolated protein, wherein the protein comprises an amino acid sequence that is greater than 29% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

Further, the present invention also provides a nucleic acid encoding the genome or part of a genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said nucleic acid further encodes sequences of other viruses.

Further, the present invention also provides a nucleic acid encoding the genome or part of a genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumnovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said genome may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

Further, the present invention also provides an infectious chimeric virus, wherein the chimeric virus comprises

(a) at least two contiguous kilobasebairs of nucleotide sequence derived from a mammalian MPV; and

(b) sequences of other viruses.

Further, the present invention also provides an infectious chimeric virus, wherein the chimeric virus comprises the genome of a mammalian MPV, wherein one or more of the open reading frames in the genome of the mammalian MPV have been replaced by the analogous open reading frame from an avian MPV.

Further, the present invention also provides an infectious chimeric virus, wherein the chimeric virus comprises the genome of an avian MPV, wherein one or more of the open reading frames in the genome of the avian MPV have been replaced by the analogous open reading frame from mammalian MPV.

Further, the present invention also provides a pharmaceutical composition, wherein the pharmaceutical composition comprises (i) an isolated mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, and (ii) a pharmaceutically acceptable carrier.

Further, the present invention also provides a pharmaceutical composition comprising a nucleic acid encoding the genome or part of a genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said nucleic acid further encodes sequences of other viruses.

Further, the present invention also provides a pharmaceutical composition comprising a nucleic acid encoding the genome or part of a genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said genome may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

Further, the present invention also provides a pharmaceutical composition, wherein the pharmaceutical composition comprises

(a) an isolated mammalian metapneumovirus, wherein

(i) the metapneumovirus belongs to the subfamily *Pneumovirinae* of the family *Paramyxoviridae;* and

(ii) the metapneumovirus is identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus corresponds phylogenetically to the genus Metapneumovirus if the nucleic acid sequence of the virus in a phylogenetic tree analysis using 100 bootstraps and 3 jumbles is more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis, and

(b) a pharmaceutically acceptable carrier.

Although phylogenetic analyses provides a convenient method of identifying a virus as an MPV several other possibly more straightforward albeit somewhat more course methods for identifying said virus or viral proteins or nucleic from said virus are herein also provided. As a rule of thumb an MPV can be identified by the percentages of a homology of the virus, proteins or nucleic acids to be identified in comparison with isolates, viral proteins, or nucleic acids identified herein by sequence or deposit. It is generally known that virus species, especially RNA virus species, often constitute a quasi species wherein a cluster of said viruses displays heterogeneity among its members. Thus it is expected that each isolate may have a somewhat different percentage relationship with one of the various isolates as provided herein.

Thus, the present invention provides a method of detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with an antibody or a fragment thereof, that specifically recognizes a protein or a fragment of a protein, comprising,

(a) a sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 and 99-1 as shown in figure 20;

(b) a sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 and 99-1 as shown in figure 21;

(c) a sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 and 99-1 as shown in figure 22;

(d) a sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 and 99-1 as shown in figure 23:

(e) a sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 and 99-1 as shown in figure 24;

(f) a sequence that is greater than *56%* identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 and 99-1 as shown in figure 25;

(g) a sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in figure 28;

(h) a sequence that is greater than 29% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 and 99-1 as shown in figure 26; or

(i) a sequence that is greater than 29% identical to the amino acid sequence of the G protein of MPV isolate 00-1 and 99-1 as shown in figure 27,

wherein sequence identity is determined over the entire length of the protein.

Thus, the present invention also provides a method for detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with a first group of one or more nucleic acids that hybridize under stringent conditions to a second group of one or more nucleic acids, that encodes a protein, or fragment thereof, comprising,

(a) a sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 and 99-1 as shown in figure 20;

(b) a sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 and 99-1 as shown in figure 21;

(c) a sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 and 99-1 as shown in figure 22;

(d) a sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 and 99-1 as shown in figure 23:

(e) a sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 and 99-1 as shown in figure 24;

(f) a sequence that is greater than 56% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 and 99-1 as shown in figure 25;

(g) a sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in figure 28;

(h) a sequence that is greater than 29% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 and 99-1 as shown in figure 26; or

(i) a sequence that is greater than 29% identical to the amino acid sequence of the G protein of MPV isolate 00-1 and 99-1 as shown in figure 27,

wherein sequence identity is determined over the entire length of the protein.

Thus, the present invention also provides a method for detecting a mammalian metapneumovirus in a sample, wherein the method comprises:

(i) contacting a cell with the sample;

(ii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPW, then

(iii) testing for the presence of PIV, influenza virus, and RSV,

wherein, if PIV, influenza virus, and RSV are not present in the sample, then the mammalian metapneumovirus is in the sample.

Thus, the present invention also provides a method for detecting a human metapneumovirus in a sample obtained from a human, wherein the method comprises:

(i) contacting a cell with the sample;

(ii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPIV, then

(iii) testing for the presence of hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, hRSV, influenza virus type A and influenza virus type B,

wherein, if hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, hRSV, influenza virus type A and influenza virus type B are not present in the sample, then the human metapneumovirus is in the sample.

Thus, the present invention also provides a method for evaluating the risk of a mammalian metapneumovirus infection in a subject, wherein the method comprises:

(i) obtaining a sample from the subject;

(ii) contacting a cell with the sample;

(iii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPIV, then

(iv) testing for the presence of PIV, influenza virus, and RSV,

wherein, if PIV, influenza virus, and RSV are not present in the sample, then the subject is at risk of being infected with mammalian metapneumovirus.

Thus, the present invention also provides a method for detecting a mammalian metapneumovirus in a sample, wherein the method comprises:

(i) contacting a cell with the sample;

(ii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPIV, then

(iii) testing for the presence of *Paramyxovirinae,* hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, sendai virus, simian virus type 5, New-Castle disease virus, hRSV, morbilli virus, mumps virus, Nipah virus, Hendra virus, Tupaia virus and Mapuera virus,

wherein, if *Paramyxovirinae,* hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, sendai virus, simian virus type *5,* New-Castle disease virus, hRSV, morbilli virus, mumps virus, Nipah virus, Hendra virus, Tupaia virus and Mapuera virus are not present in the sample, then the mammalian metapneumovirus is in the sample.

When one wishes to compare with the deposited virus I-2614, the invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogentically corresponding to the genus Metapneumovirus by determining an amino acid sequence of said virus and determining that said amino acid sequence has a percentage amino acid homology to a virus isolate deposited as I-2614 with CNCM, Paris which is essentially higher than the percentages provided herein for the L protein, the M protein, the N protein, the P protein, or the F protein, in comparison with APV-C or, likewise, an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family Pneumovirinae of the family Paramyxoviridae is provided as identifiable as phylogenetically corresponding to the genus Metapneumovirus by determining a nucleic acid sequence of said virus and determining that said nucleic acid sequence has a percentage nucleic acid identity to a virus isolate deposited as I-2614 with CNCM, Paris which is essentially higher than the percentages identified herein for the nucleic acids encoding the L protein, the M protein, the N protein, the P protein, or the F protein as identified herein below in comparison with APV-C.

Again as a rule of thumb one may consider an MPV as belonging to one of the two serological groups of MPV as identified herein when the isolates or the viral proteins or nuclear acids of the isolates that need to be identified have percentages homology that fall within the bounds and metes of the percentages of homology identified herein for both separate groups, taking isolates 00-1 or 99-1 as the respective isolates of comparison. However, when the percentages of homology are smaller or there is more need to distinguish the viral isolates from for example APV-C it is better advised to resort to the phylogenetic analyses as identified herein.

Again one should keep in mind that said percentages can vary somewhat when other isolates are selected in the determination of the percentage of homology.

With the provision of this MPV, the invention provides diagnostic means and methods and therapeutic means and methods to be employed in the diagnosis and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans. However, due to the , albeit distant, genetic relationship of the essentially mammalian MPV with the essentially avian APV, in particular with APV-C, the invention also provides means and methods to be employed in the diagnosis and treatment of avian disease. In virology, it is most advisory that diagnosis and/or treatment of a specific viral infection is performed with reagents that are most specific for said specific virus causing said infection. In this case this means that it is preferred that said diagnosis and/or treatment of an MPV infection is performed with reagents that are most specific for MPV. This by no means however excludes the possibility that less specific, but sufficiently cross-reactive reagents are used instead, for example because they are more easily available and sufficiently address the task at hand. Herein it is for example provided to perform virological and/or serological diagnosis of MPV infections in mammals with reagents derived from APV, in particular with reagents derived from APV-C, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of MPV infections in mammals can be achieved by using an ELISA specifically designed to detect APV antibodies in birds. A particular useful test for this purpose is an ELISA test designed for the detection of APV antibodies (e.g in serum or egg yolk), one commercialy available version of which is known as APV-Ab SVANOVIR ® which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden. The reverse situation is also the case, herein it is for example provided to perform virological and/or serological diagnosis of APV infections in mammals with reagents derived from MPV, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of APV infections in birds can be achieved by using an ELISA designed to detect MPV antibodies. Considering that antigens and antibodies have a lock-and-key relationship, detection of the various antigens can be achieved by selecting the appropriate antibody having sufficient cross-reactivity. Of course, for relying on such cross-reactivity, it is best to select the reagents (such as antigens or antibodies) under guidance of the amino acid homologies that exist between the various (glyco)proteins of the various viruses, whereby reagents relating to the most homologous proteins will be most useful to be used in tests relying on said cross-reactivity.

For nucleic aciddetection, it is even more straightforward, instead of designing primers or probes based on heterologous nucleic acid sequences of the various viruses and thus that detect differences between the essentially mammalian or avian *Metapneumoviruses*, it suffices to design or select primers or probes based on those stretches of virus-specific nucleic acid sequences that show high homology. In general, for nucleic acid sequences, homology percentages of 90% or higher guarantee sufficient cross-reactivity to be relied upon in diagnostic tests utilizing stingent conditions of hybridisation.

The invention for example provides a method for virologically diagnosing a MPV infection of an animal, in particular of a mammal, more in particular of a human being, comprising determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a MPV specific nucleic acid a or antibody according to the invention, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against an MPV or

component thereof by reacting said sample with a MPV-specific proteinaceous molecule or fragment thereof or an antigen according to the invention.
The invention also provides a diagnostic kit for diagnosing an MPV infection comprising an MPV, an MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody according to the invention, and preferably a means for detecting said MPV, MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody, said means for example comprising an excitable group such as a fluorophore or enzymatic detection system used in the art (examples of suitable diagnostic kit format comprise IF, ELISA, neutralization assay, RT-PCR assay). To determine whether an as yet unidentified virus component or synthetic analogue thereof such as nucleic acid, proteinaceous molecule or fragment thereof can be identified as MPV-specific, it suffices to analyse the nucleic acid or amino acid sequence of said component, for example for a stretch of said nucleic acid or amino acid, preferably of at least 10, more preferably at least 25, more preferably at least 40 nucleotides or amino acids (respectively), by sequence homology comparison with known MPV sequences and with known non-MPV sequences APV-C is preferably used) using for example phylogenetic analyses as provided herein. Depending on the degree of relationship with said MPV or non-MPV sequences, the component or synthetic analogue can be identified.

The invention also provides method for virologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a cross-reactive nucleic acid derived from APV (preferably serotype C) or a cross-reactive antibody reactive with said APV, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a cross-reactive antibody that is also directed against an APV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from APV. Furthermore, the invention provides the use of a diagnostic kit initially designed for AVP or AVP-antibody detection for diagnosing an MPV infection, in particular for detecting said MPV infection in humans.

The invention also provides method for virologically diagnosing an APV infection in a bird comprising determining in a sample of said bird the presence of a viral isolate or component thereof by reacting said sample with a cross-reactive nucleic acid derived from MPV or a cross-reactive antibody reactive with said MPV, and a method for serologically diagnosing an APV infection of a bird comprising determining in a sample of said bird the presence of a cross-reactive antibody that is also directed against an MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from MPV. Furthermore, the invention provides the use of a diagnostic kit initially designed for MPV or MPV-antibody detection for diagnosing an APV infection, in particular for detecting said APV infection in poultry such as a chicken, duck or turkey.

As said, with treatment, similar use can be made of the cross-reactivity found, in particular when circumstances at hand make the use of the more homologous approach less straightforward. Vaccinations that can not wait, such as emergency vaccinations against MPV infections can for example be performed with vaccine preparations derived from APV(preferably type C) isolates when a more homologous MPV vaccine is not available, and, vice versa, vaccinations against APV infections can be contemplated with vaccine preparations derived from MPV. Also, reverse genetic techniques make it possible to generate chimeric APV-MPV virus constructs that are useful as a vaccine, being sufficiently dissimilar to field isolates of each of the respective strains to be attenuated to a desirable level. Similar reverse genetic techniques will make it also possible to generate chimeric paramyxovirus-metapneumovirus constructs, such as RSV-MPV or PI3-MPV constructs for us in a vaccine preparation. Such constructs are particularly useful as a combination vaccine to combat respiratory tract illnesses.

The invention thus provides a novel etiological agent, an isolated essentially mammalian negative-sense single stranded RNA virus (herein also called MPV) belonging to the subfamily *Pneumovirinae* of the family *Paramyxoviridae* but not identifiable as a classical pneumovirus, and belonging to the genus *Metapneumovirus*, and MPV-specific components or synthetic analogues thereof. Mammalian viruses resembling metapneumoviruses, i.e. metapneumoviruses isolatable from mammals that essentially function as natural host for said virus or cause disease in said mammals, have until now not been found. Metapneumoviruses, in general thought to be essentially restricted to poultry as natural host or aetiological agent of disease, are also known as avian pneumoviruses. Recently, an APV isolate of duck was described (FR 2 801 607), further demonstrating that APV infections are essentially restricted to birds as natural hosts.

The invention provides an isolated mammalian pneumovirus (herein also called MPV) comprising a gene order and amino acid sequence distinct from that of the genus *Pneumovirus* and which is closely related and considering its phylogenetic relatedness likely belonging to the genus *Metapneumovirus* within the subfamily *Pneumovirinae* of the family *Paramyxoviridae*. Although until now, metapneumoviruses have only been isolated from birds, it is now shown that related, albeit materially distinct, viruses can be identified in other animal species such as mammals. Herein we show repeated isolation of MPV from humans, whereas no such reports exists for APV. Furthermore, unlike APV, MPV essentially does not or only little replicates in chickens and turkeys where it easily does in cynomolgous macaques. No reports have been found on replication of APV in mammals. In addition, whereas specific anti-sera raised against MPV neutralize MPV, anti-sera raised against APV A, B or C do not neutralize MPV to the same extent, and this lack of full cross reactivity provides another proof for MPV being a different metapneumovirus. Furthermore, where APV and MPV share a similar gene order, the G and SH proteins of MPV are largely different from the ones known of APV in that they show no significant sequence homologies on both the amino acid or nucleic acid level. Diagnostic assays to discriminate between APV and MPV isolates or antibodies directed against these different viruses can advantageously be developed based on one or both of these proteins (examples are IF, ELISA, neutralization assay, RT-PCR assay). However, also sequence and/or antigenic information obtained from the more related N, P, M, F and L proteins of MPV and analyses of sequence homologies with the respective proteins of APV, can also be used to discriminate between APV and MPV. For example, phylogenetic analyses of sequence information obtained from MPV revealed that MPV and APV are two different viruses. In particular, the phylogenetic trees show that APV and MPV are two different lineages of virus. We have also shown that MPV is circulating in the human population for at least 50 years, therefore interspecies transmission has probably taken place at least 50 years ago and is not an everyday event.Since MPV CPE was virtually indistinguishable from that caused by hRSV or hPIV-1 in tMK or other cell cultures, the MPV may have well gone unnoticed until now. tMK (tertiary monkey kidney cells, i.e. MK cells in a third passage in cell culture) are preferably used due to their lower costs in comparison to primary or secondary culltures. The CPE is, as well as with some of the classical *Paramyxoviridae,* characterized by syncytium formation after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer. The cells usually (but not always) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV-1.

Classically, as devastating agents of disease, paramyxoviruses account for many animal and human deaths worldwide each year. The *Paramyxoviridae* form a family within the order of *Mononegavirales* (negative-sense single stranded RNA viruses), consisting of the sub-familys *Paramyxovirinae* and *Pneumovirinae*. The latter sub-family is at present taxonomically divided in the genera *Pneumovirus* and *Metapneumovirus* [1]. Human respiratory syncytial virus (hRSV), the type species of the *Pneumovirus* genus, is the single most important cause of lower respiratory tract infections during infancy and early childhood worldwide[2]. Other members of the *Pneumovirus* genus include the bovine and ovine respiratory syncytial viruses and pneumonia virus of mice (PVM).

Avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis, an upper respiratory tract infection of turkeys[3], is the sole member of the recently assigned *Metapneumovirus* genus, which, as said was until now not associated with infections, or what is more, with disease of mammals. Serological subgroups of APV can be differentiated on the basis of nucleotide or amino acid sequences of the G glycoprotein and neutralization tests using monoclonal antibodies that also recognize the G glycoprotein, Within subgroups A, B and D the G protein shows 98.5 to 99.7% aa sequence identity within subgroups while between the subgroups only 31.2- 38% aa identity is observed. See for example Collins, M.S., Gough, R.E. and Alexander, D.J., *Antigenic differentiation of avian pneumovirus isolates using polyclonal antisera and mouse monoclonal antibodies.* Avian Pathology, 1993. **22**: p. 469-479.; Cook, J.K.A., Jones, B.V., Ellis, M.M., *Antigenic differentiation of strains of turkey rhinotracheitis virus using monoclonal antibodies.* Avian Pathology, 1993. **22**: p. 257-273; Bayon-Auboyer, M.H., et al., *Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup.* J Gen Virol, 2000. 81(Pt 11): p. 2723-33; Seal, B.S., *Matrix protein gene nucleotide and predicted amino acid sequence demonstrate that the first US avian pneumovirus isolate is distinct from European strains.* Virus Res, 1998. **58**(1-2): p. 45-52; Bayon-Auboyer, M.H., et al., *Comparison of F-, G- and N-based RT-PCR protocols with conventional virological* *procedures for the detection and typing of turkey rhinotracheitis virus.* Arch Virol, 1999. 144(6): p. 1091-109; Juhasz, K. and A.J. Easton, *Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups.* J Gen Virol, 1994. **75**(Pt 11): p. 2873-80.

A further serotype of APV is provided in WO00/20600, which describes the Colorado isolate of APV and compared it to known APV or TRT strains with in *vitro* serum neutralization tests. First, the Colorado isolate was tested against monospecific polyclonal antisera to recognized TRT isolates. The Colorado isolate was not neutralized by monospecific antisera to any of the TRT strains. It was, however, neutralized by a hyperimmune antiserum raised against a subgroup A strain. This antiserum neutralized the homologous virus to a titre of 1:400 and the Colorado isolate to a titer of 1: 80. Using the above method, the Colorado isolate was then tested against TRT monoclonal antibodies. In each case, the reciprocal neutralization titer was <10. Monospecific antiserum raised to the Colorado isolate was also tested against TRT strains of both subgroups. None of the TRT strains tested were neutralized by the antiserum to the Colorado isolate.

The Colorado strain of APV does not protect SPF chicks against challenge with either a subgroup A or a subgroup B strain of TRT virus. These results suggest that the Colorado isolate may be the first example of a further serotype of avian pneumovirus, as also suggested by Bayon-Auboyer et al (J. Gen. Vir. 81:2723-2733 (2000).

In a preferred embodiment, the invention provides an isolated MPV taxonomically corresponding to a (hereto unknown mammalian) metapneumovirus comprising a gene order distinct from that of the pneumoviruses within the sub-family *Pneumovirinae* of the family *Paramyxoviridae.* The classification of the two genera is based primarily on their gene constellation; metapneumoviruses generally lack non-structural proteins such NS1 or NS2 (see also Randhawa et al., J. Vir. 71:9849-9854 (1997) and the gene order is different from that of pneumoviruses (RSV: '3-NS1-NS2-N-P-M-SH-G-F-M2-L-5', APV: '3-N-P-M-F-M2-SH-G-L-5') [4,5,6]. MPV as provided by the invention or a virus isolate taxonomically corresponding therewith is upon EM analysis revealed by paramyxovirus-like particles. Consistent with the classification, MPV or virus isolates phylogenetically corresponding or taxonomically corresponding therewith are sensitive to treatment with chloroform; are cultured optimally on tMK cells or cells functionally equivalent thereto and are essentially trypsine dependent in most cell cultures. Furthermore, the typical CPE and lack of haemagglutinating activity with most classically used red blood cells suggested that a virus as provided herein is, albeit only distantly, related to classical pneumoviruses such as RSV. Although most paramyxoviruses have haemagglutinating acitivity, most of the pneumoviruses do not [13]. An MPV according to the invention also contains a second overlapping ORF (M2-2) in the nucleic acid fragment encoding the M2 protein, as in general most other pneumoviruses such as for example also demonstrated in Ahmadian et al., J. Gen. Vir. 80:2011-2016 (1999)

To find further viral isolates as provided by the invention it suffices to test a sample, optionally obtained from a diseased animal or human, for the presence of a virus of the sub-family *Pneumovirinae*, and test a thus obtained virus for the presence of genes encoding (functional) NS1 or NS2 or essentially demonstrate a gene order that is different from that of pneumoviruses such as RSV as already discussed above. Furthermore, a virus isolate phylogenetically corresponding and thus taxonomically corresponding with MPV may be found by cross-hybridisation experiments using nucleic acid from a here provided MPV isolate, or in classical cross-serology experiments using monoclonal antibodies specifically directed against and/or antigens and/or immunogens specifically derived from an MPV isolate.

Newly isolated viruses are phylogenetically corresponding to and thus taxonomically corresponding to MPV when comprising a gene order and/or amino acid sequence sufficiently similar to our prototypic MPV isolate(s), or are structurally corresponding therewith, and show close relatedness to the genus *Metapneumovirus* within the subfamily *Pneumovirinae*. The highest amino sequence homology, and defining the structural correspondence on the individual protein level, between MPV and any of the known other viruses of the same family to date (APV subtype C) is for matrix 87%, for nucleoprotein 88%, for phosphoprotein 68%, for fusionprotein 81% and for parts of the polymerase protein 56-64%, as can be deduced when comparing the sequences given in figure 6 with sequences of other viruses, in particular of AVP-C. Individual proteins or whole virus isolates with, respectively, higher homology to these mentioned maximum values are considered phylogenetically corresponding and thus taxonomically corresponding to MPV, and comprise a nucleic acid sequence structurally corresponding with a sequence as shown in figure 6. Herewith the invention provides a virus phylogenetically corresponding to the deposited virus.

It should be noted that, similar to other viruses, a certain degree of variation is found between different isolated essentially mammalian negative-sense single stranded RNA virus isolates as provided herein. In phylogenetic trees, we have identified at least 2 genetic clusters of virus isolates based on comparitive sequence analyses of parts of the L, M, N and F genes. Based on nucleotide and amino-acid differences in the viral nucleic acid or amino acid sequences (the viral sequences), and in analogy to other pneumoviruses such as RSV, these MPV genotypes represent subtypes of MPV. Within each of the genetic clusters of MPV isolates, the percentage identity at the nucleotide level was found to be 94-100 for L, 91-100 for M, 90-100 for N and 93-100 for F and at the amino acid level the percentage identity was found to be 91-100 for L, 98-100 for M, 96-100 for N and 98-100 for F. A further comparison can be found in figures 18 to 28. The minimum percentage identity at the nucleotide level for the entire group of isolated essentially mammalian negative-sense single stranded RNA virus as provided herein (MPV isolates) identified so far was 81 for L and M, 83 for N and 82 for F. At the amino acid level, this percentage was 91 for L and N, 94 for M, and 95 for F. The viral sequence of a MPV isolate or an isolated MPV F gene as provided herein for example shows less than 81%nucleotide sequence identity or less than 82%(amino acid sequence identity with the respective nucleotide or amino acid sequence of an APV-C fusion (F) gene as for example provided by Seal et al., Vir. Res. 66:139147 (2000).

Also, the viral sequence of a MPV isolate or an an isolated MPV L gene as provided herein for example shows less than 61% nucleotide sequence identity or less than 63% amino acid sequence identity with the respective nucleotide or amino acid sequence of an APV-A polymerase gene as for example provided by Randhawa et al.,, J. Gen. Vir. 77:3047-3051 (1996).

Sequence divergence of MPV strains around the world may be somewhat higher, in analogy with other viruses. Consequently, two potential genetic clusters are identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of 9 virus isolates. 90-100% nucleotide identity was observed within a cluster, and 81-88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate ned/00/01 as prototype of cluster A, and virus isolate ned/99/01 as prototype of cluster B have been used in cross neutralization assays to test whether the genotypes are related to different serotypes or subgroups. From these data we conclude that essentially mammalian virus isolates displaying percentage amino acid homology higher than 64 for L, 87 for M, 88 for N, 68 for P, 81 for F 84 for M2-1 or 58 for M2-2 to isolate I-2614 may be classified as an isolated essentially mammalian negative-sense single stranded RNA virus as provided herein. In particular those virus isolates in general that have a minimum percentage identity at the nucleotide sequence level with a prototype MPV isolate as provided herein of 81 for L and M, 83 for N and/or 82 for F are members of the group of MPV isolates as provided herein . At the amino acid level, these percentage are 91 for L and N, 94 for M, and/or 95 for F. When the percentage amino acid sequence homology for a given virus isolate is higher than 90 for L and N, 93 for M, or 94 for F, the virus isolate is similar to the group of MPV isolates displayed in figure 5. When the percentage amino acid sequence homology for a given virus isolate is higher than 94 for L, 95 for N or 97 for M and F the virus isolate can be identified to belong to one of the genotype clusters represented in figure 5. It should be noted that these percentages of homology, by which genetic clusters are defined, are similar to the degree of homology found among genetic clusters in the corresponding genes of RSV.

In short, the invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family *Pneumovirinae* of the family *Paramyxoviridae* and identifiable as phylogenetically corresponding to the genus *Metapneumovirus* by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as **I-2614** with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis.

Suitable nucleic acid genome fragments each useful for such phylogenetic tree analyses are for example any of the RAP-PCR fragments 1 to 10 as disclosed herein in the detailed description, leading to the various phylogenetic tree analyses as disclosed herein in figures 4 or 5. Phylogenetic tree analyses of the nucleoprotein (N), phosphoprotein (P), matrixprotein (M) and fusion protein (F) genes of MPV revealed the highest degree of sequence homology with APV serotype C, the avian pneumovirus found primarily in birds in the United States

In a preferred embodiment, the invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) belonging to the sub-family *Pneumovirinae* of the family *Paramyxoviridae* and identifiable as phylogenetically corresponding to the genus *Metapneumovirus* by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate deposited as **I-2614** with CNCM, Paris than it is corresponding to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis, wherein said suitable fragment comprises an open reading frame encoding a viral protein of said virus.

A suitable open reading frame (ORF) comprises the ORF encoding the N protein. When an overall amino acid identity of at least 91%, preferably of at least 95% of the analysed N-protein with the N-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. As shown, the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses. The length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaller than those of other paramyxoviruses (Barr *et al.*, 1991). Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7-11% with other paramyxoviruses (Table 6).

Barr *et al* (1991) identified 3 regions of similarity between viruses belonging to the order *Mononegavirales*: A, B and C (Figure 8). Although similarities are highest within a virus family, these regions are highly conserved between virus familys. In all three regions MPV revealed 97% aa sequence identity with APV-C, 89% with APV-B, 92 with APV-A, and 66-73% with RSV and PVM. The region between aa residues 160 and 340 appears to be highly conserved among metapneumoviruses and to a somewhat lesser extent the *Pneumovirinae* (Miyahara *et al.*, 1992; Li *et al.*, 1996; Barr *et al.*, 1991). This is in agreement with MPV being a metapneumovirus, this particular region showing 99% similarity with APV C.

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the P protein. When an overall amino acid identity of at least 70%, preferably of at least 85% of the analysed P-protein with the P-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 6). The P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses (Reviewed in Lamb and Kolakofsky, 1996; Sedlmeier *et al.*, 1998). In contrast to APV A and B and PVM and similar to RSV and APV-C the MPV P ORF lacks cysteine residues. Ling (1995) suggested that a region of high similarity between all pneumoviruses (aa 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex. This region of high similarity is also found in MPV (Figure 9) especifically when conservative substitutions are taken in account, showing 100% similarity with APV-C, 93 % with APV-A and B, and approximately 81% with RSV. The C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling *et al.*, 1995).

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the M protein. When an overall amino acid identity of at least 94%, preferably of at least 97% of the analysed M-protein with the M-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses. The M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses (Table 5) and shows high aa sequence homology with the matrix proteins of APV (76-87%) lower homology with those of RSV and PVM (37-38%) and 10% or less homology with those of other paramyxoviruses (Table 6). Easton (1997) compared the sequences of matrix proteins of all pneumoviruses and found a conservedhexapeptide at residue 14 to 19 that is also conserved in MPV (Figure 10). For RSV, PVM and APV small secondary ORFs within or overlapping with the major ORF of M have been identified (52 aa and 51 aa in bRSV, 75 aa in RSV, 46 aa in PVM and 51 aa in APV) (Yu *et al.*, 1992; Easton *et al.*, 1997; Samal *et al.*, 1991; Satake *et al.*, 1984). We noticed two small ORFs in the M ORF of MPV. One small ORF of 54 aa residues was found within the major M ORF , starting at nucleotide 2281 and one small ORF of 33 aa residues was found overlapping with the major ORF of M starting at nucleotide 2893 (data not shown). Similar to the secondary ORFs of RSV and APV there is no significant homology between these secondary ORFs and secondary ORFs of the other pneumoviruses, and apparent start or stop signals are lacking. In addition, evidence for the synthesis of proteins corresponding to these secondary ORFs of APV and RSV has not been reported.

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the F protein. When an overall amino acid identity of at least 95%, preferably of at least 97% of the analysed F-protein with the F-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The F ORF of MPV is located adjacent to the M ORF, which is characteristic for members of the *Metapneumovirus* genus. The F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C (Table 5). Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6). One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues (Morrison, 1988; Yu *et al.*, 1991). The metapneumoviruses share 12 cysteine residues in F1 (7 are conserved among all paramyxoviruses), and two in F2 (1 is conserved among all paramyxoviruses). Of the 3 potential *N*-linked glycosylation sites present in the F ORF of MPV, none are shared with RSV and two (position 66 and 389) are shared with APV. The third, unique, potential *N*-linked glycosylation site for MPV is located at position 206 (Figure 11). Despite the low sequence homology with other paramyxoviruses, the F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other *Paramyxoviridae* family members (Morrison, 1988). F proteins of *Paramyxoviridae* members are synthesized as inactive precursors (F0) that are cleaved by host cell proteases which generate amino terminal F2 subunits and large carboxy terminal F1 subunits. The proposed cleavage site (Collins *et al.*, 1996) is conserved among all members of the *Paramyxoviridae* family. The cleavage site of MPV contains the residues RQSR. Both arginine (R) residues are shared with APV and RSV, but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilliviruses (data not shown). The hydrophobic region at the amino terminus of F1 is thought to function as the membrane fusion domain and shows high sequence similarity among paramyxoviruses and morbilliviruses and to a lesser extent the pneumoviruses

(Morrison, 1988). These 26 residues (position 137-163, Figure 11) are conserved between MPV and APV-C, which is in agreement with this region being highly conserved among the metapneumoviruses (Naylor *et al.*, 1998; Seal *et al.*, 2000).

As is seen for the F2 subunits of APV and other paramyxoviruses, MPV revealed a deletion of 22 aa residues compared with RSV (position 107-128, Figure 11). Furthermore, for RSV and APV, the signal peptide and anchor domain were found to be conserved within subtypes and displayed high variability between subtypes (Plows *et al.*, 1995; Naylor *et al.*, 1998). The signal peptide of MPV (aa 10-35, Figure 11) at the amino terminus of F2 exhibits some sequence similarity with APV-C (18 out of 26 aa residues are similar) and less conservation with other APVs or RSV. Much more variability is seen in the membrane anchor domain at the carboxy terminus of F1, although some homology is still seen with APV-C.

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the M2 protein. When an overall amino acid identity of at least 85%, preferably of at least 90% of the analysed M2-protein with the M2-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. M2 gene is unique to the *Pneumovirinae* and two overlapping ORFs have been observed in all pneumoviruses. The first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Collins *et al.*, 1995; Collins, 1996) and its readthrough of intergenic regions (Hardy *et al.*, 1998; Fearns *et al.*, 1999). The M2-1 gene for MPV, located adjacent to the F gene, encodes a 187 aa protein (Table 5), and reveals the highest (84%) homology with M2-1 of APV-C (Table 6). Comparison of all pneumovirus M2-1 proteins revealed the highest conservation in the amino-terminal half of the protein (Collins *et al.*, 1990; Zamora *et al.*, 1992; Ahmadian *et al.*, 1999), which is in agreement with the observation that MPV displays 100% similarity with APV-C in the first 80 aa residues of the protein (Figure 12A). The MPV M2-1 protein contains 3 cysteine residues located within the first 30 aa residues that are conserved among all pneumoviruses. Such a concentration of cysteines is frequently found in zinc-binding proteins (Ahmadian *et al.*, 1991; Cuesta et al., 2000).

The secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA replication and transcription (Collins *et al.*, 1985; Elango *et al.*, 1985; Baybutt *et al.*, 1987; Collins et al., 1990; Ling *et al.*, 1992; Zamora *et al.*, 1992; Alansari *et al.*, 1994; Ahmadian *et al.*, 1999; Bermingham *et al.*, 1999). For MPV, the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF (Figure 7), which is exactly the same start position as for APV-C. The length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues (Table 5). Sequence comparison of the M2-2 ORF (Figure 12B) revealed 56% aa sequence homology between MPV and APV-C and only 26-27%aa sequence homology between MPV and APV-A and B (Table 6).

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the L protein. When an overall amino acid identity of at least 91%, preferably of at least 95% of the analysed L-protein with the L-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. In analogy to other negative strand viruses, the last ORF of the MPV genome is the RNA-dependent RNA polymerase component of the replication and transcription complexes. The L gene of MPV encodes a 2005 aa protein, which is 1 residue longer than the APV-A protein (Table 5). The L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6). Poch *et al.* (1989; 1990) identified six conserved domains within the L proteins of non-segmented negative strand RNA viruses, from which domain III contained the four core polymerase motifs that are thought to be essential for polymerase function. These motifs (A, B, C and D) are well conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% similarity with all pneumoviruses and in motif D MPV shares 100 % similarity with APV and 92% with RSV's. For the entire domain III (aa 625- 847 in the L ORF), MPV shares 83% identity with APV, 67-68% with RSV and 26-30% with other paramyxoviruses (Figure 15). In addition to the polymerase motifs the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif $K(X)_{21}GEGAGN(X)_{20}K$ (Stec, 1991).The MPV L ORF contains a similar motif as APV, in which the spacing of the intermediate residues is off by one: $K(x)_{22}GEGAGN(X)_{19}$ K.

A much preferred suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the SH protein. When an overall amino acid identity of at least 30%, preferably of at least 50%, more preferably of at least 75% of the analysed SH-protein with the SH-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The gene located adjacent to M2 of MPV encodes a 183 aa protein (Figure 7). Analysis of the nucleotide sequence and its deduced amino acid sequence revealed no discernible homology with other RNA virus genes or gene products. The SH ORF of MPV is the longest SH ORF known to date (Table 5). The composition of the aa residues of the SH ORF is relatively similar to that of APV, RSV and PVM, with a high percentage of threonine and serine (22%, 18%, 19%, 20.0%, 21% and 28% serine/threonine content for MPV, APV, RSV A, RSV B, bRSV and PVM respectively). The SH ORF of MPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues. All pneumoviruses have similar numbers of potential *N*-glycosylation sites (MPV 2, APV 1, RSV 2, bRSV 3, PVM 4).

The hydrophobicity profiles for the MPV SH protein and SH of APV and RSV revealed similar structural characteristics (Figure 13B). The SH ORFs of APV and MPV have a hydrophylic N-terminus (aa 1-30), a central hydrophobic domain (aa 30-53) which can serve as a potential membrane spanning domain, a second hydrophobic domain around residue 160 and a hydrophilic C-terminus. In contrast, RSV SH appears to lack the C-terminal half of the APV and MPV ORFs. In all pneumovirus SH proteins the hydrophobic domain is flanked by basic amino acids, which are also found in the SH ORF for MPV (aa 29 and 54).

Another much preferred suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the G protein. When an overall amino acid identity of at least 30%, preferably of at least 50%, more preferably of at least 75% of the analysed G-protein with the G-protein of isolate I-2614 is found, the analysed virus isolate comprises a preferred MPV isolate according to the invention. The G ORF of MPV is located adjacent to the SH gene and encodes a 236 amino acid protein. A secondary small ORF is found immediately following this ORF, potentially coding for 68 aa residues (pos. 6973-7179,), but lacking a start codon. A third major ORF, in a different reading frame, of 194 aa residues (fragment 4, Figure 7) is overlapping with both of these ORFs, but also lacks a startcodon (nucleotide 6416-7000). This major ORF is followed by a fourth ORF in the same reading frame (nt 7001-7198), possibly coding for 65 aa residues but again lacking a start codon. Finally, a potential ORF of 97 aa residues (but lacking a startcodon) is found in the third reading frame (nt 6444-6737, Figure 1). Unlike the first ORF, the other ORFs do not have apparent gene start or gene end sequences (see below). Although the 236 aa residue G ORF probably represents at least a part of the MPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no homology between the predicted aa sequences for different viruses (Ling *et al.*, 1992). The secondary ORFs in MPV G do not reveal characteristics of other G proteins and whether the additional ORFs are expressed requires further investigation. BLAST analyses with all four ORFs revealed no discernible homology at the nucleotide or aa sequence level with other known virus genes or gene products. This is in agreement with the low sequence homologies found for other G proteins such as hRSV A and B (53%) (Johnson *et al.*, 1987) and APV A and B (38%) (Juhasz *et al.*, 1994). Whereas most of the MPV ORFs resemble those of APV both in length and sequence, the G ORF of MPV is considerably smaller than the G ORF of APV (Table 5). The aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV. The G ORF also contains 8.5% proline residues, which is higher than the 8% for RSV and 7% for APV. The unusual abundance of proline residues in the G proteins of APV, RSV and MPV has also been observed in glycoproteins of mucinous origin where it is a major determinant of the proteins three dimensional structure (Collins *et al.*, 1983; Wertz *et al.*, 1985; Jentoft, 1990). The number of potential *N*-linked glycosylation sites in G of MPV is similar to other pneumoviruses: MPV has 5, whereas hRSV has 7, bRSV has 5, and APV has 3 to 5.

The predicted hydrophobicity profile of MPV G revealed characteristics similar to the other pneumoviruses. The amino-terminus contains a hydrophylic region followed by a short hydrophobic area (aa 33-53) and a mainly hydrophilic carboxy terminus (Figure 14B). This overall organisation is consistent with that of an anchored type II transmembrane protein and corresponds well with these regions in the G protein of APV and RSV. The G ORF of MPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively).

According to classical serological analyses as for example known from Francki, R.I.B., Fauquet, C.M., Knudson, D.L., and Brown, F., *Classification and nomenclature of viruses. Fifth report of the international Committee on Taxonomy of*

Viruses. Arch Virol, 1991. **Supplement 2**: p. 140-144. an MPV isolate is also identifiable as belonging to a serotype as provided herein, being defined on the basis of its immunological distinctiveness, as determined by quantitative neutralization with animal antisera (obtained from for example ferrets or guinnea pigs as provided in the detailed description). Such a serotype has either no cross-reaction with others or shows a homologous-to heterologous titer ratio >16 in both directions. If neutralization shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous tier ration of eight or 16), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA's exist. If neutralization shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous tier ration of smaller than eight), identity of serotype of the isolates under study is assumed. As said, useful prototype isolates, such as isolate I-2614, herein also known as MPV isolate 00-1, are provided herein.

A further classification of a virus as an isolated essentially mammalian negative-sense single stranded RNA virus as provided herein can be made on the basis of homology to the G and/or SH proteins. Where in general the overall amino acid sequence identity between APV (isolated from birds) and MPV (isolated from humans) N, P, M, F, M2 and L ORFs was 64 to 88 percent, and nucleotide sequence homology was also found between the non-coding regions of the APV and MPV genomes, essentially no discernable amino acid sequence homology was found between two of the ORFs of the human isolate (MPV) and any of the ORFs of other paramyxoviruses. The amino acid content, hydrophobicity profiles and location of these ORFs in the viral genome show that they represent G and SH protein analogues. The sequence homology between APV and MPV, their similar genomic organization (3'-N-P-M-F-M2-SH-G-L-5') as well as phylogenetic analyses provide further evidence for the proposed classification of MPV as the first mammalian metapneumovirus.New MPV isolates are for thus example identified as such by virus isolation and characterisation on tMK or other cells, by RT-PCR and/or sequence analysis followed by phylogenetic tree analyses, and by serologic techniques such as virus neutralisation assays, indirect immunofluorescence assays, direct immunofluorescence assays, FACs analyses or other immunological techniques. Preferably these techniques are directed at the SH and/or G protein analogues.

For example the invention provides herein a method to identify further isolates of MPV as provided herein, the method comprising inoculating a essentially MPV-uninfected or specific-pathogen-free guinea pig or ferret (in the detailed description the animal is inoculated intranasally but other ways of inoculation such as intramuscular or intradermal inoculation, and using an other experimental animal, is also feasible) with the prototype isolate I-2614 or related isolates. Sera are collected from the animal at day zero, two weeks and three weeks post inoculation. The animal specifically seroconverted as measured in virus neutralisation (VN) assay and indirect IFA against the respective isolate I-2614 and the sera from the seroconverted animal are used in the immunological detection of said further isolates.

As an example, the invention provides the characterisation of a new member in the family of *Paramyxoviridae*, a human metapneumovirus or metapneumovirus-like virus (since its final taxonomy awaits discussion by a viral taxonomy committee the MPV is herein for example described as taxonomically corresponding to APV) (MPV) which may cause severe RTI in humans. The clinical signs of the disease caused by MPV are essentially similar to those caused by hRSV, such as cough, myalgia, vomiting, fever, broncheolitis or pneumonia, possible conjunctivitis, or combinations thereof. As is seen with hRSV infected children, especifically very young children may require hospitalisation. As an example an MPV which was deposited January 19, 2001 as I-2614 with CNCM, Institute Pasteur, Paris or a virus isolate phylogenetically corresponding therewith is herewith provided. Therewith, the invention provides a virus comprising a nucleic acid or functional fragment phylogenetically corresponding to a nucleic acid sequence shown in figure 6a, 6b, 6c, or structurally corresponding therewith. In particular the invention provides a virus characterised in that after testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles it is found to be more closely phylogenetically corresponding to a virus isolate deposited as **I-2614** with CNCM, Paris than it is related to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis. It is particularly useful to use an AVP-C virus isolate as outgroup in said phylogenetic tree analyses, it being the closest relative, albeit being an essentially non-mammalian virus.

We propose the new human virus to be named human metapneumovirus or metapneumovirus-like virus (MPV) based on several observations. EM analysis revealed paramyxovirus-like particles. Consistent with the classification, MPV appeared to be sensitive to treatment with chloroform. MPV is cultured optimal on tMK cells and is trypsine dependent. The clinical symptoms caused by MPV as well as the typical CPE and lack of haemagglutinating activity suggested that this virus is closely related to hRSV. Although most paramyxoviruses have haemaglutinating acitivity, most of the pneumoviruses do not [13].

As an example, the invention provides a not previously identified paramyxovirus from nasopharyngeal aspirate samples taken from 28 children suffering from severe RTI. The clinical symptoms of these children were largely similar to those caused by hRSV. Twenty-seven of the patients were children below the age of five years and half of these were between 1 and 12 months old. The other patient was 18 years old. All individuals suffered from upper RTI, with symptoms ranging from cough, myalgia, vomiting and fever to broncheolitis and severe pneumonia. The majority of these patients were hospitalised for one to two weeks.

The virus isolates from these patients had the paramyxovirus morphology in negative contrast electron microscopy but did not react with specific antisera against known human and animal paramyxoviruses. They were all closely related to one another as determined by indirect immunofluorescence assays (IFA) with sera raised against two of the isolates. Sequence analyses of nine of these isolates revealed that the virus is somewhat related to APV. Based on virological data, sequence homology as well as the genomic organisation we propose that the virus is a member of *Metapneumovirus* genus. Serological surveys showed that this virus is a relatively common pathogen since the seroprevalence in the Netherlands approaches 100% of humans by the age of five years. Moreover, the seroprevelance was found to be equally high in sera collected from humans in 1958, indicating this virus has been circulating in the human population for more than 40 years. The identification of this proposed new member of the *Metapneumovirus* genus now also provides for the development of means and methods for diagnostic assays or test kits and vaccines or serum or antibody compositions for viral respiratory tract infections, and for methods to test or screen for antiviral agents useful in the treatment of MPV infections.

To this extent, the invention provides among others an isolated or recombinant nucleic acid or virus-specific functional fragment thereof obtainable from a virus according to the invention. In particular, the invention provides primers and/or probes suitable for identifying an MPV nucleic acid.

Furthermore, the invention provides a vector comprising a nucleic acid according to the invention. To begin with, vectors such as plasmid vectors containing (parts of) the genome of MPV, virus vectors containing (parts of) the genome of MPV. (For example, but not limited to other paramyxoviruses, vaccinia virus, retroviruses, baculovirus), or MPV containing (parts of) the genome of other viruse or other pathogens are provided. Furthermore, a number of reverse genetics techniques have been described for the generation of recombinant negative strand viruses, based on two critical parameters. First, the production of such virus relies on the replication of a partial or full-length copy of the negative sense viral RNA (vRNA) genome or a complementary copy thereof (cRNA). This vRNA or cRNA can be isolated from infectious virus, produced upon in-vitro transcription, or produced in cells upon transfection of nucleic acids. Second, the production of recombinant negative strand virus relies on a functional polymerase complex. Typically, the polymerase complex of pneumoviruses consists of N, P, L and possibly M2 proteins, but is not necessarily limited thereto. Polymerase complexes or components thereof can be isolated from virus particles, isolated from cells expressing one or more of the components, or produced upon transfection of specific expression vectors.

Infectious copies of MPV can be obtained when the above mentioned vRNA, cRNA, or vectors expressing these RNAs are replicated by the above mentioned polymerase complex [16,17,18,19,20,21,22]. For the generation of minireplicons or, a reverse genetics system for generating a full-length copy comprising most or all of the genome of MPV it suffices to use 3'end and/or 5'end nucleic acid sequences obtainable from for example APV (Randhawa et al., 1997) or MPV itself.

Also, the invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of MPV (presumably N, P, L and M2, but not necessarily limited thereto) are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the MPV genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

Infectious copies of MPV (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.

In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial MPV proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses [23,24,26] . For example, it can be envisaged that a MPV virus vector expressing one or more proteins of RSV or a RSV vector expressing one or more proteins of MPV will protect individuals vaccinated with such vector against both virus infections. A similar approach can be envisaged for PI3 or other paramyxoviruses. Attenuated and replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses [25,26] .

In a preferred embodiment, the invention provides a proteinaceous molecule or metapneumovirus-specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from a virus according to the invention. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as sub-unit vaccines. Particularly useful are the F, SH and/or G protein or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particulary useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments that are identified for phylogenetic analyses, of course preferred are those that are within the preferred bounds and metes of ORFs useful in phylogenetic analyses, in particular for eliciting MPV specific antibodies, whether in vivo (e.g. for protective puposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

Also provided herein are antibodies, be it natural polyclonal or monoclonal, or synthetic (e.g. (phage) library-derived binding molecules) antibodies that specificallyreact with an antigen comprising a proteinaceous molecule or MPV-specific functional fragment thereof according to the invention. Such antibodies are useful in a method for identifying a viral isolate as an MPV comprising reacting said viral isolate or a component thereof with an antibody as provided herein. This can for example be achieved by using purified or non-purified MPV or parts thereof (proteins, peptides) using ELISA, RIA, FACS or similar formats of antigen detection assays (*Current Protocols in Immunology*). Alternatively, infected cells or cell cultures may be used to identify viral antigens using classical immunofluorescence or immunohistochemical techniques.

Other methods for identifying a viral isolate as a MPV comprise reacting said viral isolate or a component thereof with a virus specific nucleic acid according to the invention, in particular where said mammalian virus comprises a human virus.

In this way the invention provides a viral isolate identifiable with a method according to the invention as a mammalian virus taxonomically corresponding to a negative-sense single stranded RNA virus identifiable as likely belonging to the genus *Metapneumovirus* within the sub-family *Pneumovirinae* of the family *Paramyxoviridae.*

The method is useful in a method for virologically diagnosing an MPV infection of a mammal, said method for example comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody according to the invention. Examples are further given in the detailed description, such as the use of PCR (or other amplification or hybridisation techniques well known in the art) or the use of immunofluorescence detection (or other immunological techniques known in the art)

The invention also provides a method for serologically diagnosing a MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against a MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen according to the invention

Methods and means provided herein are particularly useful in a diagnostic kit for diagnosing a MPV infection, be it by virological or serological diagnosis. Such kits or assays may for example comprise a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention.
Use of a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention is also provided for the

production of a pharmaceutical composition, for example for the treatment or prevention of MPV infections and/or for the treatment or prevention of respiratory tract illnesses, in particular in humans. Attenuation of the virus can be achieved by established methods developed for this purpose, including but not limited to the use of related viruses of other species, serial passages through laboratory animals or/and tissue/cell cultures, site directed mutagenesis of molecular clones and exchange of genes or gene fragments between related viruses.

A pharmaceutical composition comprising a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention can for example be used in a method for the treatment or prevention of a MPV infection and/or a respiratory illness comprising providing an individual with a pharmaceutical composition according to the invention. This is most useful when said individual comprises a human, especifically when said human is below 5 years of age, since such infants and young children are most likely to be infected by a human MPV as provided herein. Generally, in the acute phase patients will suffer from upper respiratory symptoms predisposing for other respiratory and other diseases. Also lower respiratory illnesses may occur, predisposing for more and other serious conditions.

The invention also provides method to obtain an antiviral agent useful in the treatment of respiratory tract illness comprising establishing a cell culture or experimental animal comprising a virus according to the invention, treating said culture or animal with an candidate antiviral agent, and determining the effect of said agent on said virus or its infection of said culture or animal. An example of such an antiviral agent comprises a MPV-neutralising antibody, or functional component thereof, as provided herein, but antiviral agents of other nature are obtained as well. The invention also provides use of an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of respiratory tract illness, especifically when caused by an MPV infection, and provides a pharmaceutical composition comprising an antiviral agent according to the invention, useful in a method for the treatment or prevention of an MPV infection or respiratory illness, said method comprising providing an individual with such a pharmaceutical composition.

The invention is further explained in the detailed description without limiting it thereto.

Figure legends

Figure 1A comprises table 1: Percentage homology found between the amino acid sequence of isolate 00-1 and other members of the Pneumovirinae. Percentages (x100) are given for the amino acid sequences of N, P, M, F and two RAP-PCR fragments in L (8 and 9/10). Accession numbers used for the analyses are described in the materials and methods section.

Fig 1B comprises table 2: Seroprevalence of MPV in humans categorised by age group using immunofluorescence and virus neutralisation assays..

Fig. 2: Schematic representation of the genome of APV with the location and size of the fragments obtained with RAP-PCR and RT-PCR on virus isolate 00-1. Fragments 1 to 10 were obtained using RAP-PCR. Fragment A was obtained with a primer in RAP-PCR fragment 1 and 2 and a primer designed based on alignment of leader and trailer sequences of APV and RSV[6]. Fragment B was obtained using primers designed in RAP-PCR fragment 1 and 2 and RAP-PCR fragment 3. Fragment C was obtained with primers designed in RAP-PCR fragment 3 and RAP-PCR fragment 4,5,6 and 7.

For all phylogenetic trees, (figures 3-5) DNA sequences were aligned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phylip 3.5 program using 100 bootstraps and 3 jumbles[15]. Previously published sequences that were used for the generation of phylogenetic trees are available from Genbank under accessions numbers : For all ORFs: hRSV: NC001781; bRSV: NC001989; For the F ORF: PVM, D11128; APV-A, D00850; APV-B, Y14292; APV-C, AF187152; For the N ORF: PVM, D10331; APV-A, U39295; APV-B, U39296; APV-C, AF176590; For the M ORF: PMV,U66893; APV-A, X58639; APV-B, U37586; APV-C, AF262571; For the P ORF: PVM, 09649; APV-A, U22110, APV-C, AF176591. Phylogenetic analyses for the nine different virus isolates of MPV were performed with APV strain C as outgroup.
Abbreviations used in figures: hRSV: human RSV; bRSV: bovine RSV; PVM: pneumonia virus of mice; APV-A,B,and C: avian pneumovirus typa A, B and C.
Fig. 3 Comparison of the N, P, M and F ORF's of members of the subfamily *Pneumovirinae* and virus isolate 00-1. The alignment shows the amino acid sequence

of the complete N, P, M and F proteins and partial L proteins of virus isolate 00-1. Amino acids that differ between isolate 00-1 and the other viruses are shown, identical amino acids are represented by periods, gaps are represented as dashes. Numbers correspond to amino acid positions in the proteins. Accession numbers used for the analyses are described in the materials and methods section. APV-A, B or C: Avian Pneumovirus type A, B or C, b-or hRSV: bovine or human respiratory syncytial virus, PVM: pneumonia virus of mice. L8: fragment 8 obtained with RAP-PCR located in L, L9/10: consensus of fragment 9 and 10 obtained with RAP-PCR, located in L. For the P allignment, no APV-B sequence was available from the Genebank, For the L allignment only bRSV, hRSV and APV-A sequences were available.

Fig. 4: Phylogenetic analyses of the N, P, M, and F ORF's of members of the genus Pneumovirinae and virus isolate 00-1. Phylogenetic analysis was performed on viral sequences from the following genes: F (panel A), N (panel B), M (panel C), and P (panel D). The phylogenetic trees are based on maximum likelyhood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree.

Fig. 5: Phylogenetic relationship for parts of the F (panel A), N (panel B), M (panel C) and L (panel D) ORFs of nine of the primary MPV isolates with APV-C, it's closest relative genetically. The phylogenetic trees are based on maximum likelyhood analyses. The scale representing the number of nucleotide changes is shown for each tree. Accesion numbers for APV-C: panel A: D00850; panel B: U39295; panel C: X58639; and panel D: U65312.

Fig. 6A: Nucleotide and amino acid sequence information from the 3'end of the genome of MPV isolate 00-1.ORF's are given. N: ORF for nucleoprotein; P: ORF for phosphoprotein; M: ORF for matrix protein; F: ORF for fusion protein; GE: gene end; GS: gene start.

Fig. 6B and C: Nucleotide and amino acid sequence information from obtained fragments in the polymerase gene (L) of MPV isolates 00-1. Positioning of the fragments in L is based on protein homologies with APV-C (accession number U65312). The translated fragment 8 (Fig. 6B.) is located at amino acid number 8 to 243, and the consensus of fragments 9 and 10 (Fig. 6C) is located at amino acid number 1358 to 1464 of the APV-C L ORF.

Figure 7

Genomic map of MPV isolate 00-1. The nucleotide positions of the start and stop codons are indicated under each ORF.. The double lines which cross the L ORF indicate the shortened representation of the L gene. The three reading frames below the map indicate the primary G ORF (nt 6262-6972) and overlapping potential secondary ORFs.

Figure 8:

Alignment of the predicted amino acid sequence of the nucleoprotein of MPV with those of other pneumoviruses. The conserved regions identified by Barr (1991) are represented by boxes and labelled A, B, and C. The conserved region among pneumoviruses (Li, 1996) is shown gray shaded. Gaps are represented by dashes, periods indicate the positions of identical amino acid residues compared to MPV.

Figure 9:

Amino acid sequence comparison of the phosphoprotein of MPV with those of other pneumoviruses. The region of high similarity (Ling, 1995) is boxed, and the glutamate rich region is grey shaded. Gaps are represented by dashes and periods indicate the position of identical amino acid residues compared to MPV.

Figure 10:

Comparison of the deduced amino acid sequence of the matrix protein of MPV with those of other pneumoviruses. The conserved hexapeptidesequence (Easton, 1997) is grey shaded. Gaps are represented by dashes and periods indicate the position of identical amino acid residues relative to MPV.

Figure 11:

Allignment of the predicted amino acid sequence of the fusion protein of MPV with those of other pneumoviruses. The conserved cysteine residues are boxed, *N*-linked glycosylation sites are underlined, the cleavage site of F0 is double underlined, the fusion peptide, signal peptide and membrane anchor domain are shown grey shaded. Gaps are represented by dashes and periods indicate the position of identical amino acids relative to MPV.

Figure 12

Comparison of amino acid sequence of the M2 ORFs of MPV with those of other pneumoviruses. The alignment of M2-1 ORFs is shown in panel A, with the conserved amino terminus (Collins, 1990; Zamora, 1999) shown grey shaded. The three conserved cysteine residues are printed bold face and indicated by #. The alignment of M2-2 ORFs is shown in panel B. Gaps are represented by dashes and periods indicate the position of identical amino acids relative to MPV.

Figure 13

Amino acid sequence analyses of the SH ORF of MPV. (A) Amino acid sequence of the SH ORFof MPV, with the serine and threonine residues grey shaded, cysteine residues in bold face and the hydrophobic region double underlined. Potential *N*- linked glycosylation sites are single underlined. Numbers indicate the positions of the basic amino acids flanking the hydrophobic domain.(B) Alignment of the hydrophobicity plots of the SH proteins of MPV, APV-A and hRSV-B. The procedure of Kyte and Doolittle (1982) was used with a window of 17 amino acids. Arrows indicate a strong hydrophobic domain. Positions within the ORF are given on the X-axis.

Figure 14

Amino acid sequence analyses of the G ORF of MPV. (A) Amino acid sequence of the G ORF of MPV, with serine, threonine and proline residues grey shaded, the cysteine residue is in bold face and the hydrophobic region double underlined. The potential *N*-linked glycosylation sites are single underlined. (B) Alingment of the hydrophobicity plots of the G proteins of MPV, APV-A and hRSV-B. The procedure of Kyte and Doolittle (1982) was used with a window of 17 amino acids. Arrows indicate the hydrophobic region, and positions within the ORF are given at the X-axis.

Figure 15

Comparison of the amino acid sequences of a conserved domain of the polymerase gene of MPV and other paramyxoviruses. Domain III is shown with the four conserved polymerase motifs (A, B, C, D) in domain III (Poch 1998, 1999) boxed.
Gaps are represented by dashes and periods indicate the position of identical amino acid residues relative to MPV. hPIV3: human parainfluenza virus type 3; SV: sendai virus; hPIV-2: human parainfluenza virus type 2; NDV: New castle disease virus; MV: measles virus;; nipah: Nipah virus.

Figure 16:

Phylogenetic analyses of the M2-1 and L ORFs of MPV and selected paramyxoviruses. The M2-1 ORF was aligned with the M2-1 ORFs of other members of the genus *Pneumovirinae* (A) and the L ORF was aligned with L ORFs members of the genus *pneumovirinae* and selected other paramyxoviruses as described in the legends of figure 15 (B). Phylogenetic trees were generated by maximum likelihood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree. Numbers in the trees represent bootstrap values based on the consensus trees.

Figure 17:

Noncoding sequences of hMPV isolate 00-1. (A) The noncoding sequences between the ORFs and at the genomic termini are shown in the positive sense. From left to right, stop codons of indicated ORFs are shown, followed by the noncoding sequences, the gene start signals and start codons of the indicated subsequent ORFs. Numbers indicate the first position of start and stop codons in the hMPV map. Sequences that display similarity to published gene end signals are underlined and sequences that display similarity to UAAAAAU/A/C are represented with a line above the sequence. (B) Nucleotide sequences of the genomic termini of hMPV. The genomic termini of hMPV are aligned with each other and with those of APV. Underlined regions represent the primer sequences used in RT-PCR assays which are based on the 3' and 5' end sequences of APV and RSV (Randhawa *et al.*, 1997; Mink *et al.*, 1991). Bold italicalized nucleotides are part of the gene start signal of the N gene. Le: leader, Tr: trailer.

Figure 18:

Comparison of two prototypic hMPV isolates with APV-A and APV-C; DNA similarity matrices for nucleic acids encoding the various viral proteins.

Figure 19:

Comparison of two prototypic hMPV isolates with APV-A and APV-C; protein similarity matrices for the various viral proteins.

Figure 20:

Amino acid alignment of the nucleoprotein of two prototype hMPV isolates

Figure 21:

Amino acid alignment of the phosphoprotein of two prototype hMPV isolates

Figure 22:

Amino acid alignment of the matrix protein of two prototype hMPV isolates

Figure 23:

Amino acid alignment of the fusion protein of two prototype hMPV isolates

Figure 24:

Amino acid alignment of the M2-1 protein of two prototype hMPV isolates

Figure 25:

Amino acid alignment of the M2-2 protein of two prototype hMPV isolates

Figure 26:
Amino acid alignment of the short hydrophobic protein of two prototype hMPV isolates

Figure 27:
Amino acid alignment of the attachement glycoprotein of two prototype hMPV isolates

Figure 28:
Amino acid alignment of the N-terminus of the polymerase protein of two prototype hMPV isolates

Figure 29: Results of RT-PCR assays on throat and nose swabs of 12 guinea pigs inoculated with ned/00/01 and/or ned/99/01.

Figure 30A: IgG response against ned/00/01 and ned/99/01 for guinea pigs infected with ned/00/01 and re-infected with ned/00/01 (GP 4, 5 and 6) or ned/99/01 (GP 1 and 3).

Figure 30B: IgG response against ned/00/01 and ned/99/01 for guinea pigs infected with ned/99/01 and re-infected with either ned/00/01 (GP's 8 and 9) or with ned/99/01 (GP's 10, 11, 12).

Figure 31: Specificity of the ned/00/01 and ned/99/01 ELISA on sera taken from guinea pigs infected with either ned/00/01 or ned/99/01.

Figure 32: Mean IgG response against ned/00/01 and ned/99/01 ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.

Figure 33: Mean percentage of APV inhibition of hMPV infected guinea pigs.

Figure 34: Virus neutralisation titers of ned/00/01 and ned/99/01 infected guinea pigs against ned/00/01, ned/99/01 and APV-C.

Figure 35: Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01.

Figure 36 A (top two panels):
IgA, IgM and IgG response against ned/00/01 of 2 cynomologous macaques (re)infected with ned/00/01.

Figure 36B (bottom panels)
IgG response against APV of 2 cynbomologous macaques infected with ned/00/01.

Figure 37: Comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera.

Detailed description

Virus isolation and characterisation

From 1980 till 2000 we found 28 unidentified virus isolates from patients with severe respiratory disease. These 28 unidentified virus isolates grew slowly in tMK cells, poorly in VERO cells and A549 cells and could not or only little be propagated in MDCK or chicken embryonated fibroblast cells. Most of these virus isolates induced CPE after three passages on tMK cells, between day ten and fourteen. The CPE was virtually indistinguishable from that caused by hRSV or hPIV in tMK or other cell cultures, characterised by syncytium formation after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer. The cells usually (sometimes later) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV.

We used the supernatants of infected tMK cells for EM analysis which revealed the presence of paramyxovirus-like virus particles ranging from 150 to 600 nanometer, with short envelope projections ranging from 13 to 17 nanaometer. Consistent with the biochemical properties of enveloped viruses such as the *Paramyxoviridae*, standard chloroform or ether treatment[8] resulted in $>10^4$ TCID50 reduction of infectivity for tMK cells. Virus-infected tMK cell culture supernatants did not display heamagglutinating activity with turkey, chicken and guinea pig erythrocytes. During culture, the virus replication appeared to be trypsine dependent on the cells tested. These combined virological data allowed that the newly identified virus was taxonomically classified as a member of the *Paramyxoviridae* family.

We isolated RNA from tMK cells infected with 15 of the unidentified virus isolates for reverse transcription and polymerase chain reaction (RT-PCR) analyses using primer-sets specific for *Paramyxovirinae*[9], hPIV 1-4, sendai virus, simian virus type 5, New-Castle disease virus, hRSV, morbilli, mumps, Nipah, Hendra, Tupaia and Mapuera viruses. RT-PCR assays were carried out at low stringency in order to detect potentially related viruses and RNA isolated from homologous virus stocks were used as controls. Whereas the available controls reacted positive with the respective virus-specific primers, the newly identified virus isolates did not react with any primer set, indicating the virus was not closely related to the viruses tested.

We used two of the virus-infected tMK cell culture supernatants to inoculate guinea pigs and ferrets intranasaly. Sera were collected from these animals at day zero, two weeks and three weeks post inoculation. The animals displayed no clinical symptoms but all seroconverted as measured in virus neutralisation (VN) assays and indirect IFA against the homologous viruses. The sera did not react in indirect IFA with any of the known paramyxoviruses described above and with PVM. Next, we screened the so far unidentified virus isolates using the guinea pig and ferret pre- and post-infection sera, of which 28 were clearly positive by indirect IFA with the post-infection sera suggesting they were serological closely related or identical.

RAP PCR

To obtain sequence information on the unknown virus isolates, we used a random PCR amplification strategy known as RAP-PCR[10]. To this end, tMK cells were infected with one of the virus isolates (isolate 00-1) as well as with hPIV-1 which served as a control. After both cultures displayed similar levels of CPE, virus in the culture supernatants was purified on continuous 20-60% sucrose gradients. The gradient fractions were inspected for virus-like particles by EM, and RNA was isolated from the fraction containing approximately 50% sucrose, in which nucleocapsids were observed. Equivalent amounts of RNA isolated from both virus fractions were used for RAP-PCR, after which samples were run side by side on a 3% NuSieve agarose gel. Twenty differentially displayed bands specific for the unidentified virus were subsequently purified from the gel, cloned in plasmid pCR2.1 (Invitrogen) and sequenced with vector-specific primers. When we used these sequences to search for homologies against sequences in the Genbank database using the BLAST software (www.ncbi.nlm.nih.gov/BLAST/) 10 out of 20 fragments displayed resemblance to APV/TRTV sequences.

These 10 fragments were located in the genes coding for the nucleoprotein (N; fragment 1 and 2), the matrix protein (M; fragment 3), the fusion protein (F; fragment 4, 5, 6, 7,) and the polymerase protein (L; fragment 8,9,10) (Fig.2). We next designed PCR primers to complete the sequence information for the 3' end of the viral genome based on our RAP PCR fragments as well as published leader and trailer sequences for the *Pneumovirinae* [6]. Three fragments were amplified, of which fragment A spanned the extreme 3' end of the N open reading frame (ORF), fragment B spanned the phosphoprotein (P) ORF and fragment C closed the gap between the M and F ORFs (Fig. 2). Sequence analyses of these three fragments revealed the absence of NS1 and NS2 ORFs at the extreme 3' end of the viral genome and positioning of the F ORF immediately adjacent to the M ORF. This genomic organisation resembles that of the metapneumovirus APV, which is also consistent with the sequence homology. Overall the translated sequences for the N, P, M and F ORFs showed an average of 30-33% homology with members of the genus *Pneumovirus* and 66-68% with members of the genus *Metapneumovirus*. For the SH and G ORF's no discernable homology was found with members of either of the genera. The amino acid homologies found for N showed about 40% homology with hRSV and 88% with APV-C, its closest relative genetically, as for example can be deduced by comparing the amino acid sequence of figure 3 with the amino acid sequence of the respective N proteins of other viruses. The amino acid sequence for P showed about 25% homology with hRSV and about 66-68% with APV-C, M showed about 36-39% with hRSV and about 87-89% with APV-C, F showed about 40% homology with hRSV and about 81% with APV-C, M2-1 showed about 34-36% homology with pneumoviruses and 84-86 % with APV-C, M2-2 showed 15-17% homology with pneumoviruses and 56% with APV-C and the fragments obtained in L showed an average of 44% with pneumoviruses and 64% with APV-C .

Phylogeny

Although BLAST searches using nucleotide sequences obtained from the unidentified virus isolate revealed homologies primarily with members of the Pneumovirinae, homologies based on protein sequences revealed some resemblance with other paramyxoviruses as well (data not shown). As an indication for the relation between the newly identified virus isolate and members of the *Pneumovirinae*, phylogenetic trees were constructed based on the N, P, M and F ORFs of these viruses. In all four phylogenetic trees, the newly identified virus isolate was most closely related to APV (Fig.4). From the four serotypes of APV that have been described[11], APV serotype C, the metapneumovirus found primarily in birds in the USA, showed the closest resemblance to the newly identified virus. It should be noted however, that only partial sequence information for APV serotype D is available.

To determine the relationship of our various newly identified virus isolates, we constructed phylogenetic trees based on sequence information obtained from eight to nine isolates (8 for F, 9 for N, M and L). To this end, we used RT-PCR with primers designed to amplify short fragments in the N, M, F and L ORFs, that were subsequently sequenced directly. The nine virus isolates that were previously found to be related in serological terms (see above) were also found to be closely related genetically. In fact, all nine isolates were more closely related to one another than to APV. Although the sequence information used for these phylogenetic trees was limited, it appears that the nine isolates can be divided in two groups, with isolate 94-1, 99-1 and 99-2 clustering in one group and the other six isolates (94-2; 93-1; 93-2; 93-3; 93-4; 00-1) in the other (Fig.5).

Seroprevalence

To study the seroprevalence of this virus in the human population, we tested sera from humans in different age categories by indirect IFA using tMK cells infected with one of the unidentified virus isolates. This analysis revealed that 25% of the children between six and twelve months had antibodies to the virus, and by the age of five nearly 100% of the children were seropositive. In total 56 serum samples tested by indirect IFA were tested by VN assay. For 51 (91%) of the samples the results of the VN assay (titre >8) coincided with the results obtained with indirect IFA (titre>32). Four samples that were found positive in IFA, were negative by VN test (titre <8) whereas one serum reacted negative in IFA (titre<32) and positive in the VN test (titre 16) (table 2).

IFA conducted with 72 sera taken from humans in 1958 (ages ranging from 8-99 years)[12,27] revealed a 100% seroprevalence, indicating the virus has been circulating in the human population for more than 40 years. In addition a number of these sera were used in VN assays to confirm the IFA data (table 2).

Genetic analyses of the N, M, P and F genes revealed that MPV has higher sequence homology to the recently proposed genus *Metapneumovirinae* (average of 63 %) as compared to the genus *Pneumovirinae* (average of 30 %) and thus demonstrates a genomic organisation similar to and resembling that of APV/TRTV. In contrast to the genomic organisation of the RSVs ('3-NS1-NS2-N-P-M-SH-G-F-M2-L-5'), metapneumoviruses lack NS1 and NS2 genes and have a different positioning of the genes between M and L ('3-N-P-M-F-M2-SH-G-L-5'). The lack of ORFs between the M and F genes in our virus isolates and the lack of NS1 and NS2 adjacent to to N, and the high amino acid sequence homology found with APV are reasons to propose the classification of MPV isolated from humans as a first member of the *Metapneumovirus* genus of mammalian, in particular of human origin.

Phylogenetic analyses revealed that the nine MPV isolates from which sequence information was obtained are closely related. Although sequence information was limited, they were in fact more closely related to one another than to any of the avian metapneumoviruses. Of the four serotypes of APV that have been described, serotype C was most closely related to MPV based on the N, P, M and F genes. It should be noted however that for serotype D only partial sequences for the F gene were available from Genbank and for serotype B only M, N and F sequences were available. Our MPV isolates formed two clusters in phylogenetic trees. For both hRSV and APV different genetic and serological subtypes have been described. Whether the two genetic clusters of MPV isolates represent serogical subgroups that are also functionally different remains unknown at presentOur serological surveys showed that MPV is a common human pathogen. The repeated isolation of this virus from clinical samples from children with severe RTI indicates that the clinical and economical impact of MPV may be high. New diagnostic assays based on virus detection and serology will allow a more detailed analysis of the incidence and clinical and economical impact of this viral pathogen.

The slight differences between the IFA and VN results (5 samples) maybe due to the fact that in the IFA only IgG serum antibodies were detected whereas the VN assay detects both classes and sub-classes of antibodies or differences may be due to the differences in sensitivity between both assays. For IFA a cut off value of 16 is used, whereas for VN a cut off value of 8 is used.

On the other hand, differences between IFA versus VN assay may also indicate possible differences between different serotypes of this newly identified virus. Since MPV seems most closely related to APV, we speculate that the human virus may have originated from birds. Analysis of serum samples taken from humans in 1958 revealed that MPV has been widespread in the human population for more then 40 years indicating that a tentative zoonosis event must have taken place long before 1958.

Materials and Methods

Specimen collection

Over the past decades our laboratory has collected nasopharyngeal aspirates from children suffering from RTI, which are routinely tested for the presence of viruses. All nasopharyngeal aspirates were tested by direct immmunofluorescence assays (DIF) using fluorescence labelled antibodies against influenza virus types A, and B, hRSV and human parainfluenza virus (hPIV) types 1 to 3. The nasopharyngeal aspirates were also processed for virus isolation using rapid shell vial techniques[14] on various celllines including VERO cells, tertiary cynomolgous monkey kidney (tMK) cells, human endothelial lung (HEL) cells and marbin dock kidney (MDCK) cells. Samples showing cytophatic effects (CPE) after two to three passages, and which were negative in DIF, were tested by indirect immunofluorescence assays (IFA) using virus specific antibodies against influenza virus types A, B and C, hRSV types A and B, measles virus, mumps virus, human parainfluenza virus (hPIV) types 1 to 4, sendai virus, simian virus type 5, and New-Castle disease virus. Although for many cases the aetiological agent could be identified, some specimens were negative for all these viruses tested.

Direct Immunofluorescence Assay (DIF)

Nasopharyngeal aspirate samples from patients suffering from RTI were used for DIF and virus isolation as described[14,15]. Samples were stored at -70 °C. In brief, nasopharyngeal aspirates were diluted with 5 ml Dulbecco MEM (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x *g*. The sediment was spread on a multispot slide (Nutacon, Leimuiden, The Netherlands), the supernatant was used for virus isolation. After drying, the cells were fixed in aceton for 1 minute at room temperature. After washing the slides were incubated for 15 minutes at 37 °C with commercial available FITC-labelled virus specific anti-sera such as influenza A and B, hRSV and hPIV 1 to 3 (Dako, Glostrup, Denmark). After three washings in PBS and one in tap water, the slides were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The slides were analysed using a Axioscop fluorescence microscope (Carl Zeiss B.V, Weesp, the Netherlands.

Virus isolation

For virus isolation tMK cells (RIVM, Bilthoven, The Netherlands) were cultured in 24 well plates containing glass slides (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium). Before inoculation the plates were washed with PBS and supplied with Eagle's MEM with Hanks' salt (ICN, Costa mesa, CA) of which half a litre was supplemented with 0.26 gram $HaHCO_3$, 0.025 M Hepes (Biowhittaker), 2 mM L-glutamine (Biowhittaker), 100 units penicilline, 100 µg streptomycine (Biowhittaker), 0.5 gram lactalbumine (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1.0 gram D-glucose (Merck, Amsterdam, The Netherlands), 5.0 gram peptone (Oxoid, Haarlem, The Netherlands) and 0.02% trypsine (Life Technologies, Bethesda, MD). The plates were inoculated with supernatant of the nasopharyngeal aspirate samples, 0,2 ml per well in triplicate, followed by centrifuging at 840x *g* for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 14 days changing the medium once a week and cultures were checked daily for CPE. After 14 days cells were scraped from the second passage and incubated 14 days. This step was repeated for the third passage. The glass slides were used to demonstrate the presence of the virus by indirect IFA as described below.

Animal immunisation

Ferret and guinea pig specific antisera for the newly discovered virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurised glove boxes. Two to three weeks later all the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for all previous described viruses with indirect IFA as described below.

Antigen detection by indirect IFA

We performed indirect IFA on slides containing infected tMK cells. After washing with PBS the slides were incubated for 30 minutes at 37 °C with virus specific anti-sera. We used monoclonal antibodies in DIF against influenza A, B and C, hPIV type 1 to 3 and hRSV as described above. For hPIV type 4, mumps virus, measles virus, sendai virus, simian virus type 5, New-Castle Disease virus polyclonal antibodies

(RIVM) and ferret and guinea pig reference sera were used. After three washings with PBS and one wash with tap water, the slides were stained with a secondary antibodies directed against the sera used in the first incubation. Secondary antibodies for the polyclonal anti sera were goat-anti-ferret (KPL, Guilford, UK, 40 fold diluted), mouse-anti-rabbit (Dako, Glostrup, Denmark, 20 fold diluted), rabbit-anti-chicken (KPL, 20 fold dilution) and mouse-anti-guinea pig (Dako, 20 fold diluted). Slides were processed as described for DIF.

Detection of antibodies in humans by indirect IFA

For the detection of virus specific antibodies, infected tMK cells were fixed with cold acetone on coverslips, washed with PBS and stained with serum samples at a 1 to 16 dilution. Subsequently, samples were stained with FITC-labelled rabbit anti human antibodies 80 times diluted in PBS (Dako). Slides were processed as described above.

Virus culture of MPV

Sub-confluent mono-layers of tMK cells in media as described above were inoculated with supernatants of samples that displayed CPE after two or three passages in the 24 well plates. Cultures were checked for CPE daily and the media was changed once a week. Since CPE differed for each isolate, all cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, aliquoted and stored frozen at -70 °C. The 50% tissue culture infectious doses (TCID50) of virus in the culture supernatants were determined as described[16].

Virus neutralisation assay

VN assays were performed with serial two-fold dilutions of human and animal sera starting at an eight-fold dilution. Diluted sera were incubated for one hour with 100 TCID50 of virus before inoculation of tMK cells grown in 96 well plates, after which the plates were centrifuged at 840 x *g*. The media was changed after three and six days and IFA was conducted with ferret antibodies against MPV 8 days after inoculation. The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in cell cultures.

Virus characterisation

Haemagglutination assays and chloroform sensitivity tests were performed as described[8,14]. For EM analyses, virus was concentrated from infected cell culture supernatants in a micro-centrifuge at 4 °C at 17000 x g, after which the pellet was resuspended in PBS and inspected by negative contrast EM. For RAP-PCR, virus was concentrated from infected tMK cell supernatants by ultra-centrifugation on a 60% sucrose cussion (2 hours at 150000 x g, 4 °C). The 60% sucrose interphase was subsequently diluted with PBS and layered on top of a 20-60% continuous sucrose gradient which was centrifuged for 16 hours at 275000 x g at 4 °C. Sucrose gradient fractions were inspected for the presence of virus-like particles by EM and polyacrylamide gel electrophoresis followed by silver staining. The approximately 50% sucrose fractions that appeared to contain nucleocapsids were used for RNA isolation and RAP-PCR.

RNA isolation

RNA was isolated from the supernatant of infected cell cultures or sucrose gradient fractions using a High Pure RNA Isolation kit according to instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands).

RT-PCR

Virus-specific oligonucleotide sequences for RT-PCR assays on known paramyxoviruses are described in addenda 1. A one-step RT-PCR was performed in 50 µl reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM $MgCl_2$, 2 mM dithiotreitol, 200 µM each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de Ijssel, The Netherlands) and 5 µl RNA. Cycling conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at 42 °C and 3 min. at 72 °C repeated 40 times and 10 min. at 72 °C once.

RAP-PCR

RAP-PCR was performed essentially as described[10]. The oligonucleotide sequences are described in addenda 2. For the RT reaction, 2 µl RNA was used in a 10 µl reaction containing 10 ng/μl oligonucleotide, 10 mM dithiotreitol, 500 μm each dNTP, 25 mM Tris-HCl pH 8.3, 75 mM KCl and 3 mM $MgCl_2$. The reaction mixture was incubated for 5 min. at 70 °C and 5 min. at 37 °C, after which 200 units Superscript RT enzyme (LifeTechnologies) were added. The incubation at 37 °C was continued for 55 min. and the reaction terminated by a 5 min. incubation at 72 °C. The RT mixture was diluted to give a 50 μl PCR reaction containing 8 ng/μl oligonucleotide, 300 μm each dNTP, 15 mM Tris-HCL pH 8.3, 65 mM KCl, 3.0 mM $MgCL_2$ and 5 units Taq DNA polymerase (PE Biosystems). Cycling conditions were 5 min. at 94 °C, 5 min. at 40 °C and 1 min. at 72 °C once, followed by 1 min. at 94 °C, 2 min. at 56 °C and 1 min. at 72 °C repeated 40 times and 5 min. at 72°C once. After RAP-PCR, 15 μl the RT-PCR products were run side by side on a 3% NuSieve agarose gel (FMC BioProducts, Heerhugowaard, The Netherlands). Differentially displayed fragments specific for MPV were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacterer.

Sequence analysis

RAP-PCR products cloned in vector pCR2.1 (Invitrogen) were sequenced with M13-specific oligonucleotides. DNA fragments obtained by RT-PCR were purified from agarose gels using Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands), and sequenced directly with the same oligonucleotides used for PCR. Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). All techniques were performed according to the instructions of the manufacturer.

Generating genomic fragments of MPV by RT-PCR

To generate PCR fragments spanning gaps A, B and C between the RAP-PCR fragments (Fig.2) we used RT-PCR assays as described before on RNA isolated from virus isolate 00-1. The following primers were used:
For fragment A: TR1 designed in the leader: (5'-AAAGAATTCACGAGAAAAAAACGC-3') and N1 designed at the 3'end of the RAP-PCR fragments obtained in N (5'-CTGTGGTCTCTAGTCCCACTTC-3')
For fragment B: N2 designed at the 5'end of the RAP-PCR fragments obtained in N: (5'-CATGCAAGCTTATGGGGC-3') and M1 designed at the 3'end of the RAP-PCR fragments obtained in M: (5'-CAGAGTGGTTATTGTCAGGGT-3').
For fragment C: M2 designed at the 5'end of the RAP-PCR fragment obtained in M: (5'-GTAGAACTAGGAGCATATG-3') and F1 designed at the 3'end of the RAP-PCR fragments obtained in F: (5'-TCCCCAATGTAGATACTGCTTC-3').
Fragments were purified from the gel, cloned and sequenced as described before.

RT-PCR for diagnosing MPV.

For the amplification and sequencing of parts of the N, M, F and L ORFs of nine of the MPV isolates, we used primers N3 (5'-GCACTCAAGAGATACCCTAG -3') and N4 (5'-AGACTTTCTGCTTTGCTGCCTG-3'), amplifying a 151 nucleotide fragments, M3 (5'-CCCTGACAATAACCACTCTG-3') and M4 (5'-GCCAACTGATTTGGCTGAGCTC-3') amplifying a 252 nucleotide fragment, F7 (5'-TGCACTATCTCCTCTTGGGGCTTTG-3') and F8 (5'-TCAAAGCTGCTTGACACTGGCC-3') amplifying a 221 nucleotide fragment and L6 (5'-CATGCCCACTATAAAAGGTCAG-3') and L7 (5'-CACCCCAGTCTTTCTTGAAA-3') amplifying a 173 nucleotide fragment respectively. RT-PCR, gel purification and direct sequencing were performed as described above. Furthermore, probes used were:

Probe used in M: 5'-TGC TTG TAC TTC CCA AAG-3'
Probe used in N: 5'-TAT TTG AAC AAA AAG TGT-3'
Probe used in L: 5'-TGGTGTGGGATATTAACAG-3'

Phylogenetic analyses

For all phylogenetic trees, DNA sequences were alligned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phylip 3.5 program using 100 bootstraps and 3 jumbles[15]. Previously published sequences that were used for the generation of phylogenetic trees are available from Genbank under accessions numbers : For all ORFs: hRSV: NC001781; bRSV: NC001989; For the F ORF: PVM, D11128; APV-A, D00850; APV-B, Y14292; APV-C, AF187152; For the N ORF: PVM, D10331; APV-A, U39295; APV-B, U39296; APV-C, AF176590; For the M ORF: PMV,U66893; APV-A, X58639; APV-B, U37586; APV-C, AF262571; For the P ORF: PVM, 09649; APV-A, U22110, APV-C, AF176591. Phylogenetic analyses for the nine different virus isolates of MPV were performed with APV strain C as outgroup.

Abbreviations used in figures: hRSV: human RSV; bRSV: bovine RSV; PVM: pneumonia virus of mice; APV-A, B,and C: avian pneumovirus typ A, B and C.

Examples of methods to identify MPV

Specimen collection

In order to find virus isolates nasopharyngeal aspirates, throat and nasal swabs, broncheo alveolar lavages preferably from mammals such as humans, carnivores (dogs, cats, mustellits, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostriches, etc) should be examined. From birds cloaca swabs and droppings can be examined as well. Sera should be collected for immunological assays, such as ELISA and virus neutralisation assays.

Collected virus specimens were diluted with 5 ml Dulbecco MEM medium (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot slide (Nutacon, Leimuiden, The Netherlands) for immunofluorescence techniques, and the supernatant was used for virus isolation.

Virus isolation

For virus isolation tMK cells (RIVM, Bilthoven, The Netherlands) were cultured in 24 well plates containing glass slides (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium). Before inoculation the plates were washed with PBS and supplied with Eagle's MEM with Hanks' salt (ICN, Costa mesa, CA) supplemented with 0.52/liter gram $NaHCO_3$, 0.025 M Hepes (Biowhittaker), 2 mM L-glutamine (Biowhittaker), 200 units/liter penicilline, 200 µg/liter streptomycine (Biowhittaker), 1gram/liter lactalbumine (Sigma-Aldrich, Zwijndrecht, The Netherlands), 2.0 gram/liter D-glucose (Merck, Amsterdam, The Netherlands), 10 gram/liter peptone (Oxoid, Haarlem, The Netherlands) and 0.02% trypsine (Life Technologies, Bethesda, MD). The plates were inoculated with supernatant of the nasopharyngeal aspirate samples, 0,2 ml per well in triplicate, followed by centrifuging at 840x *g* for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 14 days changing the medium once a week and cultures were checked daily for CPE. After 14 days, cells were scraped from the second passage and incubated for another 14 days. This step was repeated for the third passage. The glass slides were used to demonstrate the presence of the virus by indirect IFA as described below.
CPE was generally observed after the third passage, at day 8 to 14 depending on the isolate. The CPE was virtually indistinghuisable from that caused by hRSV or hPIV in tMK or other cell cultures. However, hRSV induces CPE starting around day 4. CPE was characterised by syncytia formation, after which the cells showed rapid internal disruption, followed by detachment of cells from the monolayer. For some isolates CPE was difficult to observe, and IFA was used to confirm the presence of the virus in these cultures.

Virus culture of MPV

Sub-confluent monolayers of tMK cells in media as described above were inoculated with supernatants of samples that displayed CPE after two or three passages in the 24 well plates. Cultures were checked for CPE daily and the media was changed once a week. Since CPE differed for each isolate, all cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, aliquoted and stored frozen at -70 °C. The 50% tissue culture infectious doses (TCID50) of virus in the culture supernatants were determined following established techniques used in the field[16].

Virus characterisation

Haemagglutination assays and chloroform sensitivity tests were performed following well established and described techniques used in the field[14]. For EM analyses, virus was concentrated from infected cell culture supernatants in a micro-centrifuge at 4 ° C at 17000 x g, after which the pellet was resuspended in PBS and inspected by negative contrast EM.

Antigen detection by indirect IFA

Collected specimens were processed as described and sediment of the samples was spread on a multispot slide. After drying, the cells were fixed in aceton for 1 minute at room temperature.

Alternatively, virus was cultured on tMK cells in 24 well slides containing glass slides. These glass slides were washed with PBS and fixed in aceton for 1 minute at room temperature.

After washing with PBS the slides were incubated for 30 minutes at 37 °C with polyclonal antibodies at a dilution of 1:50 to 1:100 in PBS. We used immunised ferrets and guinea pigs to obtain polyclonal antibodies, but these antibodies can be raised in various animals, and the working dilution of the polyclonal antibody can vary for each immunisation. After three washes with PBS and one wash with tap water, the slides were incubated at 37°C for 30 minutes with FITC labeled goat-anti-ferret antibodies (KPL, Guilford, UK, 40 fold diluted). After three washes in PBS and one in tap water, the slides were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The slides were analysed using an Axioscop fluorescence microscope (Carl Zeiss B.V., Weesp, the Netherlands).

Detection of antibodies in humans, mammals, ruminants or other animals by indirect IFA

For the detection of virus specific antibodies, infected tMK cells with MPV were fixed with acetone on coverslips (as described above), washed with PBS and incubated 30 minutes at 37°C with serum samples at a 1 to 16 dilution. After two washes with PBS and one with tap water, the slides were incubated 30 minutes at 37°C with FITC-labelled secondary antibodies to the species used (Dako). Slides were processed as described above.

Antibodies can be labelled directly with a fluorescent dye, which will result in a direct immuno fluorescence assay. FITC can be replaced with any fluorescent dye.

Animal immunisation

Ferret and guinea pig specific antisera for the newly discovered virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurised glove boxes. Two to three weeks later the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for all previous described viruses with indirect IFA as described below. Other animal species are also suitable for the generation of specific antibody preparations and other antigen preparations may be used.

Virus neutralisation assay (VN assay)

VN assays were performed with serial two-fold dilutions of human and animal sera starting at an eight-fold dilution. Diluted sera were incubated for one hour with 100 TCID50 of virus before inoculation of tMK cells grown in 96 well plates, after which the plates were centrifuged at 840 x *g*. The same culture media as described above was used. The media was changed after three and six days, and after 8 days IFA was performed (see above). The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in cell cultures.

RNA isolation

RNA was isolated from the supernatant of infected cell cultures or sucrose gradient fractions using a High Pure RNA Isolation kit according to instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands). RNA can also be isolated following other procedures known in the field (*Current Protocols in Molecular Biology*).

RT-PCR

A one-step RT-PCR was performed in 50 µl reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM $MgCl_2$, 2 mM dithiotreitol, 200 µM each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de Ijssel, The Netherlands) and 5 µl RNA. Cycling conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at 42 °C and 3 min. at 72 °C repeated 40 times and 10 min. at 72 °C once.

Primers used for diagnostic PCR:

In the nucleoprotein: N3 (5'-GCACTCAAGAGATACCCTAG -3') and N4 (5'-AGACTTTCTGCTTTGCTGCCTG-3'), amplifying a 151 nucleotide fragment.

In the matrixprotein: M3 (5'-CCCTGACAATAACCACTCTG-3') and M4 (5'-GCCAACTGATTTGGCTGAGCTC-3') amplifying a 252 nucleotide fragment

In the polymerase protein: L6 (5'-CATGCCCACTATAAAAGGTCAG-3') and L7 (5'-CACCCCAGTCTTTCTTGAAA-3') amplifying a 173 nucleotide fragment.

Other primers can be designed based on MPV sequences, and different buffers and assay conditions may be used for specific purposes.

Sequence analysis

Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). All techniques were performed according to the instructions of the manufacturer. PCR fragments were sequenced directly with the same oligonucleotides used for PCR, or the fragments were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacturer and subsequently sequenced with M13-specific oligonucleotides.

Oligonucleotides used for analysing the 3'end of the genome (absence of NS1/NS2). Primer TR1 (5'-AAAGAATTCACGAGAAAAAAACGC-3') was designed based on published sequences of the trailer and leader for hRSV and APV, published by Randhawa (1997) and primer N1 (5'-CTGTGGTCTCTAGTCCCACTTC-3') was designed based on obtained sequences in the N protein. The RT-PCR assay and sequencing was performed as described above.
The RT-PCR gave a product of approximately 500 base pairs which is to small to contain information for two ORFS, and translation of these sequences did not reveal an ORF.

Detection of antibodies in humans, mammals, ruminants or other animals by ELISA

In *Paramyxoviridae*, the N protein is the most abundant protein, and the immune response to this protein occurs early in infection. For these reasons, a recombinant source of the N proteins is preferably used for developing an ELISA assay for detection of antibodies to MPV. Antigens suitable for antibody detection include any MPV protein that combines with any MPV-specific antibody of a patient exposed to or infected with MPV virus. Preferred antigens of the invention include those that predominantly engender the immune response in patients exposed to MPV, which therefore, typically are recognised most readily by antibodies of a patient. Particularly preferred antigens include the N, F and G proteins of MPV.
Antigens used for immunological techniques can be native antigens or can be modified versions thereof. Well known techniques of molecular biology can be used to alter the amino acid sequence of a MPV antigen to produce modified versions of the antigen that may be used in immunologic techniques.
Methods for cloning genes, for manipulating the genes to and from expression vectors, and for expressing the protein encoded by the gene in a heterologous host are well-known, and these techniques can be used to provide the expression vectors, host cells, and the for expressing cloned genes encoding antigens in a host to produce

recombinant antigens for use in diagnostic assays. See for instance: *Molecular cloning, A laboratory manual* and *Current Protocols in Molecular Biology.*

A variety of expression systems may be used to produce MPV antigens. For instance, a variety of expression vectors suitable to produce proteins in *E.Coli, B.subtilis,* yeast, insect cells and mammalian cells have been described, any of which might be used to produce a MPV antigen suitable to detect anti-MPV antibodies in exposed patients.

The baculovirus expression system has the advantage of providing necessary processing of proteins, and is therefor preferred. The system utilizes the polyhedrin promoter to direct expression of MPV antigens. (Matsuura et al. 1987, J.Gen.Virol. 68: 1233-1250).

Antigens produced by recombinant baculo-viruses can be used in a variety of immunological assays to detect anti-MPV antibodies in a patient. It is well established, that recombinant antigens can be used in place of natural virus in practically any immunological assay for detection of virus specific antibodies.

The assays include direct and indirect assays, sandwich assays, solid phase assays such as those using plates or beads among others, and liquid phase assays. Assays suitable include those that use primary and secondary antibodies, and those that use antibody binding reagents such as protein A. Moreover, a variety of detection methods can be used in the invention, including colorimetric, fluorescent, phosphorescent, chemiluminescent, luminescent and radioactive methods.

Example 1 of indirect anti-MPV IgG EIA using recombinant N protein

An indirect IgG EIA using a recombinant N protein (produced with recombinant baculo-virus in insect (Sf9) cells) as antigen can be performed. For antigen preparation, Sf9 cells are infected with the recombinant baculovirus and harvested 3-7 days post infection. The cell suspension is washed twice in PBS, pH 7.2, adjusted to a cell density of 5.0X 10^6 cells/ml, and freeze-thawed three times. Large cellular debris is pelleted by low speed centrifugation (500 x g for 15 min.) and the supernatant is collected and stored at -70°C until use. Uninfected cells are processed similarly for negative control antigen.

100 μl of a freeze-thaw lysate is used to coat microtiter plates, at dilutions ranging from 1:50 to 1:1000. An uninfected cell lysate is run in duplicate wells and serves as a

negative control. After incubation overnight, plates are washed twice with PBS/0.05%Tween.Test sera are diluted 1:50 to 1:200 in ELISA buffer (PBS, supplemented to 2% with normal goat sera, and with 0.5% bovine serum albumine and 0.1% milk), followed by incubation wells for 1 hour at 37°C.

Plates are washed two times with PBS/0.05%Tween. Horseradish peroxidase labelled goat anti-human (or against other species) IgG, diluted 1:3000 to 1:5000 in ELISA buffer, added to wells, and incubated for 1 hour at 37°. The plates are then washed two times with PBS/0.05%Tween and once with tap water, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3,3',5,5' tetramethylbenzidine, such as that obtained from Sigma, and the reaction is stopped with 100 µl of 2 M phosphoric acid. Colorimetric readings are measured at 450 nm using an automated microtiter plate reader.

Example 2: Capture anti-MPV IgM EIA using a recombinant nucleoprotein

A capture IgM EIA using the recombinant nucleoprotein or any other recombinant protein as antigen can be performed by modification of assays as previously described by Erdman et al (1990) J.Clin.Microb. 29: 1466-1471.
Affinity purified anti-human IgM capture antibody (or against other species), such as that obtained from Dako, is added to wells of a microtiter plate in a concentration of 250 ng per well in 0.1 M carbonate buffer pH 9.6. After overnight incubation at room temperature, the plates are washed two times with PBS/0.05% Tween. 100 µl of test serum diluted 1:200 to_1:1000 in ELISA buffer is added to triplicate wells and incubated for 1 hour at 37°C. The plates are then washed two times with in PBS/0.05%Tween.
The freeze-thawed (infected with recombinant virus) Sf21 cell lysate is diluted 1:100 to 1: 500 in ELISA buffer is added to the wells and incubated for 2 hours at 37°C. Uninfected cell lysate serves as a negative control and is run in duplicate wells.
The plates are then washed three times in PBS/0.05% Tween and incubated for 1 hour at 37°C with 100 µl of a polyclonal antibody against MPV in a optimal dilution in ELISA buffer. After 2 washes with PBS/0.05% Tween , the plates are incubated

with horseradish peroxide labeled secondary antibody (such as rabbit anti ferret), and the plates are incubated 20 minutes at 37°C.
The plates are then washed five times in PBS/0/05% Tween, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3,3',5,5' tetramethylbenzidine, as, for instance obtained from "Sigma", and the reaction is stopped with 100 µl of 2M phosphoric acid. Colormetric readings are measured at 450 nm using automated microtiter plate reader.

The sensitivities of the capture IgM EIAs using the recombinant nucleoprotein (or other recombinant protein) and whole MPV virus are compared using acute-and convalescent-phase serum pairs form persons with clinical MPV virus infection. The specificity of the recombinant nucleoprotein capture EIA is determined by testing serum specimens from healthy persons and persons with other paramyxovirus infections.

Potential for EIAs for using recombinant MPV fusion and glycoprotein proteins produced by the baculovirus expression.

The glycoproteins G and F are the two transmembraneous envelope glycoproteins of the MPV virion and represent the major neutralisation and protective antigens. The expression of these glycoproteins in a vector virus system sych as a baculovirus system provides a source of recombinant antigens for use in assays for detection of MPV specific antibodies. Moreover, their use in combination with the nucleoprotein, for instance, further enhances the sensitivity of enzyme immunoassays in the detection of antibodies against MPV.

A variety of other immunological assays (*Current Protocols in Immunology*) may be used as alternative methods to those described here.
In order to find virus isolates nasopharyngeal aspirates, throat and nasal swabs, broncheo alveolar lavages and throat swabs preferable from but not limited to humans, carnivores (dogs, cats, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostridges, etc) can be examined. From birds, cloaca and intestinal swabs and droppings can be examined as well. For all samples,

serology (antibody and antigen detection etc.), virus isolation and nucleic acid detection techniques can be performed for the detection of virus.
Monoclonal antibodies can be generated by immunising mice (or other animals) with purified MPV or parts thereof (proteins, peptides) and subsequently using established hybridoma technology (*Current protocols in Immunology*). Alternatively, phage display technology can be used for this purpose (*Current protocols in Immunology*). Similarly, polyclonal antibodies can be obtained from infected humans or animals, or from immunised humans or animals (*Current protocols in Immunology*).

The detection of the presence or absence of NS1 and NS2 proteins can be performed using western-blotting, IFA, immuno precipitation techniques using a variety of antibody preparations. The detection of the presence or absence of NS1 and NS2 genes or homologues thereof in virus isolates can be performed using PCR with primer sets designed on the basis of known NS1 and/or NS2 genes as well as with a variety of nucleic acid hybridisation techniques.

To determine whether NS1 and NS2 genes are present at the 3' end of the viral genome, a PCR can be performed with primers specific for this 3' end of the genome. In our case, we used a primer specific for the 3' untranslated region of the viral genome and a primer in the N ORF. Other primers may be designed for the same purpose. The absence of the NS1/NS2 genes is revealed by the length and/or nucleotide sequence of the PCR product. Primers specific for NS1 and/or NS2 genes may be used in combination with primers specific for other parts of the 3' end of the viral genome (such as the untranslated region or N, M or F ORFs) to allow a positive identification of the presence of NS1 or NS2 genes. In addition to PCR, a variety of techniques such as molecular cloning, nucleic acid hybridisation may be used for the same purpose.

Example 3: Different serotypes/subgroups of MPV

Two potential genetic clusters are identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of 9 virus isolates. 90 -100% nucleotide identity was observed within a cluster, and 81-88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate ned/00/01 as prototype of cluster A, and virus isolate ned/99/01 as prototype of cluster B have been used in cross neutralization assays to test whether the genotypes are related to different serotypes or subgroups.

Results

Using RT-PCR assays with primers located in the polymerase gene, we identified 30 additional virus isolates from nasopharyngeal aspirate samples. Sequence information of parts of the matrix and polymerase genes of these new isolates together with those of the previous 9 isolates were used to construct phylogenetic trees (Figure 16). Analyses of these trees confirmed the presence of two genetic clusters, with virus isolate ned/00/00-1 as the prototype virus in group A and virus isolate ned/99/01 as the prototype virus in group B. The nucleotide sequence identity within a group was more than 92%, while between the clusters the identity was 81-85%.

Virus isolates ned/00/01 and ned/99/01 have been used to inoculate ferrets to raise virus-specific antisera. These antisera were used in virus neutralization assays with both viruses.

Table 3:

Virus neutralization titers

	isolate 00-1	isolate 99-1
preserum ferret A (00-1)	□2	□2
ferret A 22 dpi (00-1)	64	□2
preserum ferret B (99-1)	□2	□ 2
ferret B 22 dpi (99-1)	4	64

For isolate 00-1 the titer differs 32 (64/2) fold
For isolate 99-1 the titer differs 16 (64/4) fold

In addition, 6 guinea pigs have been inoculated with either one of the viruses (ned/00/01 and ned/99/01). RT-PCR assays on nasopharyngeal aspirate samples showed virus replication from day 2 till day 10 post infection. At day 70 post infection the guinea pigs have been challenged with either the homologous or the heterologous virus, and for in all four cases virus replication has been noticed.

Table 4

	primary infection	virus replication	secondary infection	virus replication
guinea pig 1-3	00-1	2 out of 3	99-1	1 out of 2
guinea pig 4-6	00-1	3 out of 3	00-1	1 out of 3
guinea pig 7-9	99-1	3 out of 3	00-1	2 out of 2
guinea pig 10-12	99-1	3 out of 3	99-1	1 out of 3

note: for the secondary infection guinea pig 2 and 9 were not there any more .

Virus neutralization assays with anti sera after the first challenge showed essentially the same results as in the VN assays performed with the ferrets (> 16-fold difference in VN titer).

The results presented in this example confirm the existence of two genotypes, which correspond to two serotypes of MPV, and show the possibility of repeated infection with heterologous and homologous virus

Example 4: Further sequence determination

This example describes the further analysis of the sequences of MPV open reading frames (ORFs) and intergenic sequences as well as partial sequences of the genomic termini.
Sequence analyses of the nucleoprotein (N), phosphoprotein (P), matrixprotein (M) and fusion protein (F) genes of MPV revealed the highest degree of sequence homology with APV serotype C, the avian pneumovirus found primarily in birds in the United States. These analyses also revealed the absence of non-structural proteins NS1 and NS2 at the 3'end of the viral genome and positioning of the fusion protein immediately adjacent to the matrix protein. Here we present the sequences of the 22K (M2) protein, the small hydrophobic (SH) protein, the attachment (G) protein and the polymerase (L) protein genes, the intergenic regions and the trailer sequence. In combination with the sequences described previously the sequences presented here complete the genomic sequence of MPV with the exception of the extreme 12-15 nucleotides of the genomic termini and establish the genomic organisation of MPV. Side by side comparisons of the sequences of the MPV genome with those of APV subtype A, B and C, RSV subtype A and B, PVM and other paramyxoviruses provides strong evidence for the classification of MPV in the *Metapneumovirus* genus.

Results

Sequence strategy

MPV isolate 00-1 (van den Hoogen *et al.*, 2001) was propagated in tertiary monkey kidney (tMK) cells and RNA isolated from the supernatant 3 weeks after inoculation was used as template for RT-PCR analyses. Primers were designed on the basis of the partial sequence information available for MPV 00-1 (van den Hoogen *et al.*, 2001) as well as the leader and trailer sequences of APV and RSV (Randhawa *et al.*, 1997; Mink *et al.*, 1991). Initially, fragments between the previously obtained products, ranging in size from 500 bp to 4 Kb in length, were generated by RT-PCR amplification and sequenced directly. The genomic sequence was subsequently confirmed by generating a series of overlapping RT-PCR fragments ranging in size from 500 to 800 bp that represented the entire MPV genome. For all PCR fragments, both strands were sequenced directly to minimize amplification and sequencing errors. The nucleotide and amino acid sequences were used to search for homologies with sequences in the Genbank database using the BLAST software (www.ncbi.nlm.nih.gov/BLAST). protein names were assigned to open reading frames (ORFs) based on homology with known viral genes as well as their location in the genome. Based on this information, a genomic map for MPV was constructed (Figure 7). The MPV genome is 13378 nucleotides in length and its organization is similar to the genomic organization of APV. Below, we present a comparison between the ORFs and non-coding sequences of MPV and those of other paramyxoviruses and discuss the important similarities and differences.

The nucleoprotein (N) gene

As shown, the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses. The length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaller than those of other paramyxoviruses (Barr *et al.*, 1991). Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7-11% with other paramyxoviruses (Table 6).

Barr *et al* (1991) identified 3 regions of similarity between viruses belonging to the order *Mononegavirales*: A, B and C (Figure 8). Although similarities are highest within a virus family, these regions are highly conserved between virus familys. In all three regions MPV revealed 97% aa sequence identity with APV-C, 89% with APV-B, 92% with APV-A, and 66-73% with RSV and PVM. The region between aa residues 160 and 340 appears to be highly conserved among metapneumoviruses and to a somewhat lesser extent the *Pneumovirinae* (Miyahara *et al.*, 1992; Li *et al.*, 1996; Barr *et al.*, 1991). This is in agreement with MPV being a metapneumovirus, showing 100% similarity with APV C.

The phosphoprotein (P) gene

The second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 6). The P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses (Reviewed in Lamb and Kolakofsky, 1996; Sedlmeier *et al.*, 1998).

In contrast to APV A and B and PVM and similar to RSV and APV-C the MPV P ORF lacks cysteine residues. Ling (1995) suggested that a region of high similarity between all pneumoviruses (aa 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex. This region of high similarity is also found in MPV (Figure 9) especifically when conservative substitutions are taken in account, showing 100% similarity with APV-C, 93 % with APV-A and B, and approximately 81% with RSV. The C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling *et al.*, 1995).

The matrix (M) protein gene

The third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses. The M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses (Table 5) and shows high aa sequence homology with the matrix proteins of APV (78-87%), lower homology with those of RSV and PVM (37-38%) and 10% or less homology with those of other paramyxoviruses (Table 6).

Easton (1997) compared the sequences of matrix proteins of all pneumoviruses and found a conserved heptadpeptide at residue 14 to 19 that is also conserved in MPV (Figure 10). For RSV, PVM and APV small secondary ORFs within or overlapping with the major ORF of M have been identified (52 aa and 51 aa in bRSV, 75 aa in RSV, 46 aa in PVM and 51 aa in APV) (Yu *et al.*, 1992; Easton *et al.*, 1997; Samal *et al.*, 1991; Satake *et al.*, 1984). We noticed two small ORFs in the M ORF of MPV. One small ORF of 54 aa residues was found within the major M ORF (fragment 1, Figure 7), starting at nucleotide 2281 and one small ORF of 33 aa residues was found overlapping with the major ORF of M starting at nucleotide 2893 (fragment 2, Figure 7). Similar to the secondary ORFs of RSV and APV there is no significant homology between these secondary ORFs and secondary ORFs of the other pneumoviruses, and apparent start or stop signals are lacking. In addition, evidence for the synthesis of proteins corresponding to these secondary ORFs of APV and RSV has not been reported.

The fusion protein (F) gene

The F ORF of MPV is located adjacent to the M ORF, which is characteristic for members of the *Metapneumovirus* genus. The F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C (Table 5). Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6). One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues (Morrison, 1988; Yu *et al.*, 1991). The metapneumoviruses share 12 cysteine residues in F1 (7 are conserved among all paramyxoviruses), and two in F2 (1 is conserved among all paramyxoviruses). Of the 3 potential *N*-linked glycosylation sites present in the F ORF of MPV, none are shared with RSV and two (position 74 and 389) are shared with APV. The third, unique, potential *N*-linked glycosylation site for MPV is located at position 206 (Figure 11).

Despite the low sequence homology with other paramyxoviruses, the F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other *Paramyxoviridae* family members (Morrison, 1988). F proteins of *Paramyxoviridae* members are synthesized as inactive precursors (F0) that are cleaved by host cell proteases which generate amino terminal F2 subunits and large carboxy terminal F1 subunits. The proposed cleavage site (Collins *et al.*, 1996) is conserved among all members of the *Paramyxoviridae* family. The cleavage site of MPV contains the residues RQSR. Both arginine (R) residues are shared with APV and RSV, but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilliviruses (data not shown).

The hydrophobic region at the amino terminus of F1 is thought to function as the membrane fusion domain and shows high sequence similarity among paramyxoviruses and morbilliviruses and to a lesser extent the pneumoviruses (Morrison, 1988). These 26 residues (position 137-163, Figure 11) are conserved between MPV and APV-C, which is in agreement with this region being highly conserved among the metapneumoviruses (Naylor *et al.*, 1998; Seal *et al.*, 2000).

As is seen for the F2 subunits of APV and other paramyxoviruses, MPV revealed a deletion of 22 aa residues compared with RSV (position 107-128, Figure 11). Furthermore, for RSV and APV, the signal peptide and anchor domain were found to be conserved within subtypes and displayed high variability between subtypes (Plows *et al.*, 1995; Naylor *et al.*, 1998). The signal peptide of MPV (aa 10-35, Figure 11) at the amino terminus of F2 exhibits some sequence similarity with APV-C (18 out of 26 aa residues are similar) and less conservation with other APVs or RSV. Much more variability is seen in the membrane anchor domain at the carboxy terminus of F1, although some homology is still seen with APV-C.

The 22K (M2) protein

The M2 gene is unique to the *Pneumovirinae* and two overlapping ORFs have been observed in all pneumoviruses. The first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Collins *et al.*, 1995; Collins, 1996) and its readthrough of intergenic regions (Hardy *et al.*, 1998; Fearns *et al.*, 1999). The M2-1 gene for MPV, located adjacent to the F gene, encodes a 187 aa protein (Table 5), and reveals the highest (84%) homology with M2-1 of APV-C (Table 6). Comparison of all pneumovirus M2-1 proteins revealed the highest conservation in the amino-terminal half of the protein (Collins *et al.*, 1990; Zamora *et al.*, 1992; Ahmadian *et al.*, 1999), which is in agreement with the observation that MPV displays 100% similarity with APV-C in the first 80 aa residues of the protein (Figure 12A). The MPV M2-1 protein contains 3 cysteine residues located within the first 30 aa residues that are conserved among all pneumoviruses. Such a concentration of cysteines is frequently found in zinc-binding proteins (Ahmadian *et al.*, 1991; Cuesta et al., 2000).

The secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA replication and transcription (Collins *et al.*, 1985; Elango *et al.*, 1985; Baybutt *et al.*, 1987; Collins et al., 1990; Ling *et al.*, 1992; Zamora *et al.*, 1992; Alansari *et al.*, 1994; Ahmadian *et al.*, 1999; Bermingham *et al.*, 1999). For MPV, the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF (Figure 7), which is exactly the same start position as for APV-C. The length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues (Table 5). Sequence comparison of the M2-2 ORF (Figure 12B) revealed 64% aa sequence homology between MPV and APV-C and only 44-48% aa sequence homology between MPV and APV-A and B (Table 6).

The small hydrophobic protein (SH) ORF

The gene located adjacent to M2 of hMPV probably encodes a 183 aa SH protein (Fig. 1 and 7). There is no discernible sequence identity between this ORF and other RNA virus genes or gene products. This is not surprising since sequence similarity between pneumovirus SH proteins is generally low. The putative SH ORF of hMPV is the longest SH ORF known to date (Table 1). The aa composition of the SH ORF is relatively similar to that of APV, RSV and PVM, with a high percentage of threonine and serine residues (22%, 18%, 19%, 20.0%, 21% and 28% for hMPV, APV, RSV A, RSV B, bRSV and PVM respectively). The SH ORF of hMPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues. The SH ORF of hMPV contains two potential *N*-linked glycosylation sites (aa 76 and 121), whereas APV has one, RSV has two or three and PVM has four.

The hydrophilicity profiles for the putative hMPV SH protein and SH of APV and RSV revealed similar characteristics (Fig. 7B). The SH ORFs of APV and hMPV have a hydrophilic N-terminus, a central hydrophobic domain which can serve as a potential membrane spanning domain (aa 30-53 for hMPV), a second hydrophobic domain (aa 155-170) and a hydrophilic C-terminus. In contrast, RSV SH appears to lack the C-terminal part of the APV and hMPV ORFs. In all pneumovirus SH proteins the hydrophobic domain is flanked by basic aa residues, which are also found in the SH ORF for hMPV (aa 29 and 54).

The attachment glycoprotein (G) ORF

The putative G ORF of hMPV is located adjacent to the putative SH gene and encodes a 236 aa protein (nt 6262-6972, Fig. 1). A secondary small ORF is found immediately following this ORF, potentially coding for 68 aa residues (nt 6973-7179) but lacking a start codon. A third potential ORF in the second reading frame of 194 aa residues is overlapping with both of these ORFs but also lacks a start codon (nt 6416-7000). This ORF is followed by a potential fourth ORF of 65 aa residues in the same reading frame (nt 7001-7198), again lacking a start codon. Finally, a potential ORF of 97 aa residues (but lacking a start codon) is found in the third reading frame (nt 6444-6737, Fig. 1). Unlike the first ORF, the other ORFs do not have apparent gene start or gene end sequences (see below). Although the 236 aa G ORF probably represents at least a part of the hMPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no sequence identity between the predicted aa sequences for different viruses (Ling *et al.*, 1992). The secondary ORFs in hMPV G do not reveal characteristics of other G proteins and whether the additional ORFs are expressed requires further investigation.

BLAST analyses with all ORFs revealed no discernible sequence identity at the nucleotide or aa sequence level with other known virus genes or gene products. This is in agreement with the low percentage sequence identity found for other G proteins such as those of hRSV A and B (53%) (Johnson *et al.*, 1987) and APV A and B (38%) (Juhasz and Easton, 1994).

Whereas most of the hMPV ORFs resemble those of APV both in length and sequence, the putative G ORF of 236 aa residues of hMPV is considerably smaller than the G ORF of APV (Table 1). The aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV. The putative G ORF also contains 8.5% proline residues, which is higher than the 8% for RSV and 7% for APV. The unusual abundance of proline residues in the G proteins of APV, RSV and hMPV has also been observed in glycoproteins of mucinous origin where it is a major determinant of the proteins three dimensional structure (Collins and Wertz, 1983; Wertz *et al.*, 1985; Jentoft, 1990). The G ORF of hMPV contains five potential *N*-linked glycosylation sites, whereas hRSV has seven, bRSV has five and APV has three to five.

The predicted hydrophilicity profile of hMPV G revealed characteristics similar to the other pneumoviruses. The N-terminus contains a hydrophilic region followed by a short hydrophobic area (aa 33-53 for hMPV) and a mainly hydrophilic C-terminus (Fig. 8B). This overall organization is consistent with that of an anchored type II transmembrane protein and corresponds well with these regions in the G protein of APV and RSV. The putative G ORF of hMPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively). Of note, only two of the four secondary ORFs in the G gene contained one additional cysteine residue and these four potential ORFs revealed 12-20% serine and threonine residues and 6-11% proline residues.

The polymerase gene (L)

In analogy to other negative strand viruses, the last ORF of the MPV genome is the RNA-dependent RNA polymerase component of the replication and transcription complexes. The L gene of MPV encodes a 2005 aa protein, which is 1 residue longer than the APV-A protein (Table 5). The L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6). Poch *et al.* (1989; 1990) identified six conserved domains within the L proteins of non-segmented negative strand RNA viruses, from which domain III contained the four core polymerase motifs that are thought to be essential for polymerase function. These motifs (A, B, C and D) are well conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% similarity with all pneumoviruses and in motif D MPV shares 100 % similarity with APV and 92% with RSV's. For the entire domain III (aa 627- 903 in the L ORF), MPV shares 77% identity with APV, 61-62% with RSV and 23-27% with other paramyxoviruses (Figure 15). In addition to the polymerase motifs the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif $K(X)_{21}GEGAGN(X)_{20}K$ (Stec, 1991).The MPV L ORF contains a similar motif as APV, in which the spacing of the intermediate residues is off by one: $K(x)_{22}GEGAGN(X)_{19}$ K.

Phylogenetic analyses

As an indicator for the relationship between MPV and members of the *Pneumovirinae*, phylogenetic trees based on the N, P, M, and F ORFs have been constructed previously (van den Hoogen *et al.*, 2001) and revealed a close relationship between MPV and APV-C. Because of the low homology of the MPV SH and G genes with those of other paramyxoviruses, reliable phylogenetic trees for these genes can not be constructed. In addition, the distinct genomic organization between members of the *Pneumovirus* and *Metapneumovirus* genera make it impossible to generate phylogenetic trees based on the entire genomic sequence. We therefore only constructed phylogenetic trees for the M2 and L genes in addition to those previously published. Both these trees confirmed the close relation between APV and MPV within the *Pneumovirinae* subfamily (Figure 16).

MPV non-coding sequences

The gene junctions of the genomes of paramyxoviruses contain short and highly conserved nucleotide sequences at the beginning and end of each gene (gene start and gene end signals), possibly playing a role in initiation and termination of transcription (Curran *et al.*, 1999). Comparing the intergenic sequences between all genes of MPV revealed a consensus sequence for the gene start signal of the N, P, M, F, M2 and G: GGGACAAGU (Figure 17A), which is identical to the consensus gene start signal of the metapneumoviruses (Ling *et al.*, 1992; Yu *et al.*, 1992; Li *et al.*, 1996; Bäyon-Auboyer *et al.*, 2000). The gene start signals for the SH and L genes of MPV were found to be slightly different from this consensus (SH: GGGAUAAAU, L: GAGACAAAU). For APV the gene start signal of L was also found to be different from the consensus: AGGACCAAT (APV-A) (Randhawa *et al.*, 1996) and GGGACCAGT (APV-D) (Bäyon-Auboyer *et al.*, 2000).
In contrast to the similar gene start sequences of MPV and APV, the consensus gene end sequence of APV, UAGUUAAUU (Randhawa *et al.*, 1996), could not be found in the MPV intergenic sequences. The repeated sequence found in most genes, except the G-L intergenic region, was U AAAAA U/A/C, which could possibly act as gene end signal. However, since we sequenced viral RNA rather than mRNA, definitive gene end signals could not be assigned and thus requires further investigation. The intergenic regions of pneumoviruses vary in size and sequence (Curran *et al.*, 1999; Blumberg *et al.*, 1991; Collins et al., 1983;). The intergenic regions of MPV did not reveal homology with those of APV and RSV and range in size from 10 to 228 nucleotides (Figure 17B). The intergenic region between the M and F ORFs of MPV contains part of a secondary ORF, which starts in the primary M ORF (see above). The intergenic region between SH and G contains 192 nucleotides, and does not appear to have coding potential based on the presence of numerous stop-codons in all three reading frames. The intergenic region between G and L contains 241 nucleotides, which may include additional ORFs (see above). Interestingly, the start of the L ORF is located in these secondary ORFs. Whereas the L gene of APV does not start in the preceding G ORF, the L ORF of RSV also starts in the preceding M2 gene. At the 3' and 5'extremities of the genome of paramyxoviruses short extragenic

region are referred to as the leader and trailer sequences, and approximately the first 12 nucleotides of the leader and last 12 nucleotides of the trailer are complementary, probably because they each contain basic elements of the viral promoter (Curran *et al.*, 1999; Blumberg *et al.*, 1991; Mink *et al.*, 1986). The 3'leader of MPV and APV are both 41 nucleotides in length, and some homology is seen in the region between nucleotide 16 and 41 of both viruses (18 out of 26 nucleotides) (Figure 17B). As mentioned before the first 15 nucleotides of the MPV genomic map are based on a primer sequence based on the APV genome. The length of the 5'trailer of MPV (188 nucleotides) resembles the size of the RSV 5'trailer (155 nucleotides), which is considerably longer than that of APV (40 nucleotides). Alignments of the extreme 40 nucleotides of the trailer of MPV and the trailer of APV revealed 21 out of 32 nucleotides homology, apart from the extreme 12 nucleotides which represent primer sequences based on the genomic sequence of APV. Our sequence analyses revealed the absence of NS1 and NS2 genes at the 3'end of the genome and a genomic organisation resembling the organisation of metapneumoviruses (3'-N-P-M-F-M2-SH-G-L-5'). The high sequence homology found between MPV and APV genes further emphasises the close relationship between these two viruses. For the N, P, M, F, M2-1 and M2-2 genes of MPV an overall amino acid homology of 79% is found with APV-C. In fact, for these genes APV-C and MPV revealed sequence homologies which are in the same range as sequence homologies found between subgroups of other genera, such as RSV- A and B or APV-A and B. This close relationship between APV-C and MPV is also seen in the phylogenetic analyses which revealed MPV and APV-C always in the same branch, separate from the branch containing APV-A and B. The identical genomic organisation, the sequence homologies and phylogentic analyses are all in favour of the classification of MPV as the first member in the *Metapneumovirus* genus that is isolatable from mammals. It should be noted that the found sequence variation between different virus isolates of MPV in the N, M, F and L genes revealed the possible existence of different genotypes (van den Hoogen *et al.*, 2001). The close relationship between MPV and APV-C is not reflected in the host range, since APV infects birds in contrast to MPV (van den Hoogen *et al.*, 2001). This difference in host range may be determined by the differences between the SH and G proteins of both viruses that are highly divergent. The SH and G proteins of MPV did not reveal significant aa sequence homology with SH and G proteins of any other virus. Although the amino acid content and hydrophobicity plots are in favour of defining these ORFs as SH and G, experimental data are required to assess their function. Such analyses will also shed light on the role of the additional overlapping ORFs in these SH and G genes. In addition, sequence analyses on the SH and G genes of APV-C might provide more insight in the function of the SH and G proteins of MPV and their relationship with those of APV-C. The noncoding regions of MPV were found to be fairly similar to those of APV. The 3'leader and 5' trailer sequences of APV and MPV displayed a high degree of homology. Although the lengths of the intergenic regions were not always the same for APV and MPV, the consensus gene start signals of most of the ORFs were found to be identical. In contrast, the gene end signals of APV were not found in the MPV genome. Although we did find a repetitive sequence (U AAAAA U/A/C) in most intergenic regions, sequence analysis of viral mRNAs is required to formally delineate those gene end sequences. It should be noted that sequence information for 15 nucleotides at the extreme 3'end and 12 nucleotides at the extreme 5'end is obtained by using modified rapid amplification of cDNA ends (RACE) procedures. This technique has been proven to be successful by others for related viruses (Randhawa, J.S. et al., Rescue of synthetic minireplicons establishes the absence of the NS1 and NS2 genes from avian pneumovirus. J. Virol, 71, 9849-9854 (1997); Mink, M.A., et al. Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA. Virology 185, 615-24 (1991).) To determine the sequence of the 3' vRNA leader sequence, a homopolymer A tail is added to purified vRNA using poly-A-polymerase and the leader sequence subsequently amplified by PCR using a poly-T primer and a primer in the N gene. To determine the sequence of the 5' vRNA trailer sequence, a cDNA copy of the trailer sequence is made using reverse transcriptase and a primer in the L gene, followed by homopolymer dG tailing of the cDNA with terminal transferase. Subsequently, the trailer region is amplified using a poly-C primer and a primer in the L gene. As an alternative strategy, vRNA is ligated to itself or synthetic linkers, after which the leader and trailer regions are amplified using primers in the L and N genes and linker-specific primers. For the 5' trailer sequence direct dideoxynucleotide sequencing of purified vRNA is also feasible (Randhawa, 1997). Using these approaches, we can analyse the exact sequence of the ends of the hMPV genome.. The sequence information provided here is of importance for the generation of diagnostic tests, vaccines and antivirals for MPV and MPV infections.

Materials and Methods

Sequence analysis

Virus isolate 00-1 was propagated to high titers (approximately 10,000 TCID50/ml) on tertiary monkey kidney cells as described previously (van den Hoogen *et al.*, 2001). Viral RNA was isolated from supernatants from infected cells using a High Pure RNA Isolating Kit according to instructions from the manufacturer (Roch Diagnostics, Almere, The Netherlands). Primers were designed based on sequences published previously (van den Hoogen *et al.*, 2001) in addition to sequences published for the leader and trailer of APV/RSV (Randhawa *et al.*, 1997; Mink *et al.*, 1991) and are available upon request. RT-PCR assays were conducted with viral RNA, using a one-tube assay in a total volume of 50µl with 50 mM Tris pH 8.5, 50 mM NaCl, 4.5 mM $MgCl_2$, 2 mM DTT, 1 µM forward primer, 1µM reverse primer, 0.6 mM dNTP's, 20 units RNAsin (Promega, Leiden, The Netherlands), 10 U AMV reverse transcriptase (Promega, Leiden, The Netherlands), and 5 units Taq Polymerase (PE Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). Reverse transcription was conducted at 42°C for 30 minutes, followed by 8 minutes inactivation at 95°C. The cDNA was amplified during 40 cycles of 95°C, 1 min.; 42°C, 2 min.72°C, 3 min. with a final extension at 72°C for 10 minutes. After examination on a 1% agarose gel, the RT-PCR products were purified from the gel using a Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and sequenced directly using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, the Netherlands) and an ABI 373 automatic DNA sequencer (PE Applied Biosystem, Nieuwerkerk aan den IJssel, the Netherlands), according to the instructions of the manufacturer.

Sequence alignments were made using the clustal software package available in the software package of BioEdit version5.0.6. (http://jwbrown.mbio.ncsu.edu/ Bioedit// bioedit.html; Hall, 1999).

Phylogenetic analysis

To construct phylogenetic trees, DNA sequences were aligned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phylip 3.5 program using 100 bootstraps and 3 jumbles. Bootstrap values were computed for consensus trees created with the consense package (Felsenstein, 1989).

The MPV genomic sequence is available from Genbank under accession number AF371337. All other sequences used here are available from Genbank under accession numbers AB046218 (measles virus, all ORFs), NC-001796 (human parainfluenza virus type 3, all ORFs), NC-001552 (Sendai virus, all ORFs), X57559 (human parainfluenza virus type 2, all ORFs), NC-002617 (New Castle Disease virus, all ORFs), NC-002728 (Nipah virus, all ORFs), NC-001989 (bRSV, all ORFs), M11486 (hRSV A, all ORFs except L), NC-001803 (hRSV, L ORF), NC-001781 (hRSV B, all ORFs), D10331 (PVM, N ORF), U09649 (PVM, P ORF), U66893 (PVM, M ORF), U66893 (PVM, SH ORF), D11130 (PVM, G ORF), D11128 (F ORF). The PVM M2 ORF was taken from Ahmadian (1999), AF176590 (APV-C, N ORF), U39295 (APV-A, N ORF), U39296 (APV-B, N ORF), AF262571 (APV-C, M ORF), U37586 (APV-B, M ORF), X58639 (APV-A, M ORF), AF176591 (APV-C, P ORF), AF325443 (APV-B, P ORF), U22110 (APV-A, P ORF), AF187152 (APV-C, F ORF), Y14292 (APV-B, F ORF), D00850 (APV-A, F ORF), AF176592 (APV-C, M2 ORF), AF35650 (APV-B, M2 ORF), X63408 (APV-A, M2 ORF), U65312 (APV-A, L ORF), S40185 (APV-A, SH ORF).

Table 5: Lengths of the ORFs of MPV and other paramyxoviruses.

	N[1]	P	M	F	M2-1	M2-2	SH	G	L
MPV	394	294	254	539	187	71	183	236	2005
APV A	391	278	254	538	186	73	174	391	2004
APV B	391	279	254	538	186	73	-[2]	414	-[2]
APV C	394	294	254	537	184	71	-[2]	-[2]	-[2]
APV D	-[2]	-[2]	-[2]	-[2]	-[2]	-[2]	-[2]	389	-[2]
hRSV A	391	241	256	574	194	90	64	298	2165
hRSV B	391	241	249	574	195	93	65	299	2166
bRSV	391	241	256	569	186	93	81	257	2162
PVM	393	295	257	537	176	77	92	396	-[2]
others[3]	418-542	225-709	335-393	539-565	-[4]	-[4]	-[4]	-[4]	2183-2262

Footnotes:

[1] length in amino acid residues.

[2] sequences not available

[3] others: human parainfluenza virus type 2 and 3, Sendai virus, measles virus, nipah virus, phocine distemper virus, and New Castle Disease virus.

[4] ORF not present in viral genome

Table 6: Amino acid sequence identity between the ORFs of MPV and those of other paramyxoviruses[1].

	N	P	M	F	M2-1	M2-2	L
APV A	69	55	78	67	72	26	64
APV B	69	51	76	67	71	27	-[2]
APV C	88	68	87	81	84	56	-[2]
hRSV A	42	24	38	34	36	18	42
hRSV B	41	23	37	33	35	19	44
bRSV	42	22	38	34	35	13	44
PVM	45	26	37	39	33	12	-[2]
others[3]	7-11	4-9	7-10	10-18	-[4]	-[4]	13-14

Footnotes:

1. No sequence homologies were found with known G and SH proteins and were thus excluded
2. Sequences not available.
3. See list in table 5, footnote 3.
4. ORF absent in viral genome.

References

Current Protocols in Molecular Biology, volume 1-3 (1994-1998). Ed. by Ausubel, F.M., Brent, R., Kinston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Published by John Wiley and sons, Inc., USA.

Current Protocols in Immunology, volume 1-3. Ed. by Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M. and Strobe, W. Published by John Wiley and sons, Inc., USA.

Sambrook et al. Molecular cloning, a laboratory manual, second ed., vol. 1-3. (Cold Spring Harbor Laboratory, 1989).

Fields, Virology. 1996. Vol. 1-2 3rd. Edition , Ed. by: Fields, B.N., Knipe, D.M. and Howley, P.M. Lippincott-Raven, Philadelpia, USA.

1. Pringle, C.R. Virus taxonomy at the Xith international congress of virology, Sydney, Australia 1999. *Arch. Virol.* **144/2**, 2065-2070 (1999).
2. Domachowske, J.B. & Rosenberg, H.F. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin. Microbio. Rev. **12(2)**, 298-309 (1999). Review.
3. Giraud, P., Bennejean, G., Guittet, M. & Toquin, D. Turkey rhinotracheitis in France: preliminary investigations on a ciliostatic virus. *Vet. Rec.* **119**, 606-607 (1986).
4. Ling, R., Easton, A.J. & Pringle, C.R. Sequence analysis of the 22K, SH and G genes of turkey rhinotracheitis virus and their intergenic regions reveals a gene order different from that of other pneumoviruses. *J. Gen. Virol.* **73**, 1709-1715 (1992).
5. Yu, Q., Davis, P.J., Li, J. & Cavanagh, D. Cloning and sequencing of the matrix protein (M) gene of turkey rhinotracheitis virus reveal a gene order different from that of respiratory syncytial virus. *Virology* **186**, 426-434 (1992).
6. Randhawa, J.S., Marriott, A.C., Pringle, C.R. & Easton, A.J. Rescue of synthetic minireplicons establishes the absence of the NS1 and NS2 genes from avian pneumovirus. *J. Virol.* **71**, 9849-9854 (1997).

7. Evans, A.S. In: *Viral Infections of Humans. Epidemiology and control.* 3th edn. (ed. Evans, A.S) 22-28 (Plenum Publishing Corporation, New York, 1989).

8. Osterhaus, A.D.M.E., Yang, H., Spijkers, H.E.M., Groen, J., Teppema, J.S. & van Steenis, G. The isolation and partial characterization of a highly pathogenic herpesvirus from the Harbor Seal (*Phoca vitulina*). *Arch.of Virol.* **86**, 239-251 (1985).

9. K.B. Chua *et al.* Nipah virus: a recently emergent deadly paramyxovirus. *Science* **288**, 1432-1435 (2000).

10. Welsh, J., Chada, K., Dalal, S.S., Cheng, R., Ralph, D. & McClelland, M. Arbitrarily primed PCR fingerprinting of RNA. *NAR.* **20**, 4965-4970 (1992).

11. Bayon-Auboyer, M., Arnauld, C., Toquin, D. & Eterradossi, N. Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup. *J. of Gen. Virol.* **81**, 2723-2733 (2000).

12. Mulder, J. & Masurel, N. Pre-epidemic antibody against 1957 strain of asiatic influenza in serum of older people living in The Netherlands. *The Lancet*, **april 19**, 810-814 (1958).

13. Pringle, C.R. In: *The Paramyxoviruses.* 1th edn.(ed. D.W. Kingsbury) 1-39 (Plenum Press, New York,1991).

14. Rothbarth, P.H., Groen, J., Bohnen, A.M., Groot, de R., & Osterhaus, A.D.M.E. Influenza virus serology-a comparative study. *J.of Virol. Methods* **78**, 163-169 (1999).

15. Brandenburg, A.H., Groen, J., van Steensel-Moll, H.A., Claas, E.J.C., Rothbarth, P.H., Neijens, H.J. & Osterhaus, A.D.M.E. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. *J.Med.Virol.* **52**, 97-104 (1997).

16. Lennette, D.A. et al. In: *Diagnostic procedures for viral, rickettsial, and chlamydial infections.* 7th edn. (eds. Lennette, E.H., Lennette, D.A. & Lennette, E.T.) 3-25; 37-138; 431-463; 481-494; 539-563 (American public health association, Washington, 1995).

15. Felsenstein, J. Department of Genetics, Universtity of Washington. Http://evolution.genetics.washington.edu/phylip.html

16. Schnell et al EMBO J 13, 4195-4203, 1994

17. Collins, P.L., Hill, M.G., Camargo, E., Grosfeld, H., Chanock, R.M. & Murphy, B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an esential role for the transcription elongation factor from the 5' proximal

open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. *PNAS* **92**, 11563-11567 (1995).

18. Hoffmann, E., Neumann, G., Kawakao, Y., Hobom, G. & Webster, R.G. A DNA transfection system for generation of influenza virus from eight plasmids. *PNAS* **97**, 6108-6113 (2000).

19. Bridgen, A., Elliot, R.M. Rescue of a segmented negative-strand virus entirely from cloned complementary DNAs. *PNAS* **93**, 15400-15404 (1996).

20. Palese, P., Zheng, H., Engelhardt, O.G., Pleschka, S. & Garcia-Sastre, A. Negative-strand RNA viruses: genetic engineering and applications. *PNAS* **93**, 11354-11358 (1996).

21. Peeters, B.P., de Leeuw, O.S., Koch, G. & Gielkens, A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. *J.Virol.* **73**, 5001-5009 (1999).

22. Durbin, A.P., Hall, S.L., Siew, J.W., Whitehead, S.S., Collins, P.L. & Murphy, B.R. Recovery of infectious human parainfluenza virus type 3 from cDNA. *Virology* **235**, 323-332 (1997).

23. Tao, T., Durbin, A.P., Whitehead, S.S., Davoodi, F., Collins, P.L. & Murphy, B.R. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. *J. Virol.* **72**, 2955-2961 (1998).

24. Durbin, A.P., Skiadopoulos, M.H., McAuliffe, J.M., Riggs, J.M., Surman, S.R., Collins, P.L. & Murphy, B.R. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. *J.Virol.* **74**, 6821-6831 (2000).

25. Skiadopoulos, M.H., Durbin, A.P., Tatem, J.M., Wu, S.L., Paschalis, M., Tao, T., Collins, P.L. & Murphy, B.R. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. *J. Virol.* **72**, 1762-1768 (1998).

26.Teng, N., Whitehead, S.S., Bermingham, A., St.Claire, M., Elkins, W.R., Murphy, B.R. & Collins, P.L. *J.Virol.* **74**, 9317-9321 (2000).

27. Masurel, N. Relation between Hong Kong virus and former human A2 isolates and the A/EQU12 virus in human sera collected before 1957. *The Lancet* **May 3**, 907-910 (1969).

Further references used with example 4.

AHMADIAN, G., CHAMBERS, P., and EASTON, A. J. (1999). Detection and characterisation of proteins encoded by the second ORF of the M2 gene of pneumoviruses. *J Gen Virol* **80,** 2011-6.

ALANSARI, H., and POTGIETER, L. N. (1994). Molecular cloning and sequence analysis of the phosphoprotein, nucleocapsid protein, matrix protein and 22K (M2) protein of the ovine respiratory syncytial virus. *J Gen Virol* **75,** 3597-601.

BARR, J., CHAMBERS, P., PRINGLE, C. R., and EASTON, A. J. (1991). Sequence of the major nucleocapsid protein gene of pneumonia virus of mice: sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. *J Gen Virol* **72,** 677-85.

BAYBUTT, H. N., and PRINGLE, C. R. (1987). Molecular cloning and sequencing of the F and 22K membrane protein genes of the RSS-2 strain of respiratory syncytial virus. *J Gen Virol* **68**, 2789-96.

BÄYON-AUBOYER, M. H., ARNAULD, C., TOQUIN, D., and ETERRADOSSI, N. (2000). Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup. *J Gen Virol* **81,** 2723-33.

BERMINGHAM, A., and COLLINS, P. L. (1999). The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. *Proc Natl Acad Sci U S A* **96,** 11259-64.

BLUMBERG, B.M., CHAN, J., AND UDEM, S.A. (1991). Function of Paramyxovirus 3' and 5'end sequences: In therory and practice. *In* "the Paramyxoviruses" (D. Kingsbury, Ed.), pp. 235-247. Plenum, New York.

COLLINS, P. L., and WERTZ, G. W. (1983). cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. *Proc Natl Acad Sci U S A* **80,** 3208-12.

COLLINS, P. L., and WERTZ, G. W. (1985). The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide SEQUENCE of the mRNA and a related polytranscript. *J Virol* **54,** 65-71.

COLLINS, P.L., DICKENS, L.E., BUCKLER-WHITE, A., OLMSTED, R.A., SPRIGGS, M.K., CAMARGO, E., AND COELINGH, K.V.W. (1986). Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. *Proc Natl Acad Sci U S A* **83**, 4594-98.

COLLINS, P. L., HILL, M. G., and JOHNSON, P. R. (1990). The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. *J Gen Virol* **71,** 3015-20.

COLLINS, P. L., HILL, M. G., CAMARGO, E., GROSFELD, H., CHANOCK, R. M., and MURPHY, B. R. (1995). Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. *Proc Natl Acad Sci U S A* **92,** 11563-7.

COLLINS, P. L., MCINTOSH, K. AND CHANOCK, R.M. (1996). "Respiratory syncytial virus." *In*: Fields virology (B. N. Knipe, Howley, P.M., Ed.) Lippencott-Raven, Philadelphia.

COOK, J. K. (2000). Avian rhinotracheitis. *Rev Sci Tech* **19,** 602-13.

CUESTA, I., GENG, X., ASENJO, A., AND VILLANUEVA, N. (2000). Structural phosphoprotein M2-1 of the human respiratory syncytial virus is an RNA binding protein. *J. Gen. Virol* **74**, 9858-67.

CURRAN, J., AND KOLAKOFSKY, D. (1999). Replication of paramyxoviruses. *Adv. Virus Res.* **50**, 403-422.

EASTON, A. J., and CHAMBERS, P. (1997). Nucleotide sequence of the genes encoding the matrix and small hydrophobic proteins of pneumonia virus of mice. *Virus Res* **48,** 27-33.

ELANGO, N., SATAKE, M., and VENKATESAN, S. (1985). mRNA sequence of three respiratory syncytial virus genes encoding two nonstructural proteins and a 22K structural protein. *J Virol* **55,** 101-10.

FEARNS, R., and COLLINS, P. L. (1999). Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. *J Virol* **73,** 5852-64.

FELSENSTEIN, J. (1989). "PHYLIP-Phylogeny Inference Package (Version 3.2. Cladistics 5).".

GIRAUD, P., BENNEJEAN, G., GUITTET, M., and TOQUIN, D. (1986). Turkey rhinotracheitis in France: preliminary investigations on a ciliostatic virus. *Vet Rec* **119,** 606-7.

Hall, T.A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucl. Acids. Symp. Ser.* 41, 95-98.

HARDY, R. W., and WERTZ, G. W. (1998). The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. *J Virol* **72,** 520-6.

HORVATH, C. M., and LAMB, R. A. (1992). Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in cell fusion. *J Virol* **66,** 2443-55.

JENTOFT, N. (1990). Why are proteins O-glycosylated? *Trends Biochem Sci* **15,** 291-4.

JOHNSON, P. R., JR., OLMSTED, R. A., PRINCE, G. A., MURPHY, B. R., ALLING, D. W., WALSH, E. E., and COLLINS, P. L. (1987). Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. *J Virol* **61,** 3163-6.

JUHASZ, K., and EASTON, A. J. (1994). Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups. *J Gen Virol* **75,** 2873-80

Kyte, J. and Doolittle, R.F. (1982). A Simple Method for Displaying the Hydrophobic Character of a Protein. *J. Mol. Biol.* **157**, 105-142.

LAMB, R. A., AND KOLAKOFSKY, D. (1996). "Paramyxoviridae: the viruses and their replication". *In:* Fields virology (B. N. Knipe, Howley, P.M., Ed.) Lippencott-Raven, Philadelphia.

LI, J., LING, R., RANDHAWA, J. S., SHAW, K., DAVIS, P. J., JUHASZ, K., PRINGLE, C. R., EASTON, A. J., and CAVANAGH, D. (1996). Sequence of the nucleocapsid protein gene of subgroup A and B avian pneumoviruses. *Virus Res* **41,** 185-91.

LING, R., EASTON, A. J., and PRINGLE, C. R. (1992). Sequence analysis of the 22K, SH and G genes of turkey rhinotracheitis virus and their intergenic regions reveals a gene order different from that of other pneumoviruses. *J Gen Virol* **73,** 1709-15.

LING, R., DAVIS, P. J., YU, Q., WOOD, C. M., PRINGLE, C. R., CAVANAGH, D., and EASTON, A. J. (1995). Sequence and in vitro expression of the phosphoprotein gene of avian pneumovirus. *Virus Res* **36,** 247-57.

MARRIOT, A.C., SMITH, J.M., AND EASTON, A. (2001). Fidelity of leader and trailer sequence usage by the respiratory syncytial virus and avian pneumovirus replication complexes. *J. Virol.* **75**, 6265-72.

MINK, M. A., STEC, D. S., and COLLINS, P. L. (1991). Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA. *Virology* **185**, 615-24.

MIYAHARA, K., KITADA, S., YOSHIMOTO, M., MATSUMURA, H., KAWANO, M., KOMADA, H., TSURUDOME, M., KUSAGAWA, S., NISHIO, M., and ITO, Y. (1992). Molecular evolution of human paramyxoviruses. Nucleotide sequence analyses of the human parainfluenza type 1 virus NP and M protein genes and construction of phylogenetic trees for all the human paramyxoviruses. *Arch Virol* **124**, 255-68.

MORRISON, T. G. (1988). Structure, function, and intracellular processing of paramyxovirus membrane proteins. *Virus Res* **10**, 113-35.

NAYLOR, C. J., BRITTON, P., and CAVANAGH, D. (1998). The ectodomains but not the transmembrane domains of the fusion proteins of subtypes A and B avian pneumovirus are conserved to a similar extent as those of human respiratory syncytial virus. *J Gen Virol* **79**, 1393-8.

PLOWS, D. J., and PRINGLE, C. R. (1995). Variation in the fusion glycoprotein gene of human respiratory syncytial virus subgroup A. *Virus Genes* **11**, 37-45.

POCH, O., BLUMBERG, B. M., BOUGUELERET, L., and TORDO, N. (1990). Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. *J Gen Virol* **71**, 1153-62.

POCH, O., SAUVAGET, I., DELARUE, M., and TORDO, N. (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. *Embo J* **8**, 3867-74.

RANDHAWA, J. S., MARRIOTT, A. C., PRINGLE, C. R., and EASTON, A. J. (1997). Rescue of synthetic minireplicons establishes the absence of the NS1 and NS2 genes from avian pneumovirus. *J Virol* **71**, 9849-54.

RANDHAWA, J. S., WILSON, S. D., TOLLEY, K. P., CAVANAGH, D., PRINGLE, C. R., and EASTON, A. J. (1996). Nucleotide sequence of the gene encoding the viral polymerase of avian pneumovirus. *J Gen Virol* **77**, 3047-51.

SAMAL, S. K., and ZAMORA, M. (1991). Nucleotide sequence analysis of a matrix and small hydrophobic protein dicistronic mRNA of bovine respiratory syncytial virus demonstrates extensive sequence divergence of the small hydrophobic protein from that of human respiratory syncytial virus. *J Gen Virol* **72,** 1715-20.

SATAKE, M., and VENKATESAN, S. (1984). Nucleotide sequence of the gene encoding respiratory syncytial virus matrix protein. *J Virol* **50,** 92-9.

SEAL, B. S., SELLERS, H. S., and MEINERSMANN, R. J. (2000). Fusion protein predicted amino acid sequence of the first US avian pneumovirus isolate and lack of heterogeneity among other US isolates. *Virus Res* **66,** 139-47.

SEDLMEIER, R., and NEUBERT, W. J. (1998). The replicative complex of paramyxoviruses: structure and function. *Adv Virus Res* **50,** 101-39.

STEC, D.S., HILL, M.G., 3RD, AND COLLINS, P.L. (1991). Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. *Virology* **183,** 273-87

VAN DEN HOOGEN, B. G., DE JONG, J. C., GROEN, J., KUIKEN, T., DE GROOT, R., FOUCHIER, R. A., and OSTERHAUS, A. D. (2001). A newly discovered human pneumovirus isolated from young children with respiratory tract disease. *Nat Med* 7(6), 719-24.

VIRUS TAXONOMY (2000). Seventh report of the international Committee on Taxonomy of Viruses.

WERTZ, G. W., COLLINS, P. L., HUANG, Y., GRUBER, C., LEVINE, S., and BALL, L. A. (1985). Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. *Proc Natl Acad Sci USA* **82,** 4075-9.

YU, Q., DAVIS, P. J., BARRETT, T., BINNS, M. M., BOURSNELL, M. E., and CAVANAGH, D. (1991). Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilliviruses. *J Gen Virol* **72,** 75-81.

YU, Q., DAVIS, P. J., LI, J., and CAVANAGH, D. (1992). Cloning and sequencing of the matrix protein (M) gene of turkey rhinotracheitis virus reveal a gene order different from that of respiratory syncytial virus. *Virology* **186,** 426-34.

ZAMORA, M., and SAMAL, S. K. (1992). Sequence analysis of M2 mRNA of bovine respiratory syncytial virus obtained from an F-M2 dicistronic mRNA suggests structural homology with that of human respiratory syncytial virus. *J Gen Virol* **73,** 737-41.

Primers used for RT-PCR detection of known paramyxo-viruses. Primers for hPIV-1 to 4, mumps, measles, Tupaia, Mapuera and Hendra are developed in house and based on allignments of available sequences. Primers for New Castle Disease Virus are taken from Seal, J., J. et al; Clin. Microb., 2624-2630, 1995. Primers for Nipah and general paramyxovirus-PCR are taken from: Chua, K.B., et al; Science, 288 26 may 2000

Virus		primers	located in protein
HPIV-1	fwd	5’-TGTTGTCGAGACTATTCCAA-3’	HN
	Rev	5’-TGTTG(T/A)ACCAGTTGCAGTCT-3’	
HPIV-2	Fwd	5’-TGCTGCTTCTATTGAGAAACGCC-3’	N
	Rev	5’-GGTGAC/T TC(T/C)AATAGGGCCA-3’	
HPIV-3	Fwd	5’-CTCGAGGTTGTCAGGATATAG-3’	HN
	Rev	5’-CTTTGGGAGTTGAACACAGTT-3’	
HPIV-4	Fwd	5’-TTC(A/G)GTTTTAGCTGCTTACG-3’	N
	Rev	5’-AGGCAAATCTCTGGATAATGC-3’	
Mumps	Fwd	5’-TCGTAACGTCTCGTGACC-3’	SH
	Rev	5’-GGAGATCTTTCTAGAGTGAG-3’	
NDV	Fwd	5’-CCTTGGTGAiTCTATCCGIAG-3’	F
	Rev	5’-CTGCCACTGCTAGTTGiGATAATCC-3’	
Tupaia	Fwd	5’-GGGCTTCTAAGCGACCCAGATCTTG-3’	N
	Rev	5’-GAATTTCCTTATGGACAAGCTCTGTGC-3’	
Mapuera	Fwd	5’-GGAGCAGGAACTCCAAGACCTGGAG-3’	N
	Rev:	5’-GCTCAACCTCATCACATACTAACCC-3’	
Hendra	Fwd	5’-GAGATGGGCGGGCAAGTGCGGCAACAG-3’	N
	Rev	5’-GCCTTTGCAATCAGGATCCAAATTTGGG-3’	
Nipah	Fwd	5’-CTGCTGCAGTTCAGGAAACATCAG-3’	N
	Rev	5’-ACCGGATGTGCTCACAGAACTG-3’	
HRSV	Fwd	5’-TTTGTTATAGGCATATCATTG-3’	F
	Rev	5’-TTAACCAGCAAAGTGTTA-3’	
Measles	Fwd	5’-TTAGGGCAAGAGATGGTAAGG-3’	N
	Rev	5’-TTATAACAATGATGGAGGG-3’	

General Paramyxoviridae :

Fwd	5'-CATTAAAAAGGGCACAGACGC-3'	P
Rev	5'-TGGACATTCTCCGCAGT-3'	

Primers for RAP-PCR:

ZF1: 5'-CCCACCACCAGAGAGAAA-3'
ZF4: 5'-ACCACCAGAGAGAAACCC-3'
ZF7: 5'-ACCAGAGAGAAACCCACC-3'
ZF10: 5'-AGAGAGAAACCCACCACC-3'
ZF13: 5'-GAGAAACCCACCACCAGA-3'
ZF16: 5'-AAACCCACCACCAGAGAG-3'

CS1: 5'-GGAGGCAAGCGAACGCAA-3'
CS4: 5'-GGCAAGCGAACGCAAGGA-3'
CS7: 5'-AAGCGAACGCAAGGAGGC-3'
CS10:5'-CGAACGCAAGGAGGCAAG-3'
CS13:5'-ACGCAAGGAGGCAAGCGA-3'
CS16:5'-CAAGGAGGCAAGCGAACG-3'

20 fragments successfully purified and sequenced:

10 fragments found with sequence homology in APV

Fragment 1	ZF 7, 335 bp	N gene
Fragment 2	ZF 10, 235 bp	N gene
Fragment 3	ZF 10, 800 bp	M gene
Fragment 4	CS 1, 1250 bp	F gene
Fragment 5	CS 10, 400 bp	F gene
Fragment 6	CS 13, 1450 bp	F gene
Fragment 7	CS 13, 750 bp	F gene
Fragment 8	ZF 4, 780 bp	L gene (protein level)
Fragment 9	ZF 10, 330 bp	L gene (protein level)
Fragment 10	ZF10, 250bp	L gene (protein level)

Primers used for RAP-PCR amplification of nucleic acids from the prototype isolate.

Example 5

Further exploration of the two subtypes of hMPV

Based on phylogenetic analysis of the different isolates of hMPV obtained so far, two genotypes have been identified with virus isolate 00-1 being the prototype of genotype A and isolate 99-1 the prototype of genotype B.
We hypothesise that the genotypes are related to subtypes and that re-infection with viruses from both subgroups occur in the presence of pre-existing immunity and the antigenic variation may not be strictly required to allow re-infection.
Furthermore, hMPV appears to be closely related to avian pneumovirus, a virus primarily found in poultry. The nucleotide sequences of both viruses show high percentages of homology, with the exception of the SH and G proteins. Here we show that the viruses are cross-reacting in tests, which are based primarily on the nucleoprotein and matrixprotein, but they respond differently in tests, which are based on the attachment proteins. The differences in virus neutralisation titers provide further proof that the two genotypes of hMPV are two different serotypes of one virus, where APV is a different virus.

The cross reaction between the two serotypes and the cross reaction between APV an hMPV

Methods

Protocol for IgG , IgA and IgM antibody detection for hMPV:
The indirect IgG EIA for hMPV was performed in microtitre plates essentially as described previously (Rothbarth, P.H. et al., 1999; Influenza virus serology-a comparative study. J. of Vir. Methods 78 (1999) 163-169.
Briefly, concentrated hMPV was solubilized by treatment with 1% Triton X-100 an coated for 16 hr at room temperature into microtitre plates in PBS after determination of the optimal working dilution by checkerboard titration. Subsequently, 100 ul volumes of 1:100 diluted human serum samples in EIA buffer were added to the wells and incubated for 1 h at 37C. Binding of human IgG was detected by adding a goat anti-human IgG peroxidase conjugate (Biosource, USA).

Adding TMB as substrate developed plates and OD was measured at 450 nm. the results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.

hMPV antibodies of the IgM and IgA classes were detected in sera by capture EIA essentially as described previously (Rothbarth, P.H et al. 1999; Influenza virus serolgy-a comparative study. J. Vir. methods 78 (1999) 163-169. For the detection of IgA and IgM commercially available microtiter plates coated with anti human IgM or IgA specific monoclonal antibodies were used. Sera were diluted 1:100 and after incubation of 1 hr at 37C, an optimal working dilution of hMPV is added at each well (100 ul). Incubated 1 hr 37C. After washing polyclonal anti hMPV labeled with peroxidase was added, the plate was incubated 1 hr 37C. Adding TMB as substrate developed plates and OD was measured at 450 nm. the results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.

AVP antibodies were detected in an AVP inhibition assay. Protocol for APV inhibition test is included the APV-Ab SVANOVIR ® enzyme immunoassay which is manufactured by SVANOVA Biotech AB, Uppsal Science Park Glunten SE-751 83 Uppsala Sweden. The results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.

1. Guinea pigs

A. (re) infection of guinea pigs with both subtypes of hMPV

Virus isolates ned/00/01 (subtype A) and ned/99/01 (subtype B) have been used to inoculate 6 guinea pigs per subtype (intratracheal, nose and eyes).
6 GP's infected with hMPV 00-1 (10e6,5 TCID50)
6 GP's infected with hMPV 99-1 (10e4,1 TCID50)

54 Days after the primary infection, the guinea pigs have been inoculated with the homologous and heterologous subtypes (10e4 TCID50/ml):

2 guinea pigs: 1st infection 00-1; 2nd 99-1 (heterologous)
3 guinea pigs: 1st infection 00-1; 2nd 00-1 (homologous)
2 guinea pigs: 1st infection 99-1; 2nd 00-1 (heterologous)
3 guinea pigs: 1st infection 99-1; 2nd 99-1 (homologous)

Throat and nose swabs have been collected for 12 days (1st infection) or 8 days (2nd infection) post infection, and have been tested for presence of the virus by RT-PCR assays.

Results of RT-PCR assay: Figure 29

Summary of results: guinea pigs inoculated with virus isolate ned/00/01 show infection of the upper respiratory tract day 1 to 10 post infection. Guinea pigs inoculated with ned/99/01 show infection of the upper respiratory tract day 1 to 5 post infection. Infection with ned/99/01 appears to be less severe than infection with ned/00/01. A second inoculation of the guinea pigs with the heterologous virus results in re-infection in 3 out of 4 guinea pigs and with the homologous virus in 2 out of 6 guinea pigs. No or only little clinical symptoms were noted in those animals that became re-infected, and no clinical symptoms were seen in those animals that were protected against the re-infections, demonstrating that even with wild-type virus, a protective effect of the first infection is evident, showing the possible use of heterologous (and of course homologues) isolates as a vaccine, even in an unattenuated form.

Both subtypes of hMPV are able to infect guinea pigs, although infection with subtype B (ned/99/01) seems less severe (shorter period of presence of the virus in nose and throat) than infection with subtype A (ned/00/01). This may be due to the higher dose given for subtype A, or to the lower virulence of subtype B.

Although the presence of pre-existing immunity does not completely protect against re-infection with both the homologous and heterologous virus, the infection appears to be less prominent in that a shorter period of presence of virus was noted and not all animals became virus positive.

|

B. Serology of guinea pigs infected with both subtypes of hMPV

At day 0, 52, 70, 80, 90, 110, 126 and 160 sera were collected from the guinea pigs and tested at a 1:100 dilution in a whole virus ELISA against ned/00/01 and ned/99/01 antigen.

Figure 30 A and B: IgG response against ned/00/01 and ned/99/01 for each individual guinea pig
Figure 31: Specificity of the ned/00/01 and ned/99/01 ELISA. Only data from homologous reinfected guinea pigs have been used.
Figure 32: Mean IgG response against ned/00/01 and ned/99/01 ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.

Summary of results:
Only a minor difference in response to the two different ELISA's is observed.
Whole virus ELISA against 00-1 or 99-1 cannot be used to discriminate between the two subtypes.

C.Reactivity of sera raised against hMPV in guinea pigs with APV antigen

Sera collected from the infected guinea pigs have been tested with an APV inhibition ELISA

Figure 33: Mean percentage of APV inhibition of hMPV infected guinea pigs.

Summary of results:
Sera raised against hMPV in guinea pigs, react in the APV inhibition test in a same manner as they react in the hMPV IgG ELISA's.

Sera raised against ned/99/01 reveal a lower percentage of inhibition in the APV inhibition ELISA than sera raised against ned/00/01. Guinea pigs infected with ned/99/01 might have a lower titer (as is seen in the hMPV ELISA's) or the cross-reaction of ned/99/01 with APV is less than that of ned/00/01. Nevertheless, the APV-Ab inhibition ELISA can be used to detect hMPV antibodies in guinea pigs.

{D. Virus neutralisation assays with sera raised against hMPV in guinea pigs.

Sera collected at day 0, day 52, 70 and 80 post infection were used in a virus (cross) neutralisation assay with ned/00/01, ned/99/01 and APV-C. Starting dilution was 1 to 10 and 100 TCID50 virus per well was used. After neutralisation, the virus was brought on tMK cells, 15 min. centrifuged at 3500 RPM, after which the media was refreshed.
The APV tests were grown for 4 days and the hMPV tests were grown for 7 days. Cells were fixed with 80% aceton, and IFA's were conducted with monkey-anti hMPV fitc labeled. Wells that were negative in the staining were considered as the neutralising titer. For each virus a 10-log titration of the virus stock and 2 fold titration of the working solution was included.
Figure 34: Virus neutralisation titers of ned/00/01 and ned/99/01 infected guinea pigs against ned/00/01, ned/99/01 and APV-C

2. Cynomologous macaques

A. (re) infection of cynomologous macaques with both subtypes of hMPV

Virus isolates ned/00/01 (subtype A) and ned/99/01 (subtype B) (1^e5 TCID50) have been used to inoculate 2 cynomologous macaques per subtype (intratracheal, nose and eyes). Six months after the primary infection, the macaque have been inoculated for the second time with ned/00/01. Throat swabs have been collected for 14 days (1st infection) or 8 days (2nd infection) post infection, and have been tested for presence of the virus by RT-PCR assays.

Figure 35: Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01.

Summary of results:

Summary of results: cynomologous macaques inoculated with virus isolate ned/00/01 show infection of the upper respiratory tract day 1 to 10 post infection. Clinical symptoms included a suppurative rhinitis. A second inoculation of the macaques with the homologous virus results in re-infection, as demonstrated by PCR, however, no clinical symptoms were seen.

B. Serology on sera collected of hMPV infected cynomologous macaques.

From the macaques which received ned/00/01 sera were collected during 6 months after the primary infection (re-infcetion occurred at day 240 for monkey 3 and day 239 for monkey 6).

Sera were used to test for the presence of IgG antibodies against either ned/00/01 or APV, and for the presence against IgA and IgM antibodies against ned/00/01.

Results: Figure 36A

IgA, IgM and IgG response against ned/00/01 of 2 cynomologous macaques (re)infected with ned/00/01.

Figure 36B

IgG response against APV of 2 cynbomologous macaques infected with ned/00/01.

Summary of results:

Two macaques have been succesfully infected with ned/00/01 and in the presence of antibodies against ned/00/01 been reinfected with the homologous virus. The response to IgA and IgM antibodies shows the raise in IgM antibodies after the first infection, and the absence of it after the reinfection. IgA antibodies are only detected after the re-infection, showing the immediacy of the immune response after a first infection. Sera raised against hMPV in macaques which were tested in an APV inhibition ELISA show a similar response as to the hMPV IgG ELISA.

Discussion/conclusion

hMPV antibodies in cynomologous macaques are detected with the APV inhibition ELISA with a similar sensitivity as with an hMPV ELISA, and therefore the APV inhibition EIA is suitable for testing human samples for the presence of hMPV antibodies.

C.Virus (cross) neutralisation assays with sera collected from hMPV infected cynomologous macaques

Summary of results: The sera taken from day 0 to day 229 post primary infection show only low virus neutralisation titers against ned/00/01 (0-80), the sera taken after the secondary infection show high neutralisation titers against ned/00/01: >1280. Only sera taken after the secondary infection show neutralisation titers against ned/99/01 (80-640), and none of the sera neutralise the APV C virus.

There is no cross reaction between APV-C and hMPV in virus (cross)neutralisation assays, where there is a cross reaction between ned/00/01 and ned/99/01 after a boost of the antibody response.

3. Humans

Sera of patients ranging in age of <6 months to >20 years of age have previously been tested in IFA and virus neutralisation assays against ned/00/01. (See tabel 1 of patent).
Here we have tested a number of these sera for the presence of IgG, IgM and IgA antibodies in an ELISA against ned/00/01, and we tested the samples in the APV inhibition ELISA.

Results: Figure 37 Comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera, there is a strong correlation between the IgG hMPV test and the APV-Ab test, therefore the APV-Ab test is essentially able to detect IgG antibodies to hmPV in humans.

4. Poultry

96 chickens have been tested in both the APV inhibition ELISA and the ned/00/01 ELISA for the presence of IgG antibodies against APV.

Summary of results: Both the hMPV ELISA and the APV inhibition ELISA detect antibodies against APV (data not shown).

Summary of results.

We found two genotypes of hMPV with ned/00/01 being the prototype of subgroup A and ned/99/01 the prototype of subgroup B.

"According to classical serogical analyses (as for example known Francki, R.I.B., Fauquet, C.M., Knudson, D.L., and Brown, F., *Classification and nomenclature of viruses. Fifth report of the international Committee on Taxonomy of Viruses.* Arch Virol, 1991. **Supplement 2**: p. 140-144), two subtypes can be defined on the basis of its immunological distinctiveness, as determined by quantitative neutralization assays with animal antisera. Two distinct serotypes have either no cross-reaction with eachother or show a homologous-to heterologous titer ratio >16 in both directions. If neutralization shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ration of eight or 16), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA's exist. If neutralization shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ration of smaller than eight), identity of serotype of the isolates under study is assumed."

For RSV it is known that re-infection occurs in the presence of pre-existing immunity (both homologous and heterologous). Infection of guinea pigs and cynomologous macaques with both the homologous and heterologous serotypes of hMPV revealed that this is also true for hMPV. In addition, IgA and IgM ELISA's against hMPV revealed the reaction of IgA antibodies only occurs after re-infection. Sera raised against hMPV or APV respond in an equal way in APV and hMPV ELISAs. From the nucleotide sequence comparisons, it is known that the viruses show about 80% amino acid homology for the N, P, M, and F genes. In ELISA's the N and M proteins are the main antigens to react. Virus neutralisation assays (known to react against the surface glycoproteins G, SH and F) show a difference between the two different sera. Although APV en hMPV cross react in ELISAs, phylogenetic analyses of the nucleotide sequences of hMPV and APV, the differences in virus neutralisation titers of sera raised against the two different viruses, and the differences in host usage again reveal that APV-C and hMPV are two different viruses. Based on the results we speculate that hMPV infection in mammals is possible a result of a zoonotic event from birds to mammals. But the virus has adapted in such a way (i.e. the G and SH proteins) that a return (from mammals to birds) zoonotic event seems unlikely, considering the presence of AVP in birds.

Addendum

Background information on *Pneumovirinae*

The family of *Paramyxoviridae* contains two subfamilys: the *Paramyxovirinae* and the *Pneumovirinae*. The subfamily *Pneumovirinae* consists of two genera: *Pneumovirus* and *Metapneumovirus*. The genus *Pneumovirus* contains the human, bovine, ovine and caprine respiratory syncytial viruses and the pneumonia virus of mice (PVM). The genus *Metapneumovirus* contains the avian pneumoviruses (APV, also referred to as TRTV).

The classification of the genera in the subfamily *Pneumovirinae* is based on classical virus characteristics, gene order and gene constellation. Viruses of the genus *Pneumovirus* are unique in the family of *Paramyxoviridae* in having two nonstructural proteins at the 3'end of the genome (3'-NS1-NS2-N-P-M-SH-G-F-M2-L-5'). In contrast, viruses in the genus *Metapneumovirus* lack the NS1 and NS2 genes and the organisation of genes between the M and L coding regions is different: 3'-N-P-M-F-M2-SH-G-L-5'.

All members of the subfamily *Paramyxovirinae* have haemagluttinating activity, but this function is not a defining feature for the subfamily *Pneumovirinae,* being absent in RSV and APV but present in PMV. Neuraminidase activity is present in members of the genera *Paramyxovirus* and *Rubulavirus* (subfamily *Paramyxovirinae)* but is absent in the genus *Morbillivirus* (subfamily *Paramyxovirinae)* and the genera *Pneumovirus* and *Metapneumovirus* (subfamily *Pneumovirinae*).

A second distinguishing feature of the subfamily *Pneumovirinae* is the apparent limited utilization of alternative ORFs within mRNA by RSV. In contrast, several members of the subfamily *Paramyxovirinae,* such as Sendai and Measles viruses, access alternative ORFs within the mRNA encoding the phosphoprotein (P) to direct the synthesis of a novel protein.

The G protein of the *Pneumovirinae* does not have sequence relatedness or structural similarity to the HN or H proteins of *Paramyxovirinae* and is only approximately half the size of their chain length. In addition, the N and P proteins are smaller than their counterparts in the *Paramyxovirinae* and lack unambigous sequence homology. Most nonsegmented negative stranded RNA viruses have a single matrix (M) protein.

Members of the subfamily *Pneumovirinae* are an exception in having two such proteins, M and M2. The M protein is smaller than its *Paramyxovirinae* counterparts and lacks sequence relatedness with *Paramyxovirinae.*

When grown in cell cultures, members of the subfamily *Pneumovirinae* show typical cytopathic effects; they induce characteristic syncytia formation of cells. (Collins, 1996).

The subfamily *Pneumovirinae*, genus *Pneumovirus*

hRSV is the type-species of the genus *Pneumovirus* and is a major and widespread cause of lower respiratory tract illness during infancy and early childhood (Selwyn, 1990). In addition, hRSV is increasingly recognised as an important pathogen in other patient groups, including immune compromised individuals and the elderly. RSV is also an important cause of community-acquired pneumonia among hospitalised adults of all ages (Englund, 1991; Falsey, 2000; Dowell, 1996).

Two major antigenic types for RSV (A and B) have been identified based on differences in their reactivity with monoclonal and polyclonal antibodies and by nucleic acid sequence analyses (Anderson, 1985; Johnson, 1987; Sullender, 2000). In particular the G protein is used in distinguishing the two subtypes. RSV-A and B share only 53% amino acid sequence homology in G, whereas the other proteins show higher homologies between the subtypes (table 1) (Collins, 1996).

Detection of RSV infections has been described using monoclonal and polyclonal antibodies in immunofluorescence techniques (DIF, IFA), virus neutralisation assays and ELISA or RT-PCR assays (Rothbarth, 1988; Van Milaan, 1994; Coggins, 1998).

Closely related to hRSV are the bovine (bRSV), ovine (oRSV) and caprine RSV (oRSV), from which bRSV has been studied most extensively. Based on sequence homology with hRSV, the ruminant RSVs are classified within the *Pneumovirus* genus, subfamily *Pneumovirinae* (Collins, 1996). Diagnosis of ruminant RSV infection and subtyping is based on the combined use of serology, antigen detection, virus isolation and RT-PCR assays (Uttenthal, 1996;Valarcher, 1999; Oberst, 1993; Vilcek, 1994).

Several analyses on the molecular organisation of bRSV have been performed using human and bovine antisera, monoclonal antibodies and cDNA probes. These analyses revealed that the protein composition of hRSV and bRSV are very similar and the genomic organisation of bRSV resembles that of hRSV. For both bRSV and hRSV, the G and F proteins represent the major neutralisation and protective antigens. The G protein is highly variable between the hRSV subtypes and between hRSV and bRSV (53 and 28% respectively) (Prozzi, 1997; Lerch, 1990). The F proteins of hRSV and bRSV strains present comparable structural characteristics and antigenic relatedness. The F protein of bRSV shows 80-81% homology with hRSV, while the two hRSV subtypes share 90% homology in F (Walravens, K. 1990).

Studies based on the use of hRSV and bRSV specific monoclonal antibodies have suggested the existence of different antigenic subtypes of bRSV. Subtypes A, B, and AB are distinguished based on reaction patterns of monoclonal antibodies specific for the G protein (Furze, 1994; Prozzi, 1997; Elvander, 1998). The epidemiology of bRSV is very similar to that of hRSV. Spontaneous infection in young cattle is frequently associated with severe respiratory signs, whereas experimental infection generally results in milder disease with slight pathologic changes (Elvander, 1996).

RSV has also been isolated from naturally infected sheep (oRSV) (LeaMaster, 1983) and goats (cRSV) (Lehmkuhl, 1980). Both strains share 96% nucleotide sequence with the bovine RSV and are antigenically crossreacting. Therefore, these viruses are also classified within the *Pneumovirus* genus.

A distinct member of the subfamily *Pneumovirinae*, genus *Pneumovirus* is the Pneumonia virus of mice (PVM).

PVM is a common pathogen in laboratory animal colonies, particularly those containing atymic mice. The naturally acquired infection is thought to be asymptomatic, though passage of virus in mouse lungs resulted in overt signs of disease ranging from an upper respiratory tract infection to a fatal pneumonia (Richter, 1988; Weir, 1988).

Restricted serological crossreactivity between the nucleocapsid protein (N) and the phosphoprotein (P) of PVM and hRSV has been described but none of the external proteins show cross-reactivity, and the viruses can be distinguished from each other in virus neutralisation assays (Chambers, 1990a; Gimenez, 1984; Ling, 1989a).

The glycoproteins of PVM appear to differ from those of other paramyxoviruses and resemble those of RSV in terms of their pattern of glycosylation. They differ, however, in terms of processing. Unlike RSV, but similar to the other paramyxoviruses, PVM has haemagglutinating activity with murine erythrocytes, for which the G protein appears to be responsible since a monoclonal antibody to this protein inhibits haemagglutination (Ling, 1989b).

The genome of PVM resembles that of hRSV, including two nonstructural proteins at its 3'end and a similar genomic organisation (Chambers, 1990a; Chambers, 1990b). The nucleotide sequences of the PVM NS1/NS2 genes are not detectably homologous with those of hRSV (Chambers, 1991). Some proteins of PVM show strong homology with hRSV (N: 60%, and F: 38 to 40%) while G is distinctly different (the amino acid sequence is 31 % longer) (Barr, 1991; Barr, 1994; Chambers, 1992). The PVM P gene, but not that of RSV or APV, has been reported to encode a second ORF, representing a unique PVM protein (Collins, 1996). New PVM isolates are identified by virus isolation, heamagglutination assays, virus neutralisation assay and various immunofluorescence techniques.

Table with addedum: Amino acid homology between the different viruses within the genus *Pneumovirus* of the subfamily *Pneumovirinae.*

Gene	hRSV's	bRSV's	oRSV v. hRSV	bRSV v. hRSV	bRSV v. oRSV	PVM vs. hRSV
NS1	87			68-69	89	*
NS2	92			83-84	87	*
N	96		93			60
P	-		81			
M	-		89			
F	89			80-81		38-40
G	53	88-100	21-29	38-41	60-62	*
M2	92		94			41
SH	76		45-50		56	
L	-					

* No detectable sequence homology

The genus *Metapneumovirus*

Avian pneumoviruses (APV) has been identified as the aetiological agent of turkey rhinotracheitis (McDougall, 1986; Collins, 1988) and is therefore often referred to as turkey rhinotracheitis virus (TRTV). The disease is an upper respiratory tract infection of turkeys, resulting in high morbidity and variable, but often high, mortality. In turkey hens, the virus can also induce substantial reductions in egg production. The same virus can also infect chickens, but in this species, the role of the virus as a primary pathogen is less clearly defined, although it is commonly associated with swollen head syndrome (SHS) in breeder chicken (Cook, 2000).

The virions are pleiomorphic, though mainly spherical, with sizes ranging from 70 to 600 nm and the nucleocapsid, containing the linear, non-segmented, negative-sense RNA genome, shows helical symmetry (Collins, 1986; Giraud, 1986). This morphology resembles that of members of the family *Paramyxoviridae*. Analyses of the APV-encoded proteins and RNAs suggested that of the two subfamilys of this family (*Paramyxovirinae* and *Pneumovirinae*), APV most closely resembled the *Pneumovirinae* (Collins, 1988; Ling, 1988; Cavanagh, 1988).

APV has no non-structural proteins (NS1 and NS2) and the gene order (3'-N-P-M-F-M2-SH-G-L-5') is different from that of mammalian pneumoviruses such as RSV. APV has therefore recently been classified as the type species for the new genus *Metapneumovirus* (Pringle, 1999).

Differences in neutralisation patterns, ELISA and reactivity with monoclonal antibodies have revealed the existence of different antigenic types of APV. Nucleotide sequencing of the G gene led to the definition of two virus subtypes (A and B), which share only 38% amino acid homology (Collins, 1993; Juhasz, 1994). An APV isolated from Colorado, USA (Cook, 1999), was shown to cross-neutralize poorly with subtype A and B viruses and based on sequence information was designated to a novel subtype, C (Seal, 1998; Seal 2000). Two non-A/non-B APVs were isolated in France, and were shown to be antigenically distinct from subtypes A, B and C. Based on amino acid sequences of the F, L and G genes, these viruses were classified again as a novel subtype, D (Bayon-Auboyer, 2000).

Diagnosis of APV infection can be achieved by virus isolation in chicken or turkey tracheal organ cultures (TOCs) or in Vero cell cultures. A cytopathic effect (CPE) is generally observed after one or two additional passages. This CPE is characterised by scattered focal areas of cell rounding leading to synctyial formation (Buys, 1989). A number of serology assays, including IF and virus neutralisation assays have been developed. Detection of antibodies to APV by ELISA is the most commonly used method (O'Loan, 1989; Gulati, 2000). Recently, the polymerase chain reaction (PCR) has been used to diagnose APV infections. Swabs taken from the oesophagus can be used as the starting material (Bayon-Auboyer, 1999; Shin, 2000)

Alansari, H. and Potgieter, L.N.D. 1994. Nucleotide and predicted amino acid sequence analysis of the ovine respiratory syncytial virus non-structural 1C and 1B genes and the small hydrophobic protein gene. J.Gen.Virol. 75: 401-404.

Alansari, H., Duncan R.B., Baker, J.C. and Potgieter, L.N. 1999. Analysis of ruminant respiratory syncytial virus isolates by RNAse protection of the G glycoprotein transcripts. J.Vet.Diagn.Invest. 11: 215-20

Anderson, L.J, Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernic, B.F., Stone, Y. and McIntosh, K. 1985. Antigenic characterisation of respiratory syncytial virus strains with monoclonal antibodies. J. Inf. Dis. 151: 626-633.

Barr, J., Chambers, Pringle, C.R., Easton, A.J. 1991. Sequence of the major nucleocapsid protein gene of pneumonia virus of mice: sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. J.Gen.Virol. 72: 677-685.

Barr, J., Chambers, P., Harriott, P., Pringle, C.R. and Easton, A.J. 1994. Sequence of the phosphoprotein gene of pneumonia virus of mice: expression of multiple proteins from two overlapping rading frames. J. Virol. 68: 5330-5334.

Bayon-Auboyer, M.H., Jestin, V., Toquin, D., Cherbonnel, M. and Eterradosi, N. 1999. Comparison of F-, G- and N-based RT-PCR protocols with conventional virological procedures for the detection and typing of turkey rhinotracheitis virus. Arch.Vir. 144: 1091-1109.

Bayon-Auboyer, M.H., Arnauld, C., Toquin, D., and Eterradossi, N. 2000. Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup. J.Gen.Virol. 81: 2723-2733.

Buys, S.B., Du Preez, J.H. and Els, H.J. 1989. The isolation and attenuation of a virus causing rhinotracheitis in turkeys in South Africa. Onderstepoort J.Vet.Res. 56: 87-98.

Cavanagh, D. and Barrett, T. 1988. Pneumovirus-like characteristics of the mRNA and proteins of turkey rhinotracheitis virus. Virus Res. 11: 241-256.

Chambers, P., Pringle, C.R. and Easton, A.J. 1990a. Molecular cloning of pneumonia virus of mice. J. Virol. 64: 1869-1872.

Chambers, P., Matthews, D.A, Pringle, C.R. and Easton, A.J. 1990b. The nucleotide sequences of intergenic regions between nine genes of pneumonia virus of mice establish the physical order of these genes in the viral genome. Virus Res. 18: 263-270.

Chambers, P., Pringle, C.R., and Easton, A.J. 1991. Genes 1 and 2 of pneumonia virus of mice encode proteins which have little homology with the 1C and 1B proteins of human respiratory syncytial virus. J.Gen.Vir. 72: 2545-2549.

Chambers, P. Pringle CR, Easton AJ. 1992. Sequence analysis of the gene encding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in pramyxovirus fusion glycoproteins. J. Gen. Virol. 73: 1717-1724.

Coggins, W.B., Lefkowitz, E.J. and Sullender, W.M. 1998. Genetic variability among group A and group B respiratory syncytial viruses in a children's hospital. J. Clin. Microbiol. 36: 3552-3557.

Collins, M.S. and Gough, R.E., Lister, S.A., Chettle, N. and Eddy, R. 1986. Further characterisation of a virus associated with turkey rhiotracheitis. Vet. Rec. 119: 606.

Collins, M.S. and Gough, R.E. 1988. Characterisation of a virus associated with turkey rhinotracheitis. J. Gen.Virol. 69: 909-916.

Collins, M.S., Gough, R.E., and Alexander, D.J. 1993. Antigenic differentiation of avian pneumovirus isolates using polyclonal antisera and mouse monoclonal antibodies. Avian Pathology 22: 469-479.

Collins, P.L., McIntosh, K., Chanock, R.M. 1996. Respiratory syncytial virus. P. 1313-1351. In: B.N. Fields, D.M. Knipe, and P.M. Howley (ed.). Fields virology, 3rd ed., vol. 1 Lippincott-Raven, Philadelphia, Pa, USA.

Cook,, J.K.A., Huggins, M.B., Orbell, S.J. and Senne, D.A. 1999. Preliminiary antigenic characterization of an avian pneumovirus isolated from commercial turkeys in Colorado, USA. Avian pathol. 28: 607-617.

Cook, J.K.A. 2000. Avian rhinotracheitis. Rev. Sci.tech. off int. Epiz. 19 : 602-613.

Dowell, S.F., Anderson, L.J.,Gary, H.E., Erdman, D.D., Plouffe, J.F., File, T.M., Marston, B.J. and Breiman, R.F. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect .Dis.174: 456-462.

Elvander, M. 1996. Severe respiratory disease in dairy cows caused by infection with bovine respiratory syncytial virus. Vet. Rec. 138: 101-105.

Elvander, M., Vilcek, S., Baule, C., Uttenthal, A., Ballagi-Pordany, A. and Belak, S. 1998.
Genetic and antigenic analysis of the G attachment protein of bovine respiratory syncytial virus strains. J. Gen. Virol. 79: 2939-2946.

Englund, J.A., Anderson, L.J., and Rhame, F.S. 1991. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J. Clin. Microbiol. 29: 115-119.

Falsey, A.R. and Walsh, E.E. 2000. Respiratory syncytial virus infection in adults. Clin. Microb. Rev. 13: 371-84.

Furze, J., Wertz, G., Lerch, R. and Taylor, G. 1994. Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus. J. Gen. Virol. 75: 363-370.

Gimenez, H.B., Cash, P. and Melvin, W.T. 1984. Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. J. Gen. Virol. 65: 963-971.

Gulati, B.R., Cameron, K.T., Seal, B.S, Goyal, S.M., Halvorson, D.A. and Njenga, M.K. 2000.
Development of a highly sensitive and specific enzyme-linked immunosorbent assay based on recombinant matrix protein for detection of avian pneumovirus antibodies. J. Clin. Microbiol. 38: 4010-4.

Johnson, P.R., Spriggs M.K., Olmsted, R.A. and Collins, P.L. 1987. The G glycoprotein of human respiratory syncytial virus subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84: 5625-5629.

Juhasz, K. and Easton, A.J. 1994. Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups. J. Gen. Virol. 75: 2873-2880.

LeaMaster, B.R., Evermann, J.F., Mueller, M.K., Prieur, M.K. and Schlie, J.V. 1983. Serologic studies on naturally occurring respiratory syncytial virus and *Haemophilus sommus* infections in sheep. American Association of Veterinary Laboratory Diagnosticians 26: 265-276.

Lehmkuhl, H.D., Smith, M.H., Cutlip, R.C. 1980. Morphogenesis and structure of caprine respiratory syncytial virus. Arch.Vir. 65: 269-76.

Lerch, R.A., Anderson, K and Wertz, G.W. 1990. Nucleotide sequence analysis and expression from recombinant vectors demonstrate that the attachment protein G of bovine respiratory syncytial virus is distinct from that of human respiratory syncytial virus. J.Virol. 64: 5559-5569.

Ling, R. and Pringle, C.R. 1988. Turkey rhinotracheitis virus: *in vivo* and *in vitro* polypeptide synthesis. J. Gen. Virol. 69: 917-923.

Ling, R. and Pringle, C.R. 1989a. Polypeptides of pneumonia virus of mice. I. Immunological cross-reactions and post-translational modifications. J. Gen. Virol. 70: 1427-1440.

Ling, R. and Pringle, C.R. 1989b. Polypeptides of pneumonia virus of mice. II. Characterization of the glycoproteins. J.Gen.Virol. 70: 1441-1452.

McDougall, J.S. and Cook, J.K.A. 1986. Turkey rhinotracheitis: preliminary investigations. Vet. Rec. 118: 206-207.

Oberst, R.D., M.P. Hays, K.J. Hennessy, L.C. Stine, J.F. Evermann, and Kelling, C.L. 1993. Characteristic differences in reverse transcription polymerase chain reaction products of ovine, bovine and human respiratory syncytial viruses. J. Vet. Diagn. Investig. 5: 322-328.

O'Loan, C.J., Allan, G., Baxter-Jones, C. and McNulty, M.S. 1989. An improved ELISA and serum neutralisation test for the detection of turkey rhinotracheitis virus antibodies. J. Virol. Meth. 25: 271-282.

Paccaud, M.F. and Jacquier, C., 1970. A respiratory syncytial virus of bovine origin. Arch. Ges.Virusforsch. 30: 327-342.

Pringle, C.R. 1999 Virus taxonomy at the Xith international congress of virology, Sydney, Australia 1999. *Arch. Virol.* 144/2: 2065-2070.

Prozzi, D., Walravens, K., Langedijk, J.P.M , Daus, F., Kramps, J.A. and Letesson, J.J. 1997. Antigenic and molecular analysis of the variability of bovine respiratory syncytial virus G glycoprotein. J. Gen. Virol. 78: 359-366.

Randhawa, j.S., Marriott, A.C., Pringle, C.R., and A.J. Easton 1997. Rescue of synthetic minireplicons establish the absence of the NS1 and NS2 genes from avian pneumoviruses. J. Virol. 71: 9849-9854.

Richter,C.B., Thigpen, J.E., Richter, C.S. and Mackenzie, J.M. 1988. Fatal pneumonia with terminal emaciation in nude mice caused by pneumonia vrius of mice. Lab. Anim. Sci. 38: 255-261.

Rothbarth, P.H., Habova, J.J. and Masurel, N. 1988. Rapid diagnosis of infections caused by respiratory syncytial virus. Infection 16:252.

Seal, B.S. 1998. Matrix protein gene nucleotide and predicted amino acid sequence demonstrate that the first US avian pneumovirus isolate is distinct form European strans. Virus Res. 58, 45-52.

Seal, B.S., Sellers, H.S., Meinersmann, R.J. 2000. Fusion protein predicted amino acid sequence of the first US avian pneumovirus isolate and lack of heterogeneity among other US isolates. Virus Res. 66: 139-147.

Selwyn, B.J. 1990. The epidemiology of acute respiratory tract infection in young children: comparison findings from several developing countries. Rev. Infect. Dis. 12: S870-S888.

Shin, H.J., Rajashekara, G., Jirjis, F.F., Shaw, D.P., Goyal, S.M., Halvorson, D.A. and Nagaraja, K.V 2000. Specific detection of avian pneumovirus (APV) US isolates by RT-PCR. Arch. Virol. 145: 1239-1246.

Sullender, W.M. 2000. Respiratory syncytial virus genetic and antigenic diversity. Clin. Microb. Rev. 13: 1-15.

Trudel, M., Nadon, F., Sinnard, C., Belanger, F., Alain, R., Seguin, C. and Lussier, G. 1989. Comparison of caprine, human and bovine strains of respiratory syncytial virus. Arch. Vir. 107: 141-149.

Uttenthal, A., Jensen, N.P.B. and Blom, J.Y. 1996. Viral aetiology of enzootic pneumonia in Danish dairy herds, diagnostic tools and epidemiology. Vet. Rec. 139, 114-117.

Valarcher, J., Bourhy, H., Gelfi, J. and Schelcher, F. 1999. Evaluation of a nested reverse transcription-PCR assay based on the nucleoprotein gene for diagnosis of spontaneous and experimental bovine respiratory syncytial virus infections. J. Clin. Microb. 37: 1858-1862

Van Milaan, A.J., Sprenger, J.J., Rothbarth, P.H., Brandenburg, A.H., Masurel, N. and Claas, E.C. 1994. Detection of respiratory syncytial virus by RNA-polymerase chain reaction and differentiation of subgroups with oligonucleotide probes. J.Med.Virol. 44:80-87.

Vilcek, S, Elvander, M., Ballagi-Pordany, A., and Belak, S. 1994. Development of nested PCR assays for detection of bovine respiratory syncytial virus in clinical samples. J. Clin. Microb. 32: 2225-2231.

Walravens, K., Kettmann, R., Collard, A., Coppe, P. and Burny, A.. 1990. Sequence comparison between the fusion protein of human and bovine respiratory syncytial viruses. J. Gen. Virol. 71: 3009-3014.

Weir, E.C., Brownstein, D.G., Smith, A.L. and Johnson, E.A. 1988. Respiratory disease and wasting in athymic mice infected with pneumonia virus of mice. Lab. Anim. Sci. 34: 35-37.

Throughout the description and the claims of this specification the word “comprise” and variations of the word, such as “comprising” and “comprises” is not intended to exclude other additives, components, integers or steps.

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

The claims defining the invention are as follows:

1. An isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is capable of infecting mammalian cells.

2. An isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is phylogenetically more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

3. An isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is phylogenetically more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than related to APV type C.

4. An isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is phylogenetically more closely related to a virus isolate comprising the nucleotide sequence of HMPV as shown in Figure 6A, 6B, or 6C than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

5. An isolated negative-sense single stranded RNA metapneumovirus, wherein

(i) the metapneumovirus belongs to the subfamily *Pneumovirinae* of the family *Paramyxoviridae;* and

(ii) the metapneumovirus is identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus corresponds phylogenetically to the genus Metapneumovirus if the nucleic acid sequence of the virus in a phylogenetic tree analysis using 100 bootstraps and 3 jumbles is more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

6. An isolated negative-sense single stranded RNA metapneumovirus, wherein

(i) the metapneumoviris belongs to the subfamily *Pneumovirinae* of the family *Paramyxoviridae;* and

(ii) the metapneumovirus is identifiable as phylogenetically corresponding to the genus Metapneumoviris, wherein the virus corresponds phylogenetically to the genus Metapneumovirus if the nucleic acid sequence of the virus in a phylogenetic tree analysis using 100 bootstraps and 3 jumbles is more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than it is related to APV type C.

7. An isolated negative-sense single stranded RNA metapneumovirus, wherein the isolated negative-sense single stranded RNA metapneumovirus comprises:

(i) an N Protein with an amino acid sequence greater than 88% identical to the amino acid sequence of the N Protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) a P protein with an amino acid sequence greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) an M protein with an amino acid sequence greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) an F protein with an amino acid sequence greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) an M2-1 protein with an amino acid sequence greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24;

(vi) an M2-2 protein with an amino acid sequence at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;

(vii) an L protein with an amino acid sequence greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(viii) an SH protein with an amino acid sequence at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(ix) a G Protein with an amino acid sequence at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27;

wherein sequence identity is determined over the entire length of the protein.

8. An isolated negative-sense single stranded RNA metapneumovirus, wherein the negative-sense single stranded RNA metapneumovirus encodes at least two proteins of the following;

(i) a N protein with greater than 88% amino acid sequence identity to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) a P protein with greater than 68% amino acid sequence identity to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) a M protein with greater than 87% amino acid sequence identity to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) a F protein with greater than 81% amino acid sequence identity to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) a M2-1 protein with greater than 84% amino acid sequence identity to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-l as shown in Figure 24; or

(vi) a M2-2 protein with at least 85% amino acid sequence identity to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25,

(vii) a L protein with greater than 90% amino acid sequence identity to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(viii) a SH protein with at least 75% amino acid sequence identity to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(ix) a G protein with at least 75% amino acid sequence identity to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27,

wherein sequence identity is determined over the entire length of the respective protein.

9. An isolated negative-sense single stranded RNA metapneumovirus, wherein the negative-sense single stranded RNA metapneumovirus encodes:

(i) a N protein with greater than 88% amino acid sequence identity to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) a P protein with greater than 68% amino acid sequence identity to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) a M protein with greater than 87% amino acid sequence identity to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) a F protein with greater than 81% amino acid sequence identity to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) a M2-1 protein with greater than 84% amino acid sequence identity to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24; or

(vi) a M2-2 protein with at least 85% amino acid sequence identity to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;

(vii) a L protein with greater than 90% amino acid sequence identity to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(viii) a SH protein with at least 75% amino acid sequence identity to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26, or

(ix) a G protein with at least 75% amino acid sequence identity to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27,

wherein sequence identity is determined over the entire length of the respective protein.

10 An isolated negative-sense single stranded RNA metapneumovirus, wherein the genome of the virus comprises a nucleotide sequence of HMPV as shown in Figure 6A, 6B, or 6C.

11 The virus of any one of claims 1-10, wherein the virus is an attenuated virus.

12 An immunogenic composition, wherein the immunogenic composition comprises the virus of any one of claims 1-10.

13 The immunogenic composition of claim 12, wherein the infectious recombinant virus is an attenuated virus.

14 An isolated nucleic acid, wherein the nucleic acid encodes a protein comprising:

(i) an amino acid sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) an amino acid sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) an amino acid sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) an amino acid sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) an amino acid sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24;

(vi) an amino acid sequence that is at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;

(vii) an amino acid sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(viii) an amino acid sequence that is at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(ix) an amino acid sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

15. An isolated nucleic acid, wherein the isolated nucleic acid hybridizes specifically under high stringency conditions with any of the nucleic acids of claim 14.

16. The isolated nucleic acid of claim 15, wherein said high stringency conditions comprise hybridization in a buffer consisting of 6X SSC, 50mM Tris-HCl (pH=7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA and 100 µg/ml denatured salmon sperm DNA, for 48 hours at 65°C.,washing in a buffer consisting of 2X SSC, 0.01% PVP, 0.01% Ficoll and 0.01% BSA, for 45 minutes at 37°C, and washing in a buffer consisting of 0.IX SSC, for 45 minutes at 50°C.

17. A method of detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with any of the nucleic acids of claim 14.

18. The method of claim 17, wherein the mammalian MPV is a human MPV.

19. A vector comprising any of the nucleic acids of claim 14.

20. A host cell comprising any of the nucleic acids of claim 14.

21. An isolated protein, wherein the protein comprises:
    (i) an amino acid sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;
    (ii) an amino acid sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;
    (iii) an amino acid sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;
    (iv) an amino acid sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;
    (v) an amino acid sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24;
    (vi) an amino acid sequence that is at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;
    (vii) an amino acid sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;
    (viii) an amino acid sequence that is at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(ix) an amino acid sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

22. An antibody, wherein the antibody binds specifically to a protein consisting of:

(i) an amino acid sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(ii) an amino acid sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 21;

(iii) an amino acid sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(iv) an amino acid sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(v) an amino acid sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24;

(vi) an amino acid sequence that is at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;

(vii) an amino acid sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(viii) an amino acid sequence that is at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(ix) an amino acid sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

23. A method of detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with any of the antibodies of claim 22.

24. A viral isolate wherein the viral isolate is identifiable with a method according to claim 17 or 23 as a mammalian negative-sense single stranded RNA virus within the sub-family *pneumovirinae* of the family *Paramyxoviridae* and identifiable as phylogenetically corresponding to the genus *Metapneumovirus*.

25. A method for virologically diagnosing a MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by contacting the sample with any of the nucleic acids of claim 14.

26. A method for serologically diagnosing a MPV infection in a mammal, wherein said method comprises detecting in a sample from the mammal the presence of an antibody specifically directed against an MPV or component thereof by reacting said sample with any of the proteins of claim 21 or a virus of any one of claims 1-10 or a portion thereof.

27. A nucleic acid encoding the genome or an MPV-specific functional fragment of the genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said nucleic acid further encodes sequences of other viruses.

28. A nucleic acid encoding the genome or an MPV-specific functional fragment of the genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said genome may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

29. An infectious chimeric virus, wherein the chimeric virus comprises
(a) at least two contiguous kilobase pairs of nucleotide sequence derived from a mammalian MPV; and
(b) sequences of other viruses.

30. An infectious chimeric virus, wherein the chimeric virus comprises the genome of a mammalian MPV, wherein one or more of the open reading frames in the genome of the mammalian MPV have been replaced by the analogous open reading frame from an avian MPV.

31. An infectious chimeric virus, wherein the chimeric virus comprises the genome of an avian MPV, wherein one or more of the open reading frames in the genome of the avian MPV have been replaced by the analogous open reading frame from mammalian MPV.

32. A pharmaceutical composition, wherein the pharmaceutical composition comprises (i) an isolated mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, and (ii) a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising a nucleic acid encoding the genome or an MPV-specific functional fragment of the genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said nucleic acid further encodes sequences of other viruses.

34. A pharmaceutical composition comprising a nucleic acid encoding the genome or an MPV specific functional fragment of the genome of a mammalian negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus; wherein said

genome may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

35. A pharmaceutical composition, wherein the pharmaceutical composition comprises:

(a) an isolated mammalian metapneumovirus, wherein

(i) the metapneumovirus belongs to the subfamily *Pneumovirinae* of the family *Paramyxoviridae;* and

(ii) the metapneumovirus is identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus corresponds phylogenetically to the genus Metapneumovirus if the nucleic acid sequence of the virus in a phylogenetic tree analysis using 100 bootstraps and 3 jumbles is more closely related to a virus isolate deposited as **I-2614** with CNCM, Paris than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis, and

(b) a pharmaceutically acceptable carrier.

36. An isolated or recombinant nucleic acid or MPV-specific functional fragment thereof, obtained from a virus according to any one of claims 1 to 10.

37. An isolated or recombinant peptide, protein or MPV-specific functional fragment thereof encoded by a nucleic acid according to claim 36.

38. An antigen comprising a peptide, protein or MPV-specific functional fragment thereof according to claim 37.

39. A diagnostic kit for diagnosing an MPV infection comprising a virus according to any one of claims 1 to 10, a nucleic acid according to claim 36, a peptide, protein or Fragment thereof according to claim 37, an antigen according to claim 38, or an antibody according to claim 22.

40. The composition according to any one of claims 32 to 35 when used for

the treatment or prevention of an MPV infection.

41. The composition according to any one of claims 32 to 35 when used for the treatment or prevention of a respiratory illness.

42. A method of detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with an antibody or a fragment thereof; that specifically recognizes a protein or a fragment of a protein, comprising,

(a) a sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 and 99-1 as shown in figure 20;

(b) a sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 and 99-1 as shown in figure 21;

(c) a sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 and 99-1 as shown in figure 22;

(d) a sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 and 99-1 as shown in figure 23;

(e) a sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 and 99-1 as shown in figure 24;

(f) a sequence that is at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 and 99-1 as shown in figure 25;

(g) a sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in figure 28;

(h) a sequence that is at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 and 99-1 as shown in figure 26; or

(i) a sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 and 99-1 as shown in figure 27,

wherein sequence identity is determined over the entire length of the protein.

43. A method for detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with a first group of one or more nucleic acids that hybridize under stringent conditions to a second group of one or more nucleic acids, that encodes a protein, or fragment thereof comprising,

(a) a sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 and 99-1 as shown in figure 20;

(b) a sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 and 99-1 as shown in figure 21;

(c) a sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1and 99-1 as shown in figure 22;

(d) a sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 and 99-1 as shown in figure 23;

(e) a sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 and 99-1 as shown in figure 24;

(f) a sequence that is least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 and 99-1 as shown in figure 25;

(g) a sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-i as shown in figure 28;

(h) a sequence that is at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 and 99-1 as shown in figure 26; or

(i) a sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 and 99-1 as shown in figure 27,

wherein sequence identity is determined over the entire length of the protein.

44. The method of claim 43, wherein said first group of nucleic acids is at least 18, at least 20, at least 23 or at least 25 nucleotides in length.

45. A method for detecting a mammalian metapneumovirus in a sample, wherein the method comprises:

(i) contacting a cell with the sample;

(ii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPW, then

(iii) testing for the presence of PIV, influenza virus, and RSV,

wherein, if PIV, influenza virus, and RSV are not present in the sample, then the mammalian metapneumovirus is in the sample.

46. A method for detecting a human metapneumovirus in a sample obtained from a human, wherein the method comprises:

(i) contacting a cell with the sample;

(ii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPIV, then

(iii) testing for the presence of hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, hRSV, influenza virus type A and influenza virus type B,

wherein, if hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, hRSV, influenza virus type A and influenza virus type B are not present in the sample, then the human metapneumovirus is in the sample.

47. A method for evaluating the risk of a mammalian metapneumovirus infection in a subject, wherein the method comprises:

(i) obtaining a sample from the subject;

(ii) contacting a cell with the sample;

(iv) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPIV, then

(v) testing for the presence of PIV, influenza virus, and RSV,

wherein, if PIV, influenza virus, and RSV are not present in the sample, then the subject is at risk of being infected with mammalian metapneumovirus.

48. A method for detecting a mammalian metapneumovirus in a sample, wherein the method comprises:

(i) contacting a cell with the sample;

(ii) monitoring the cytopathic effect on the cell, if the cytopathic effect is similar to the cytopathic effect of hRSV or hPIV, then

(iii) testing for the presence of *Paramyxovirinae,* hPIV type 1, hPIV type 2, hPIV type 3, hPIV type 4, sendai virus, simian virus type 5, New-Castle disease virus, hRSV. morbilli virus, mumps virus, Nipah virus, Hendra virus, Tupaia virus and Mapuera virus.

wherein, if *Paramyxovirinae*. hPIV type 1, hPIV type 2, hPIV type 3. hPIV type 4, sendai virus. simian virus type 5, New-Castle disease virus, hRSV, morbilli virus, mumps virus, Nipah virus, Hendra virus, Tupaia virus and Mapuera virus are not present in the sample, then the mammalian metapneumovirus is in the sample.

49. The method of claim 45, 46, 47 or 48, wherein the cytopathic effect is characterized by syncytium formation and subsequent rapid internal disruption, followed by detachment of the cell from the monolayer.

50. The method of claim 45, 46, 47 or 48, wherein the cell displays the cytopathic effect three passages after contacting the cell with the sample.

51. The method of claim 45, 46, 47 or 48, wherein the cell is a tMK cell, a VERO cell or a A549 cell.

52. The method of claim 45, 46, 47 or 48, wherein said testing step comprises detecting a nucleic acid of PIV, RSV and/or influenza virus.

53. The method of claim 52, wherein said testing step comprises an RT-

PCR assay at low stringency.

54. The method of claim 45, 46, 47 or 48, wherein said testing step comprises detecting a protein of PIV, RSV and/or influenza virus.

55. The method of claim 54, wherein said testing step comprises an immune fluorescence assay.

56. The method of claim 45, 46, 47 or 48, wherein the method further comprises contacting the sample with a nucleic acid encoding an amino acid sequence that is:

(a) an amino acid sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(b) an amino acid sequence that is greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(c) an amino acid sequence that is greater than 87% identical to the amino acid sequence of the M protein of' MPV isolate 00-1 or 99-1 as shown in Figure 22;

(d) an amino acid sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(e) an amino acid sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-1 as shown in Figure 24;

(f) an amino acid sequence that is at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;

(g) an amino acid sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(h) an amino acid sequence that is at least 75% identical to the amino acid sequence of the SH protein of MW isolate 00-1 or 99-

1 as shown in Figure 26; or

(i) an amino acid sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

57. The method of claim 45, 46, 47 or 48, wherein the method further comprises contacting the sample the sample with an antibody that specifically binds to a protein that is:

(a) greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 or 99-1 as shown in Figure 20;

(b) greater than 68% identical to the amino acid sequence of the P protein of MPV isolate 00-1 or 99-1 as shown in Figure2l;

(c) greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 or 99-1 as shown in Figure 22;

(d) greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 or 99-1 as shown in Figure 23;

(e) greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 or 99-l as shown in Figure 24;

(f) at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 or 99-1 as shown in Figure 25;

(g) greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28:

(h) at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 or 99-1 as shown in Figure 26; or

(i) at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 or 99-1 as shown in Figure 27.

58. The method of claim 45, 46, 47 or 48, wherein the method further comprises contacting the sample with a first group of one or more nucleic acids that hybridize under stringent conditions to a second group of one or more nucleic acids, that encodes a protein, or fragment thereof, comprising,

(a) a sequence that is greater than 88% identical to the amino acid sequence of the N protein of MPV isolate 00-1 and 99-1 as shown in Figure 20;

(b) a sequence that is greater than 68% identical to the amino acid sequence of' the P protein of MPV isolate 00-1 and 99-1 as shown in Figure 21;

(c) a sequence that is greater than 87% identical to the amino acid sequence of the M protein of MPV isolate 00-1 and 99-1 as shown in Figure 22;

(d) a sequence that is greater than 81% identical to the amino acid sequence of the F protein of MPV isolate 00-1 and 99-1 as shown in Figure 23;

(e) a sequence that is greater than 84% identical to the amino acid sequence of the M2-1 protein of MPV isolate 00-1 and 99-1 as shown in Figure 24;

(f) a sequence that is at least 85% identical to the amino acid sequence of the M2-2 protein of MPV isolate 00-1 and 99-1 as shown in Figure 25;

(g) a sequence that is greater than 90% identical to the amino acid sequence of the L protein of MPV isolate 00-1 as shown in Figure 28;

(h) a sequence that is at least 75% identical to the amino acid sequence of the SH protein of MPV isolate 00-1 and 99-1 as shown in Figure 26; or

(i) a sequence that is at least 75% identical to the amino acid sequence of the G protein of MPV isolate 00-1 and 99-1 as shown in Figure 27,

wherein sequence identity is determined over the entire length of the protein.

59. The method of claim 45, 46, 47 or 48, wherein the cytopathic effect is identical to the cytopathic effect of hRSV or hPIV.

60. The isolated negative-sense single stranded RNA virus MPV of claim 1, wherein the virus is capable of infecting human cells.

61. An isolated negative-sense single stranded RNA virus MPV of any one of claims 1 to 4, substantially as hereinbefore described.

W:\Files\699351\699351 claims 29.1.08.doc

62. A chimeric parainfluenza type 3 (PI3) virus comprising one or more heterologous nucleotide sequences encoding mammalian metapneumovirus polypeptides.

63. The chimeric PI3 virus of claim 62 wherein said nucleotide sequences are derived from any one of the nucleic acid sequences of claim 14.

64. An isolated negative-sense single stranded RNA metapneumovirus of any one of claims 5 to 10 and 61 substantially as hereinbefore described.

65. An isolated nucleic acid of claim 14, substantially as hereinbefore described.

66. An isolated protein of claim 21, substantially as hereinbefore described.

67. A nucleic acid of claim 27 or 28, substantially as hereinbefore described.

68. An infectious chimeric virus of any one of claims 29 to 31, substantially as hereinbefore described.

69. A pharmaceutical composition of any one of claims 32 to 35, substantially as hereinbefore described.

70. A method of any one of claims 43 to 48, substantially as hereinbefore described.

TABEL 1

M

	00-1	hRSV	bRSV	PMV	APV-A	APV-C	APV-B
00-1	1,00	0,37	0,37	0,37	0,77	0,87	0,75
hRSV	---	1,00	0,91	0,41	0,37	0,37	0,37
bRSV	---	---	1,00	0,42	0,35	0,36	0,35
PMV	---	---	---	1,00	0,37	0,38	0,38
APV-A	---	---	---	---	1,00	0,78	0,89
APV-C	---	---	---	---	---	1,00	0,77
APV-B	---	---	---	---	---	---	1,00

N

	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,20	0,22	0,21	0,40	0,52	0,40
hRSV	---	1,00	0,59	0,30	0,18	0,21	0,18
bRSV	---	---	1,00	0,31	0,21	0,23	0,21
PVM	---	---	---	1,00	0,21	0,23	0,21
APVA	---	---	---	---	1,00	0,42	1,00
APVC	---	---	---	---	---	1,00	0,42
APVB	---	---	---	---	---	---	1,00

F

	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,32	0,33	0,37	0,67	0,80	0,66
hRSV	---	1,00	0,82	0,40	0,35	0,35	0,35
bRSV	---	---	1,00	0,41	0,34	0,36	0,34
PVM	---	---	---	1,00	0,38	0,38	0,39
APV-A	---	---	---	---	1,00	0,72	0,84
APV-C	---	---	---	---	---	1,00	0,72
APV-B	---	---	---	---	---	---	1,00

P

	00-1	hRSV	bRSV	PMV	APV-A	APV-C
00-1	1,00	0,25	0,26	0,27	0,55	0,67
hRSV	---	1,00	0,81	0,30	0,28	0,26
bRSV	---	---	1,00	0,29	0,28	0,26
PMV	---	---	---	1,00	0,23	0,27
APV-A	---	---	---	---	1,00	0,52
APV-C	---	---	---	---	---	1,00

L8

	00-1	hRSV	bRSV	APV-A
00-1	1,00	0,36	0,35	0,56
hRSV	---	1,00	0,79	0,36
bRSV	---	---	1,00	0,35
APV-A	---	---	---	1,00

L9/10

	00-1	hRSV	bRSV	APV-A
00-1	1,00	0,30	0,30	0,53
hRSV	---	1,00	0,83	0,34
bRSV	---	---	1,00	0,32
APV-A	---	---	---	1,00

Fig. 1a

Table 2

Seroprevalence of hMPV in humans categorised by age group using immunofluorescence and virus neutralisation assays

	Immunofluorescence assays		Virus neutralisation assays		
Age (Years)	N tested	N positive	N tested	N positive	Titre range
< 1	20	5	12	3	16-32
1-2	20	11	13	4	16-32
2-5	20	14	8	3	16-512
5-10	20	20	4	4	32-256
10-20	20	20	4	3	32-128
> 20	20	20	4	3	32-128
8-99[1]	72	72	11	11	16-128

[1] Sero-archeological analysis using sera collected in 1958

Fig. 1b


0
1
2
3
4
5
6
7
8
9
10
11
12
13
13.373 Kb
N
P
M
F
M2
SH
G
L
APV
1/2
3
4/5/6/7
8
9/10
RAP PCR
A
B
C
RT-PCR

Fig. 2

Fig. 3

Nucleo protein

```
00-1 NP MSLQGIHLSDLSYKHAILKESQYTIKRDVGTTTAVTPSSLQQEITLLCGEILYAKHADYKYAAEIGIQYISTALGSERVQQILRNSGSEVQVVLTRTYSL 10
APV A    ...ES.R....E......ED.....R....A...I...E..PQVST...MV.F...T..EP...V.M........AD.T....K.......G.M.KIVT. 10
APV B    ......Q..................................R.VS...........T..SH...V.M..V..T..A..T....K.......A...K.... 10
APV C    ......Q..................................R.VS...........T..SH...V.M..V..T..A..T....K.......A...K.... 10
bRSV     .A.SKVK.N.TFN.DQL.ST.K...Q.ST.DNIDIPNYDV.KHLNK...ML.ITED.NH.FTGL..ML.AMSR..R.DTLK..KDA.YQ.RANGVDVITH 10
hRSV     .A.SKVK.N.TLN.DQL.SS.K...Q.ST.DNIDTPNYDV.KHLNK...ML.ITED.NH.FTGL..ML.AMSR..R.DTIK..KDA.YH.KANGVDITTY 10
PVM      ...DRLK.N.V.N.DSL.SNCK.SVT.ST.DV.S.SGHAM.KALARTL.MF.LTAFNRCEEV....L..AMSL..RDDSIK...EA.YN.KC.D.QLKDF 10

00-1 NP GKIKNNKGEDLQMLDIHGVEKSWVEEIDKEARKTMATLLKESSGNIPQNQRPSAPDTPIIILLCVGALIFTKLASTIEVGLETTVRRANRVLSDALKRYPR 20
APV A    SAEGSVRKREV--.N..D.GVG.ADDVERTT.EA.GAMVR.KV-QLTK..K...L.A.V....I..........V......AI...S......IS.... 19
APV B    ..G..S...E..........R..I..V.........SAT.DN..P........S..A......I..................A........N.....F.. 20
APV C    ..G..S...E..........R..I..V.........SAT.DN..P........S..A......I..................A........N.....F.. 20
bRSV     RQDV.G.EMKFEV.TLVSLTSEVQGN.EI.S..SYKKM...M-.EVAPEY.HDS..CGM.V...A..VI....AGDRS..TAVI....N..RNEM...KG 19
hRSV     RQDI.G.EMKFEV.TLSSLTSEIQVN.EI.S..SYKKM...M-.EVAPEY.HDS..CGM.I..IA..VI....AGDRS..TAVI....N..KNEI...KG 19
PVM      TIKLQG.EYKI.V...V.IDAANLADLEIQ..GVV.KE..TG-ARL.D.R.HD...CGV.V..IA..VVS...AGDRG..DAVE...LN..KAEKA...N 19

00-1 NP MDIPKIARSFYDLFEQKVYHRSLFIEYGKALGSSSTGSKAESLFVNIFMQAYGAGQTMLRWGVIARSSNNIMLGHVSVQAELKQVTEVYDLVREMGPESG 30
APV A    ....R..K..FE...K...Y.N..........T....RM............................................R..S.......K...... 29
APV B    I...................Y................................................................................ 30
APV C    I...................Y................................................................................ 30
bRSV     LIPKD..N...EV..KYPHYIDV.VHF.I.QS.TRG..RV.GI.AGL..N......V......L.K.VK......A.....ME..V...EYAQKL.G.A. 29
hRSV     LIPKD..N...EV..KHPHLIDV.VHF.I.QS.TRG..RV.GI.AGL..N...S..V......L.K.VK......A.....ME..V...EYAQKL.G.A. 29
PVM      .EVKQ..E.......R.P.YIDV..TF.L.QS.VRG...V.G..SGL..N......V.....LL.K.VK......A.....ME..V...EYAQKQ.G.A. 29

00-1 NP LLHLRQSPKAGLLSLANCPNFASVVLGNASGLGIIGMYRGRVPNTELFSAAESYAKSLKESNKINFSSLGLTDEEKEAAEHFLNVSDDSQNDYE      39
APV A    ................T.............A........K..A..L...A......RT.R.N....LAA.....D.R...TSY.GGD.ERSSKF.      39
APV B    ......N..........................L............A......R...............E.......N...INEEG.....      39
APV C    ......N..........................L............A......R...............E.......N...INEEG.....      39
bRSV     FY.ILNN...S....TQF...S.......A....M.E...TPR.QD.YD..KA..EQ...NGV..Y.V.D..T..L..IKNQ..PK.N--DVEL      39
hRSV     FY.ILNN...S....TQF...S.......A....M.E...TPR.QD.YD..KA..EQ...NGV..Y.V.D..A..L..IKNQ..PKE.--DVEL      39
PVM      FY.I.NN...S....T.....T.......A......S.K.APR.R...D..KD..ER..DN.V..Y.A.N..A..R.LISQQ..IV..TPD.DI      39
```

Phospho protein

```
00-1 P MS-FPEGKDILFMGNEAAKLAEAF---------QKSLRKPGHKRSQSIIGEKVNTVSETLELPTISRPAKPTIPSEPKLAWTDKGGATKTEIKQAIKVMDP 91
APV-A  ..-........M..S....M.D.Y---------.R...NTSAG-GR..S..PI..IA.KVP..PLCN.TT.-------------..SCI.PNKAPVP..K-- 76
APV-C  ..-........L.......A....---------.R..K.I..R.T...V.D.II.....V.K....KST.V.T.P.R.N..GE.PDT.RSQTEE.RNEAT. 91
bRSV   .-------------..........---------.................................................................. 80
hRSV   .EK.APE----.H.ED.NNK.TK.LES---------------------------IKGKF---------------------------ASSKDPKK.DS.ISVNS 45
PVM    .EK.APE----.V.ED.N.K..E.LKHRSFPSE.P.AGIPNTATHVTKYNMPPILRSSFK..SPRVA.NL.E..A.-----PTTPPP.PPQN.EEQPKESD 92

00-1 P IEEEESTEKKVLPSSDGKTPAEKKLKPSTNT-----KKKVSFTPNEP---GKYTKLEKDALDLLSDNEEEDAE-SSILTFEE--RDTSSLSIEARLESIE 18
APV-A  --.I..IYP.LPTAPVATDTYTSTSTE.AKK-----S...K.DNPKV---.......EEG.E....P..DND.K........--K..A.T.......A.. 16
APV-C  EDASRLY.EVEA.T.........GKETPEKP-----....T.KND.S---.R.....ME..E......DD...-..V.....--K...A..L.......D 18
bRSV   ...............................-----...........---.......................-........--................ 16
hRSV   .DI.VTK.SPITSGTNIIN.TSEADSTPETKANYPR.PL...KEDLTPSDNPFS..Y.ETIETF---DNN--.EE.SYSY..INDQ.-NDN.T...DR.D 13
PVM    VDI.TMHVC..PDNPEHSKKPCCSDDTD.KKT---R.PM.T.VEP.EKFV.LGAS.YRETMQTF---AADGYDEE.N.S...TNQEPG.S.V.Q..DR.. 18

00-1 P EKLSMILGLLRTLNIATAGPTAARDGIRDAMIGVREELIADIIKEA---KGKAAEM---MEEEMXQRSKIGNGSVKLTEKAKELNKIVEDESTSGESEEE 27
APV-A  ........M.K.........................M.....NS.MT..---.D.I...---.K..DT..A...D...............L..Q.S.....S. 25
APV-C  ..............V................V.L.............---.......---.K..AK.K........G......................... 27
bRSV   ...............................................---.......---.....X.................................... 26
hRSV   ....E...M.H..VV.S....S.........V.L...M.EK.RA..LMTNDRLEA.ARLRN..SEKMA.DTSDE.P.NPTS.K.SDLL..N--------- 23
PVM    ....Y.I...N.IMV......T...E....L..T.....EM.KSDILTVNDRIVA.EKLRD..CSRADTDDGSACY..DR.RI.D...SSNA--------- 27

00-1 P EEPKDTQDNSQEDDIY----QLIM.                                                                            29
APV-A  ..SGESESDEE.S...NLDL-.L                                                                              28
APV-C  ..EE.EEESNPD..L.SLTM-.LIKN                                                                           29
bRSV   ................----.....                                                                            28
hRSV   ----.SDNDLSL.--------DF.                                                                             24
PVM    ---EEAKEDLDV...MGINF-.LI                                                                             29
```

Matrix protein

Fig. 3, contd.

```
00-1 matrix MESYLVDTYQGIPYTAAVQVDLIEKDLLPASLTIWFPLFQANTPPAVLLDQLKTLTITTLYAASQNGPILKVNASAQGAAMFVLPKKFEVNATVAXDEYS 10
APV-B       ....II.....V..........V..NN..K..V......SS..AP.........S...Q.TV.PE..V.Q...T......SA.....S.S.AA.L.... 10
APV-A       ....II.....V..............SN..T..V......SS..AP.........S...Q.T..PE..V.Q...A......SA.....A.S.A..L.... 10
APV-C       ...........V.......T..V...Q...R..V.V....T....T...E...........T..................SA...S.D.S.S..L.D.. 10
bRSV        ..T.VNKLHE.ST......YNV....DD.......V.M..SSISADL.IKE.INVN.LVRQISTLK..S..IMINSRS.VLAQM.S..TIS.N.SL..R. 10
hRSV        ..T.VNKLHE.ST......YNVL...DD.......V.M..SSV.ADL.IKE.ASIN.LVKQISTPK..S.R.TINSRS.VLAQM.SN.IIS.N.SL..R. 10
PVM         ..A...EM.H.V.......LN.V..HSANI...V.I.M..TSL.KNSVM.L.HDV.VICTQISTVH..MI..DL.SSN.GLATM.RQ.LI..II.L.DWG 10

00-1 matrix KLEFDKLTVCEVKTVYLTTMKPYGMVSKFVSSAKSVGKKTHDLIALCDFMDLEKNTPVTIPAFIKSVSIKESESATVEAAISSEADQALTQAKIAPYAGL 20
APV-B       ..D.GV....D.RA.....L........I.TNMNT..R...........I.M.RGI......Y..A....D...........G.....I...R....... 20
APV-A       R...GT....D.RSI....L........IMTDVR...R...........I.I..GV.I....Y..A....D...........G.....I...R....... 20
APV-C       ...........L.A...............N...A...............L....GV......Y...........................G.....I...R....... 20
bRSV        ..AY.IT.P..I.ACS..CL.VKN.LTTVKDLTMKTFNP..EI....E.ENIMTSKR.V..T.LR.INV.AKDLDSL.NIATT.FKN.I.N...I..... 20
hRSV        ..AY.VT.P..I.ACS..CL.VKS.LTTVKDLTMKTFNP..EI....E.ENIMTSKR.I..TYLRPI.V.NKDLNSL.NIATT.FKN.I.N...I..... 20
PVM         NMDYEVPVAFDK.SFCV.IL..KN.LYTVP.ITPTN-RP..E...V.S.HNRVTLKSFN..V..RALY.RQQGLDS..Q....DV.H.I.T.RV...... 19

00-1 matrix IMIMTMNNPKGIFKKLGAGTQVIVELGAYVQAESISKICKTWSHQGTRYVLKSR.                                              25
APV-B       .LL.A.......R.............P......LG......N..R...-----I-----L--K----SR                                25
APV-A       .L.................M.......P......LG......N..R.....R..-.GYPK-A.-IC.C-YSQ.K                           27
APV-C       ...................V................R..RN...........---------------R                                25
bRSV        VLVI.VTDN..A..YIKPQS.F..D....LEK...YYVTTN.K.TA.KFSI.P------------IED.                                25
hRSV        VLVI.VTDN..A..YIKPQS.F..D....LEK...YYVTTN.K.TA..FSI.P------------LED.                                25
PVM         TLVINITST..A..L.K..S.ILA...P.LTQV.LHDVIMN.K.T..S.I...SS----------TSG.                                25
```

Fusion protein

```
00-1 F MSW---KVVIXFSLLI------TPXHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPS---LIKTELDLTKSALRELRTVSADQ 88
APV-A  .DV---RICLLLF.IS------N.SSCIQ.T.N......V.R..K............N..I.N...I..N....---..D...V...N.....K...... 88
APV-B  .YL---.LLLIIY.VV------GASGKIQ.T.S......V.R..K............N..I.N...I..N....---..S...S..QN..Q......... 88
APV-C  ...---...LLLV..A------..TG..E.......Y..V.R...........................T....---..R...E...N..E..K...... 88
bRSV   .ATTAMRMI.SIIFISTYVTHI.LCQNIT.EFYQST..AVSR....A.......S.V.I.LSKIQKNV.KSTD.KVK...Q..ERYNN.VV..QSLMQNE 10
hRSV   .ELLIHRLSAI.LT.AINALYL.SSQNIT.EFYQST..AVSR..F.A.......S.I.I.LSNIKETK.NGTDTKVK...Q...KY.N.VT..QLLMQNT 10
PVM    .----IPGR.FLV..VIFNTKPIHPNT.T.K.Y.ST..VE.A..K.A....HMT.MSIKLSQINIES.KSSN.---.LAH..AIYS..VD....L.SNA 93

00-1 F LAREEQ-----------------------IENPRQSRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELK 16
APV-A  V.K.SR-----------------------LSS..RR......................L.......G..K......RN...................ND.. 16
APV-B  ITK.NR-----------------------.LSH.KK.............T........L.......G..K...L..RS.............I.....ND.. 16
APV-C  ..K.AR-----------------------.MS..KA...............................G..A...G..R....................ND.. 16
bRSV   P.SFSRAKRGIPELIHYTRNSTKKFYGLMGKK.KR..L--GFL..IG--S..AS...VS.VLH..G..NK.....LS..K..VS.S...S..TSK.LD.. 19
hRSV   P.ANNRARREAPQYMNYTINTTKNLNVS.SKK.KR..L--GFL...G--S.IAS.I.VS.VLH..G..NK.....LS..K..VS.S...S..TSK.LD.. 19
PVM    -----------------------------LKSK.KK..L--GLI..LG--........L...VQ....IAL.RD.VRN.....VS.T..MS...KV.DD.. 16

00-1 F DFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGFLIGVYGSS 26
APV-A  E.I..K..P...Q...N...I...I..G.N.............S....S.V.......D..V..INR....S...S...N...........I.....DGT 26
APV-B  E.I..K..P...Q...N...IR..I..G.N.............S....S.V..........VK.INR....S...S...N...........I......GT 26
APV-C  ..I..K..P...R.....S........G.Y............................V.........S...N...............I........ 26
bRSV   NYID.E.LPQV.NHD.R.SNIETVIE.Q.K.N.L.EIA.E..V.....TPL.TYML.NS..LSLIND..ITND.K...SS.VQI..QQSYSIMSV.KEEV 29
hRSV   NYINNQ.LPIV.QQS.R.SNIETVIE.Q.K.S.L.EIN.E..V...V.TPL.TYML.NS..LSLIND..ITND.K...SS.VQI..QQSYSIMSIIKEEV 29
PVM    N.I..E.LPK..RVS..VH.ITAVIR.Q.L.K.L.E.S.E..S...L.HTV.SFML..R..TSI.GG.AV....KEI..SSK.IM..N.LAI.SS.NADT 26

00-1 F VIXMVQLPIFGVIDTPCWIVKAAPSC--SGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSXECNINISTTNYPCKVS 36
APV-A  .VY..........E....R.V...L.--RKE......I.........T.....A....KD...V.D.Y............LEVEQ..Y....SK...... 36
APV-B  .VY..........E....R.V...L.--RHERES.............T.....A.....D...V.D.Y............SEVEQ..H....ST...... 36
APV-C  .VYI..............K.....L.--...D...........................E...V.S...............KE.E...R.....K...... 36
bRSV   IAYV.....Y........KLHTS.L.TTDN.E.SNI..T.T.R....D....VSFF.QTET.KVQSNR.....MNSLTLPTDVNL..TD.FN.K.D..IM 39
hRSV   LAYV.....Y........KLHTS.L.TTNI.E.SNI..T.T.R....D....VSFF.QADT.KVQSNR.....MNSLTLPSEVSL..TD.FNSK.D..IM 39
PVM    LVYVI...L...M..D..VIRSSID.--HNIADK....A.A.N....H....LS.F.SPT...IHNGYA....LKSLT.PVT.R...S.MY....D..I. 35

00-1 F TGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVF 46
APV-A  .....V.....T...G..S..ES........K.......G...TH.P.NE...I............V...RT...A..VNN.N.IL.............. 46
APV-B  .....V.....T...G..S..E.........K...........TH.P.NE...I.....I......V...RT...A..VNN.N.LL.............. 46
APV-C  ......................D.M.......K....RP.G......S..........................T...K....N...IE.......I...... 46
bRSV   .SKTD..SSVITSI..I.S..GKTK.TASNKNR....TFSN..D.VS.KGV...SVG..L.YVN.L..KALY...E.IINYY..LV..S.E.DASIA..N 49
hRSV   .SKTD..SSVITS...I.S..GKTK.TASNKNR....TFSN..D.VS.KGV...SVG..L.YVN.L..KNLYV..E.IINYY..LV..S.E.DASIS..N 49
PVM    .SKTYV.TAV.TTM.C..S..GHN..TVIN.DK...RT.PD..H..S.KGV.R.QVG....Y...EV.KSI.VR.E.LVLKY..LS..D.K.D..IRD.E 45

00-1 F ESIENSQALVDQSNRILS----SAEKGNTGFII--VIILIAVLGSTMILVSVFIIIKKTKRPTGAP-PELSGVTNNGFIPH-N.           54
APV-A  ...DR..D.I.K..DL.G----ADA.SKA.IA.--A.VVLVI..IFFL.AVIYYCSRVR.TKPKHDY.ATT.HSSMAYV-------------S  53
APV-B  ..VDK.KD.I.K..DL.D----IEV.S.I.AAL--A.TILV..SMLI.VGIAYYVV..R.AK.SNGY.KTT.QS.M.Y.S.              53
APV-C  ..V.K..N.I....K..D----.I....A..V.--..V..VL.MLAAVG.G..FVV..R.AAPKF.-M.MN..N.K....-.-F.LLKKKKKKKK 55
bRSV   AK.NQ.L.FIRR.DEL.H--SVDVG.ST.NVV.TTI..V.V.VILML.A.GLLFYC.TKST.IMLGKDQ...IN.LS.S-----------K.    57
hRSV   .K.NQ.L.FIRR.DEL.H--NVNTG.ST.NIM.TTI..V.I.VLLSL.AIGLLLYC.AKNT.VTLSKDQ...IN.IA.S-----------K.    57
PVM    H..NQTRTFFKA.DQL.DLSENREN.NLNKSY.LTTLLFVVM.III.AVIGFILYKVLK----MIRDNK.KSKSTP.LT-----------VLS  53
```

Fig. 3, contd.

L polymerase RAP PCR fragment 8

```
00-1 fragment 8 ---------TVNVYLPDSYLKGVISFSFTNAIGSCLLKRPYLKNDNTAKVAIENPVIEHVRLKNAVNSKMKISDYK-----IVEPVNMQHE 77
APV-A           ME-ISNESV........................V.N...I.D.Y..H..MT......Q..RALFK.LTISRE.R-----V...LMI.K. 84
bRSV            MDTLIHENST....T...........C..L..Y..DG.....Y.NIISRQK.L...IN..KLSIIQSFVTK.NKGELGLE..TYF.SL 90
hRSV            MDPIINGNSA....T.G.........C..L..YIFNG.....Y.NLISRQ..L...MN..KLNITQSL..K.HKGEIKLE..TYF.SL 90

00-1 fragment 8 IM--KNVHSCEL----TLLKQFLTRSKNISTLKLNMICDWLQLK----------STSDDTSILSFIDVEFI------------------- 13
APV-A           LL--.VAAGAR.----KK..KW.G...D..EV..K.VT...K.S----------Q.PGRGK.IDR.Q..NL------------------- 13
bRSV            L.TY.SLSTS..ITTT..F.KIIR.AIE..DV.VYA.LNK.G..EKGKVDRC---DDTN.TLSNIVRDNILSVISDNTPSTKKPNNSSCK 17
hRSV            L.TY.SMT.S.QIATTN...KIIR.AIE..DV.VYA.LNK.G..EKDKIKSNNGQDE.NSV.TTI.KDDILSAVKDNQSHLKADKNHSTK 18

00-1 fragment 8 --------------------PSWVSNWFSNWYNLNKLILEFRKEEVIRTGSIL--CRSLGKLVFVVSSYGCIVKSNKSKRVSFFTYNQLL 20
APV-A           ---------------------.D.LEH..DS.LI..DV.QSY.CL..SQ.SA..--RK.SLNFF.A...F...II.R..R.IC.C..... 20
bRSV            PDQPIKTTILCKLLSSMSHP.T.LIH..NLYTK..DILTQY.TN.ARNH.Y..IDT.T..EFQ.ILNQ.....YHK.L.KITIT....F. 26
hRSV            QKDTIKTTLLKKLMCSMQHP...LIH..NLYTK..NILTQY.SN..KNH.FT.IDNQT.SGFQ.ILNQ.....YHKEL..ITVT....F. 27

00-1 fragment 8 TWKDVMLSRFNANFCIWVSNSLNENQEGVGLRSNL------Q                                                23
APV-A           ....LA.......L.V....C..SA.D.L....K.VGELLNR                                                24
bRSV            ....IS...L.VCMIT.I..C..TLNKSL...C                                                         30
hRSV            ....IS...L.VCLIT.I..C..TLNKSL.                                                            30
```

L polymerase RAP-PCR fragment 9/10

```
00-1 fragment 9/10 --KLVDKITSDQHIFSPDKIDMLTLGKMLMP--TIKGQKTDQ----FLNKRENYFHGNNLIESLSAALAXHWCGILTEQC 72
APV-A              -F.S.R..VT.....N..H..LVM...L.L.--.VRSNINNN-----KPAT..F.N...IV.A.TSC..C...TV.ILLT 72
bRSV               -ICKLNQVIQK..M.L....SLSQYVELFLSNK.L.NSPHISSNLVLVH.MSD..LHKYV---..TN..G..IM.IQLMK 76
hRSV               DIHKLKQVIQK..M.L....SLTQYVELFLSNK.L.SGSHVNSNLILAH.ISD...NTYI---..TN..G..IL.IQLMK 77

00-1 fragment 9/10 IENNIFKKDWGDGFISDHAFMDFKIFLCVFKTKLLC                                             10
APV-A              T..S..Q.E......T....IN.TW..MS...Y...HW                                           11
bRSV               DSKG..E....E.Y.T..M.L.LNV.FDAY..Y.                                               11
hRSV               DSKG..E....E.Y.T..M.INL.V.FNAY..Y                                                11
```


a
PVM
hRSV
bRSV
APV-B
APV-A
APV-C
00-1
0.1
b
PVM
hRSV
bRSV
APV-B
APV-A
APV-C
00-1
0.1
c
hRSV
bRSV
PVM
APV-B
APV-A
APV-C
00-1
0.1
d
PVM
hRSV
bRSV
APV-A
APV-C
00-1
0.1

Fig. 4


a
APV
94-1
99-1
99-2
94-2
93-1
93-2
93-3
00-1
0.1
b
APV
94-1
99-1
99-2
93-2
93-4
94-2
93-1
00-1
93-3
0.1
c
APV
94-1
99-2
99-1
00-1
93-2
93-1
94-2
93-3
93-4
0.1
d
APV
94-1
99-1
99-2
93-2
93-1
93-3
00-1
94-2
93-4
0.1

Fig. 5

```
ACGCGTATAAATTAGATTCAAAAAAATATGGGACAAGTGAAAATGTCTCTTCAAGGGATTCACCTGAGTGATTTATCATACAAGCATGCTATATTAAAAGAGTCTCAGTACACAATAAAAAGAGATGTGGGTACAACAACTGCAGTGACA 150
Trail M G Q V K M S L Q G I H L S D L S Y K H A I L K E S Q Y T I K R D V G T T T A V T
N
CCCTCATCATTGCAACAAGAAATAACACTGTTGTGTGGAGAAATTCTGTATGCTAAACATGCTGACTACAAATATGCTGCAGAAATAGGAATACAATATATTAGCACAGCTTTAGGATCAGAGAGAGTGCAGCAGATTCTGAGGAACTCA 300
P S S L Q Q E I T L L C G E I L Y A K H A D Y K Y A A E I G I Q Y I S T A L G S E R V Q Q I L R N S
N
GGCAGTGAAGTCCAAGTGGTCTTAACCAGAACGTACTCTCTGGGGAAAATTAAAAACAATAAAGGAGAAGATTTACAGATGTTAGACATACACGGGGTAGAGAAGAGCTGGGTAGAAGAGATAGACAAAGAAGCAAGGAAAACWATGGCA 450
G S E V Q V V L T R T Y S L G K I K N N K G E D L Q M L D I H G V E K S W V E E I D K E A R K T M A
N
ACCTTGCTTAAGGAATCATCAGGTAATATCCCACAAAATCAGAGGCCCTCAGCACCAGACACACCCATAATCTTATTATGTGTAGGTGCCTTAATATTCACTAAACTAGCATCAACCATAGAAGTGGGACTAGAGACCACAGTCAGAAGG 600
T L L K E S S G N I P Q N Q R P S A P D T P I I L L C V G A L I F T K L A S T I E V G L E T T V R R
N
GCTAACCGTGTACTAAGTGATGCACTCAAGAGATACCCTAGAATGGACATACCAAAGATTGCCAGATCCTTCTATGACTTATTTGAACAAAAAGTGTATCACAGAAGTTTGTTCATTGAGTATGGCAAAGCATTAGGCTCATCATCTACA 750
A N R V L S D A L K R Y P R M D I P K I A R S F Y D L F E Q K V Y H R S L F I E Y G K A L G S S S T
N
GGCAGCAAAGCAGAAAGTCTATTTGTTAATATATTCATGCAAGCTTATGGGGCCGGTCAAACAATGCTAAGGTGGGGGGTCATTGCCAGGTCATCCAACAATATAATGTTAGGACATGTATCCGTCCAAGCTGAGTTAAAACAGGTCACA 900
G S K A E S L F V N I F M Q A Y G A G Q T M L R W G V I A R S S N N I M L G H V S V Q A E L K Q V T
N
GAAGTCTATGACTTGGTGCGAGAAATGGGCCCTGAATCTGGACTTCTACATTTAAGGCAAAGCCCAAAAGCTGGACTGTTATCACTAGCCAACTGTCCCAACTTTGCAAGTGTTGTTCTCGGAAATGCCTCAGGCTTAGGCATAATCGGT 1050
E V Y D L V R E M G P E S G L L H L R Q S P K A G L L S L A N C F N F A S V V L G N A S G L G I I G
N
ATGTATCGAGGGAGAGTACCAAACACAGAATTATTTTCAGCAGCTGAAAGTTATGCCAAAAGTTTGAAAGAAAGCAATAAAATAAATTTCTCTTCATTAGGACTTACAGATGAAGAGAAAGAGGCTGCAGAACATTTCTTAAATGTGAGT 1200
M Y R G R V P N T E L F S A A E S Y A K S L K E S N K I N F S S L G L T D E E K E A A E H F L N V S
N
GACGACAGTCAAAATGATTATGAGTAATTAAAAAAGTGGGACAAGTCAAAATGTCATTCCCTGAAGGAAAAGATATTCTTTTCATGGGTAATGAAGCAGCAAAATTAGCAGAAGCTTTCCAGAAATCATTAAGAAAACCAGGTCATAAAA 1350
D D S Q N D Y E . GE GS M S F P E G K D I L F M G N E A A K L A E A F Q K S L R K P G H K
N P
GATCTCAATCTATTATAGGAGAAAAAGTGAATACTGTATCAGAAACATTGGAATTACCTACTATCAGTAGACCTGCAAAACCAACCATACCGTCAGAACCAAAGTTAGCATGGACAGATAAAGGTGGGGCAACCAAAACTGAAATAAAGC 1500
R S Q S I I G E K V N T V S E T L E L P T I S R P A K P T I P S E P K L A W T D K G G A T K T E I K
P
AAGCAATCAAAGTCATGGATCCCATTGAAGAAGAAGAGTCTACCGAGAAGAAGGTGCTACCCTCCAGTGATGGGAAAACCCCTGCAGAAAAGAAACTGAAACCATCAACTAACACCAAAAAGAAGGTTTCATTTACACCAAATGAACCAG 1650
Q A I K V M D P I E E E E S T E K K V L P S S D G K T P A E K K L K P S T N T K K K V S F T P N E P
P
GGAAATATACAAAGTTGGAAAAAGATGCTCTAGATTTGCTCTCAGATAATGAAGAAGAAGATGCAGAATCTTCAATCTTAACCTTTGAAGAAAGAGATACTTCATCATTAAGCATTGAGGCCAGATTGGAATCAATAGAGGAGAAATTAA 1800
G K Y T K L E K D A L D L L S D N E E E D A E S S I L T F E E R D T S S L S I E A R L E S I E E K L
P
GCATGATATTAGGGCTATTAAGAACACTCAACATTGCTACAGCAGGACCCACAGCAGCAAGAGATGGGATCAGAGATGCAATGATTGGCGTAAGAGAGGAATTAATAGCAGACATAATAAAGGAAGCTAAAGGGAAAGCAGCAGAAATGA 1950
S M I L G L L R T L N I A T A G P T A A R D G I R D A M I G V R E E L I A D I I K E A K G K A A E M
P
TGGAAGAGGAAATGAKTCAACGATCAAAAATAGGAAATGGTAGTGTAAAATTAACAGAAAAAGCAAAAGAGCTCAACAAAATTGTTGAAGATGAAAGCACAAGTGGAGAATCCGAAGAAGAAGAAGAACCAAAAGACACACAAGACAATA 2100
M E E E M ? Q R S K I G N G S V K L T E K A K E L N K I V E D E S T S G E S E E E E E P K D T Q D N
P
```

Fig. 6A

```
GTCAAGAAGATGACATTTACCAGTTAATTATGTAGTTTAATAAAAATAAACAATGGGACAAGTAAAAATGGAGTCCTACCTAGTAGACACCTATCAAGGCATTCCTTACACAGCAGCTGTTCAAGTTGATCTAATAGAAAAGGACCTGTT 225C
 S  Q  E  D  D  I  Y  Q  L  I  M  |▬▬▬GE▬▬▬||▬GS▬| M  E  S  Y  L  V  D  T  Y  Q  G  I  P  Y  T  A  A  V  Q  V  D  L  I  E  K  D  L  L
─────────────P──────────────────┘                 └──────────────────────────────M──────────────────────────────
ACCTGCAAGCCTAACAATATGGTTCCCTTTGTTTCAGGCCAACACACCACCAGCAGTGCTGCTCGATCAGCTAAAAACCCTGACAATAACCACTCTGTATGCTGCATCACAAAATGGTCCAATACTCAAAGTGAATGCATCAGCCCAAGG 240C
  P  A  S  L  T  I  W  F  P  L  F  Q  A  N  T  P  P  A  V  L  L  D  Q  L  K  T  L  T  I  T  T  L  Y  A  A  S  Q  N  G  P  I  L  K  V  N  A  S  A  Q  G
──────────────────────────────────────────────────────M──────────────────────────────────────────────────────
TGCAGCAATGTTTGTACTTCCCAAAAAATTTGAAGTCAATGCGACTGTAGCAMTCGATGAATATAGCAAACTGGAATTTGACAAACTCACAGTCTGTGAAGTAAAAACAGTTTACTTAACAACCATGAAACCATACGGGATGGTATCAAA 255C
  A  A  M  F  V  L  P  K  K  F  E  V  N  A  T  V  A  ?  D  E  Y  S  K  L  E  F  D  K  L  T  V  C  E  V  K  T  V  Y  L  T  T  M  K  P  Y  G  M  V  S  K
──────────────────────────────────────────────────────M──────────────────────────────────────────────────────
ATTTGTGAGCTCAGCCAAATCAGTTGGCAAAAAAACACATGATCTAATCGCACTATGTGATTTTATGGATCTAGAAAAGAACACACCTGTTACAATACCAGCATTCATCAAATCAGTTTCAATCAAAGAGAGTGAGTCAGCTACTGTTGA 270C
  F  V  S  S  A  K  S  V  G  K  K  T  H  D  L  I  A  L  C  D  F  M  D  L  E  K  N  T  P  V  T  I  P  A  F  I  K  S  V  S  I  K  E  S  E  S  A  T  V  E
──────────────────────────────────────────────────────M──────────────────────────────────────────────────────
AGCTGCTATAAGCAGTGAAGCAGACCAAGCTCTAACACAGGCCAAAATTGCACCTTATGCGGGATTAATTATGATCATGACTATGAACAATCCCAAAGGCATATTCAAAAAGCTTGGAGCTGGGACTCAAGTCATAGTAGAACTAGGAGC 285C
  A  A  I  S  S  E  A  D  Q  A  L  T  Q  A  K  I  A  P  Y  A  G  L  I  M  I  M  T  M  N  N  P  K  G  I  F  K  K  L  G  A  G  T  Q  V  I  V  E  L  G  A
──────────────────────────────────────────────────────M──────────────────────────────────────────────────────
ATATGTCCAGGCTGAAAGCATAAGCAAAATATGCAAGACTTGGAGCCATCAAGGGACAAGATATGTCTTGAAGTCCAGATAACAACCAAGCACCTTGGCCAAGAGCTACTAACCCTATCTCATAGATCATAAAGTCACCATTCTAGTTAT 300C
  Y  V  Q  A  E  S  I  S  K  I  C  K  T  W  S  H  Q  G  T  R  Y  V  L  K  S  R   |▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬GE▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
───────────────────────────────M───────────────────────────────────┘
ATAAAAATCAAGTTAGAACAAGAATTAAATCAATCAAGAACGGGACAAATAAAAATGTCTTGGAAAGTGGTGATCAKTTTTTCATTGTTAATAACACCTCRACACGGTCTTAAAGAGAGCTACTTAGAAGAGTCATGTAGCACTATAACT 315C
▬▬▬▬▬▬▬▬▬▬▬GE▬▬▬▬▬▬▬▬▬▬▬||▬GS▬| M  S  W  K  V  V  I  ?  F  S  L  L  I  T  P  ?  H  G  L  K  E  S  Y  L  E  E  S  C  S  T  I  T
                                └──────────────────────────────F──────────────────────────────
GAAGGATATCTCAGTGTTCTGAGGACAGGTTGGTACACCAATGTTTTTACACTGGAGGTAGGCGATGTAGAGAACCTTACATGTGCCGATGGACCCAGCTTAATAAAAACAGAATTAGACCTGACCAAAAGTGCACTAAGAGAGCTCAGA 330C
 E  G  Y  L  S  V  L  R  T  G  W  Y  T  N  V  F  T  L  E  V  G  D  V  E  N  L  T  C  A  D  G  P  S  L  I  K  T  E  L  D  L  T  K  S  A  L  R  E  L  R
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
ACAGTTTCTGCTGATCAACTGGCAAGAGAGGAGCAAATTGAAAATCCCAGACAATCTAGATTCGTTCTAGGAGCAATAGCACTCGGTGTTGCAACTGCAGCTGCAGTTACAGCAGGTGTTGCAATTGCCAAAACCATCCGGCTTGAAAGT 345C
 T  V  S  A  D  Q  L  A  R  E  E  Q  I  E  N  P  R  Q  S  R  F  V  L  G  A  I  A  L  G  V  A  T  A  A  A  V  T  A  G  V  A  I  A  K  T  I  R  L  E  S
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
GAAGTAACAGCAATTAAGAATGCCCTCAAAAAGACCAATGAAGCAGTATCTACATTGGGGAATGGAGTTCGTGTGTTGGCAACTGCAGTGAGAGAACTGAAAGATTTTGTGAGCAAGAATCTAACACGTGCAATCAACAAAAACAAGTGC 360C
 E  V  T  A  I  K  N  A  L  K  K  T  N  E  A  V  S  T  L  G  N  G  V  R  V  L  A  T  A  V  R  E  L  K  D  F  V  S  K  N  L  T  R  A  I  N  K  N  K  C
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
GACATTGCTGACCTGAAAATGGCCGTTAGCTTCAGTCAATTCAACAGAAGGTTCCTAAATGTTGTGCGGCAATTTTCAGACAACGCTGGAATAACACCAGCAATATCTTTGGACTTAATGACAGATGCTGAACTAGCCAGAGCTGTTTCC 375C
 D  I  A  D  L  K  M  A  V  S  F  S  Q  F  N  R  R  F  L  N  V  V  R  Q  F  S  D  N  A  G  I  T  P  A  I  S  L  D  L  M  T  D  A  E  L  A  R  A  V  S
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
AACATGCCAACATCTGCAGGACAAATAAAACTGATGTTGGAGAACCGTGCAATGGTAAGAAGAAAAGGGTTCGGATTCCTGATAGGAGTTTACGGAAGCTCCGTAATTYACATGGTGCAACTGCCAATCTTTGGGGTTATAGACACGCCT 390C
 N  M  P  T  S  A  G  Q  I  K  L  M  L  E  N  R  A  M  V  R  R  K  G  F  G  F  L  I  G  V  Y  G  S  S  V  I  ?  M  V  Q  L  P  I  F  G  V  I  D  T  P
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
TGCTGGATAGTAAAAGCAGCCCCTTCTTGTTCAGGAAAAAAGGGAAACTATGCTTGCCTCTTAAGAGAAGACCAAGGATGGTATTGTCAAAATGCAGGGTCAACTGTTTACTACCCAAATGAAAAAGACTGTGAAACAAGAGGAGACCAT 405C
 C  W  I  V  K  A  A  P  S  C  S  G  K  K  G  N  Y  A  C  L  L  R  E  D  Q  G  W  Y  C  Q  N  A  G  S  T  V  Y  Y  P  N  E  K  D  C  E  T  R  G  D  H
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
GTCTTTTGCGACACAGCAGCAGGAATCAATGTTGCTGAGCAGTCAARGGAGTGCAACATAAACATATCTACTACTAATTACCCATGCAAAGTTAGCACAGGAAGACATCCTATCAGTATGGTTGCACTATCTCCTCTTGGGGCTYTGGTT 420C
 V  F  C  D  T  A  A  G  I  N  V  A  E  Q  S  ?  E  C  N  I  N  I  S  T  T  N  Y  P  C  K  V  S  T  G  R  H  P  I  S  M  V  A  L  S  P  L  G  A  L  V
──────────────────────────────────────────────────────F──────────────────────────────────────────────────────
```

Fig. 6A, contd.

```
GCTTGCTACAAGGGAGTGAGCTGTTCCATTGGCAGCAACAGAGTAGGGATCATCAAGCAACTGAACAAAGGCTGCTCTTATATAACCAACCAAGACGCAGACACAGTGACAATAGACAACACTGTATACCAGCTAAGCAAAGTTGAAGGC   4350
 A  C  Y  K  G  V  S  C  S  I  G  S  N  R  V  G  I  I  K  Q  L  N  K  G  C  S  Y  I  T  N  Q  D  A  D  T  V  T  I  D  N  T  V  Y  Q  L  S  K  V  E  G
                                                                            F
GAACAGCATGTTATAAAAGGAAGGCCAGTGTCAAGCAGCTTTGACCCAGTCAAGTTTCCTGAAGATCAATTCAATGTTGCACTTGACCAAGTTTTCGAGAGCATTGAGAACAGTCAGGCCTTGGTGGATCAATCAAACAGAATCCTAAGC   4500
 E  Q  H  V  I  K  G  R  P  V  S  S  S  F  D  P  V  K  F  P  E  D  Q  F  N  V  A  L  D  Q  V  F  E  S  I  E  N  S  Q  A  L  V  D  Q  S  N  R  I  L  S
                                                                            F
AGTGCAGAGAAAGGAAACACTGGCTTCATCATTGTAATAATTCTAATTGCTGTCCTTGGCTCTACCATGATCCTAGTGAGTGTTTTTATCATAATAAAGAAAACAAAGAGACCCACAGGAGCACCTCCAGAGCTGAGTGGTGTCACAAAC   4650
 S  A  E  K  G  N  T  G  F  I  I  V  I  I  L  I  A  V  L  G  S  T  M  I  L  V  S  V  F  I  I  I  K  K  T  K  R  P  T  G  A  P  P  E  L  S  G  V  T  N
                                                                            F
AATGGCTTCATACCACATAATTAGTTAATTAAAAATAAATTAAAATAAATTAAAATTAAAAATAAAAATTTGGGACAAATCATAATGTC   4739
 N  G  F  I  P  H  N  .    GE                   GS     M
          F                                           M2
```

Fig. 6A, contd.

CAAGAAAAAAACTGTTCCACTGTTAATGTCTATCTTCCTGACTCATATCTTAAAGGAGTGATTTCCTTTAGTGAGACTAATGCAATTGGTTCATGTCTCTTAAAAAGACCTTACCTAAAAAATGACAACACTGCAAAAGTTGCCATAGAG 150

Q E K N C S T V N V Y L P D S Y L K G V I S F S E T N A I G S C L L K R P Y L K N D N T A K V A I E

AATCCTGTTATCGAGCATGTTAGACTCAAAAATGCAGTCAATTCTAAGATGAAAATATCAGATTACAAGATAGTAGAGCCAGTAAACATGCAACATGAAATTATGAAGAATGTACACAGTTGTGAGCTCACATTATTAAAACAGTTTTTA 300

N P V I E H V R L K N A V N S K M K I S D Y K I V E P V N M Q H E I M K N V H S C E L T L L K Q F L

ACAAGGAGTAAAAATATTAGCACTCTCAAATTAAATATGATATGTGATTGGCTGCAGTTAAAGTCTACATCAGATGATACCTCAATCCTAAGTTTTATAGATGTAGAATTTATACCTAGCTGGGTAAGCAATTGGTTTAGTAATTGGTAC 450

T R S K N I S T L K L N M I C D W L Q L K S T S D D T S I L S F I D V E F I P S W V S N W F S N W Y

AATCTCAACAAGTTGATTCTGGAATTCAGGAAAGAAGAAGTAATAAGAACTGGTTCAATCTTGTGTAGGTCATTGGGTAAATTAGTTTTTGTTGTATCATCATATGGATGTATAGTCAAGAGCAACAAAAGCAAAAGAGTGAGCTTCTTC 600

N L N K L I L E F R K E E V I R T G S I L C R S L G K L V F V V S S Y G C I V K S N K S K R V S F F

ACATACAATCAACTGTTAACATGGAAAGATGTGATGTTAAGTAGATTCAATGCAAATTTTTGTATATGGGTAAGCAACAGTCTGAATGAAAATCAAGAAGGGGTAGGGTTGAGAAGTAATTTGCAAGGCATATTAACTAATAAGCTATAT 750

T Y N Q L L T W K D V M L S R F N A N F C I W V S N S L N E N Q E G V G L R S N L Q G I L T N K L Y

GAAACTGTAGATTATATGCTTAGTTTATGTT 781

E T V D Y M L S L C

Fig. 6B

ATAAGCTAGTAGATAAGATAACTTCTGATCAACATATCTTCAGTCCAGACAAAATAGATATGTTAACACTGGGGAAAATGCTCATGCCCACTATAAAAGGTCAGAAAACAGATCAGTTCCTGAACAAGAGAGAGAATTATTTCCATGGGA 150
K L V D K I T S D Q H I F S P D K I D M L T L G K M L M P T I K G Q K T D Q F L N K R E N Y F H G

ATAATCTTATTGAGTCTTTGTCAGCAGCGTTAGCATGTCATTGGTGTGGGATATTAACAGAGCAATGTATAGAAAATAATATTTTCAAGAAAGACTGGGGTGACGGGTTCATATCGGATCATGCTTTTATGGACTTCAAAATATTCCTAT 300
N N L I E S L S A A L A C H W C G I L T E Q C I E N N I F K K D W G D G F I S D H A F M D F K I F L

GTGTCTTTAAAACTAAACTTTTATGTA 327
C V F K T K L L C

Fig. 6C


5263 5478
M2.2
3'
55
1239
1263
2147
2180
2944
3067
4686
4752
5315
5509
6060
6262
6972
7182
13199
N
P
M
F
M2
SH
G
L
5'
(13378)
Reading frame 1:
6262
6972
6973
7179
Reading frame 2:
6416
7000
7001
7198
Reading frame 3:
6444
6737

Fig. 7

Fig. 8

```
                                                        50
HMPV  MSLQGIHLSDLSYKHAILKESQYTIKRDVGTTTAVTPSSLQQEITLLCGE
APVC  ......Q..................................R.VS.....
APVB  ...ES.R....E......D......R....A...I...E..PKVST...M
APVA  ...ES.R....E......ED.....R....A...I...E..PQVST...M
HRSVA .A.SKVK.N.TLN.DQL.SS.K...Q.ST.DSIDTPNYDV.KH.NK...M
HRSVB .A.SKVK.N.TLN.DQL.SS.K...Q.ST.DNIDTPNYDV.KHLNK...M
BRSV  .A.SKVK.N.TFN.DQL.ST.K...Q.ST.DNIDIPNYDV.KHLNK...M
PVM   ...DRLK.N.V.N.DSL.SNCK.SVT.ST.DV.S.SGHAM.KALARTL.M
                                                       100
HMPV  ILYAKHADYKYAAEIGIQYISTALGSERVQQILRNSGSEVQVVLTRTYSL
APVC  ......T..SH...V.M..V..T..A..T....K.......A...K....
APVB  ..F......EP..QV.M........ADKT....KS......G.M.KIVT.
APVA  V.F...T..EP...V.M.........AD.T....K.......G.M.KIVT.
HRSVA L.ITED.NH.FTGL..ML.AMSR..R.DTIK...DA.YH.KANGVDVTTH
HRSVB L.ITED.NH.FTGL..ML.AMSR..R.DTIK..KDA.YH.KANGVDITTY
BRSV  L.ITED.NH.FTGL..ML.AMSR..R.DTLK..KDA.YQ.RANGVDVITH
PVM   F.LTAFNRCEEV....L..AMSL..RDDSIK...EA.YN.KC.D.QLKDF
                                                       150
HMPV  GKIKNNKGEDLQMLDIHGVEKSWVEEIDKEARKTMATLLKESSGNIPQNQ
APVC  ..G..S...E..........R..I..V.........SAT.DN..P.....
APVB  PAEGPIR--KREV.N..DIGPA.ADNVERT..E..SLMV..K-AQ..K..
APVA  SAEGSVR--KREV.N..D.GVG.ADDVERTT.EA.GAMVR.K-VQLTK..
HRSVA RQDI.G.EMKFEV.TLASLTTEIQIN.EI.S..SYKKM...M-.EVAPEY
HRSVB RQDI.G.EMKFEV.TLSSLTSEIQVN.EI.S..SYKKM...M-.EVAPEY
BRSV  RQDV.G.EMKFEV.TLVSLTSEVQGN.EI.S..SYKKM...M-.EVAPEY
PVM   TIKLQG.EYKI.V...V.IDAANLADLEIQ..GVV.KE..TG-ARL.D.R
                     A                                 200
HMPV  RPSAPDTPIILLCVGALIFTKLASTIEVGLETTVRRANRVLSDALKRYPR
APVC  ...S..A......I..................A........N.....F..
APVB  K...L.A.V....I...........V......AI...S......IS....
APVA  K...L.A.V....I...........V......AI...S......IS....
HRSVA .HDS..CGM.I..IA..VI....AGDRS..TAVI....N..KNEM...KG
HRSVB .HDS..CGM.I..IA..VI....AGDRS..TAVI....N..KNEI...KG
BRSV  .HDS..CGM.V...A..VI....AGDRS..TAVI....N..RNEM...KG
PVM   .HD...CGV.V..IA..VVS...AGDRG..DAVE...LN..KAEKA...N
                                                       250
HMPV  MDIPKIARSFYDLFEQKVYHRSLFIEYGKALGSSSTGSKAESLFVNIFMQ
APVC  I..................Y..............................
APVB  ....R..K..FE...K..Y.N.............T.S..RM.........
APVA  ....R..K..FE...K..Y.N.............T....RM.........
HRSVA LLPKD..N...EV..KHPHFIDV.VHF.I.QS.TRG..RV.GI.AGL..N
HRSVB LIPKD..N...EV..KHPHLIDV.VHF.I.QS.TRG..RV.GI.AGL..N
BRSV  LIPKD..N...EV..KYPHYIDV.VHF.I.QS.TRG..RV.GI.AGL..N
PVM   .EVKQ..E.......R.P.YIDV..TF.L.QS.VRG...V.G..SGL..N
          B                                     C  300
HMPV  AYGAGQTMLRWGVIARSSNNIMLGHVSVQAELKQVTEVYDLVREMGPESG
APVC  ..................................................
APVB  ..........R..V..................R..S.......K......
APVA  ................................R..S.......K......
HRSVA ......V......L.K.VK.......A....ME..V...EYAQKL.G.A.
HRSVB ...S..V......L.K.VK.......A....ME..V...EYAQKL.G.A.
BRSV  ......V......L.K.VK.......A....ME..V...EYAQKL.G.A.
PVM   ......V.....IL.K.VK.......A....ME..V...EYAQKQ.G.A.
                                                       350
HMPV  LLHLRQSPKAGLLSLANCPNFASVVLGNASGLGIIGMYRGRVPNTELFSA
APVC  ......N............................L.............A.
APVB  ...............TS............A........K..A..L.....
APVA  ...............T.............A........K..A..L...A.
HRSVA FY.ILNN...S....TQF.H.S.......A....M.E...TPR.QD.YD.
HRSVB FY.ILNN...S....TQF...S.......A....M.E...TPR.QD.YD.
BRSV  FY.ILNN...S....TQF...S.......A....M.E...TPR.QD.YD.
PVM   FY.I.NN...S....T.....T.......A......S.K.APR.R...D.
                                                  395
HMPV  AESYAKSLKESNKINFSSLGLTDEEKEAAEHFLNVSDDS-QNDYE
APVC  .....R................E.......N...INEEG-.....
APVB  .....R.........LAA....ED.R...TSY.GGDE.K-SQKF.
APVA  .....RT.R.N....LAA.....D.R...TSY.GGD.ER-SSKF.
HRSVA .KA..EQ...NGV..Y.V.D..A..L..IK.Q..PK.N--DVEL-
HRSVB .KA..EQ...NGV..Y.V.D..A..L..IKNQ..PKE.--DVEL-
BRSV  .KA..EQ...NGV..Y.V.D..T..L..IKNQ..PK.N--DVEL-
PVM   .KD..ER..DN.V..Y.A.N..A..R.LISQQ..IV..TPDD.I-
```

Fig. 9

```
                                                      50
HMPV  MSFPEGKDILFMGNEAAKLAEAFQKSLRKPGHKRS--------QSIIGEK
APVC  ..........L.......A.....R..K.I..R.T---------...V.D.
APVB  ..L.......M..S.........Y.Q.IKNSTSV.----------R..S.DP
APVA  ..........M..S....M.D.Y.R...NTSAGG----------R..S..P
HRSVA ---M.KFAPE.H.ED.NNR.TK.LE.------------------------
HRSVB ---M.KFAPE.H.ED.NNK.TK.LE.------------------------
BRSV  ---M.KFAPE.H.ED.NTK.TK.LE.------------------------
PVM   ---M.KFAPE.V.ED.N.K..E.L.HRSF.SE.PLAGIPNTATHVTKYNM
                                                     100
HMPV  VNTVSETLELPTISRPAKPTIPSEPKLAWTDKGGATKTEIKQAIKVMDPI
APVC  II.....V.K....KST.V.T.P.R.N..GE.PDT.RSQTEE.RNEAT.E
APVB  .S....KVP..PLCSSETS------------R.ACIRPT-.STLPPIK--
APVA  I..IA.KVP..PLCN.TT.-------------..SCI.PN-.APVPKVK--
HRSVA ---IKGKFTS.------------------------KDPKK.DS.ISVNS.
HRSVB ---IKGKFASS------------------------KDPKK.DS.ISVNS.
BRSV  ---LKGKFTSS------------------------KDSRK.DS.ISVNSV
PVM   PPILRSSFK..SPRVA.NL.E..A.P----TTPPP.PPQN.EEQPKESDV
                                                     150
HMPV  EEEESTEKKVLPSSDGKTPAEKKLKPSTNTKKK-----VSFTPNEPGKYT
APVC  DASRLY.EVFA.T.........GKETPEKP...-----.T.KND.S.R..
APVB  .V.SIYP.LPTAPP.AMIETAHPIGAPKKAQ.R-----.K.ESSKA....
APVA  .I.SIYP.LPTAPVATD.YTSTSTESAKKS..------.K.DNPKV....
HRSVA DI.VTK.SPITSN.TIIN.TNETDDTAG.KPNYQRKPL...KEDPTPSDN
HRSVB DI.VTK.SPITSGTNIIN.TSEADSTPETKANYPRKPL...KEDLTPSDN
BRSV  DI.LPK.SPITSTNQNINQPSEINDTIATNQVHIRKPL...KEEL.SSEN
PVM   DI.TMHVC..PDNPEHSKKPCCSDDTD.KKT---RKPM.T.VEP.EKFVG
                                                     200
HMPV  KLEKDALDLLSD-NEEEDAESSILTFEERD--TSSLSIEARLESIEEKLS
APVC  ...ME..E....-..DD.....V.....K.--..A..L.......D....
APVB  ...EE..E....PD.DN.EK..V.....K.--NAPS.......A......
APVA  ...EEG.E....PE.DN.EK........K.--.A.T.......A......
HRSVA PFS.LYKETIETFDNN--E.E.SYSY..INDQ.NDN-.T...DR.D....
HRSVB PFS.LYKETIETFDNN--E.E.SYSY..INDQ.NDN-.T...DR.D....
BRSV  PFTRLYKETIETFDNN--E.E.SYSYD.INDQ.NDN-.T...DR.D....
PVM   LGASLYRETMQTFAADGYD.E.N.S...TNQEPG.S.V.Q..DR......
                                                     250
HMPV  MILGLLRTLNIATAGPTAARDGIRDAMIGVREELIADIIKEAKGK-----
APVC  ..........V.................V.L..............-----
APVB  ....M.K..S..................V.......NS.MA.....-----
APVA  ....M.K......................M.....NS.MT...D.-----
HRSVA E...M.H..VV.S....S...........L...M.EK.RT..LMTNDRLE
HRSVE E...M.H..VV.S....S.........V.L...M.EK.RA..LMTNDRLE
BRSV  E.I.M.H..VV.S...............V.L...M.EK.RS..LMTNDRLE
PVM   Y.I...N.IMV......T...E....L..T.....EM.KSDILTVNDRIV
                                                     300
HMPV  -AAEMMEEEMSQRSKIGNGSVKLTEKAKELNKIVEDESTSGESEEEEEPK
APVC  -.....K..AK.K........G..........................EE
APVB  -I..IIK..DA..A...D.........R...RML..Q.S.....T.S.ET
APVA  -I....K..DT..A...D...............L..Q.S.....S...SG
HRSVA AM.RLRN..SEKMA.DTSDE.S.NPTSEK..NLL.G-------------N
HRSVB AM.RLRN..SEKMA.DTSDE.P.NPTS.K.SDLL..-------------N
BRSV  AM.RLRD..SEKMT.DTSDE....PTSEK..MVL..-------------E
PVM   AMEKLRD..C.RADTDDGSACY..DR.RI.D...SSNA-----------E
                    316
HMPV  DTQDNSQEDDIYQLIM
APVC  .EEESNPD..L.S.T.
APVB  EPDTDGEN....SFD.
APVA  ESESDEE.S...N.DL
HRSVA .SDNDLSLE.F-----
HRSVB .SDNDLSL..F-----
BRSV  SSDNDLSLE.F-----
PVM   EAKEDLDV...MGINF
```

Fig. 10

```
                                                      50
HMPV  MESYLVDTYQGIPYTAAVQVDLIEKDLLPASLTIWFPLFQANTPPAVLLD
APVC  ...........V.......T..V...Q...R..V.V....T....T...E
APVB  ....II.....V..........V...NN..K..V......SS..AP....
APVA  ....II.....V..............SN..T..V......SS..AP....
HRSVA ..T.VNKLHE.ST......YNVL...DD.......V.M..SSM.ADL.IK
HRSVB ..T.VNKLHE.ST......YNVL...DD.......V.M..SSV.ADL.IK
BRSV  ..T.VNKLHE.ST......YNV....DD.......V.M..SSISADL.IK
PVM   ..A...EM.H.V.......LN.V..HSANI...V.I.M..TSL.KNSVM.
                                                     100
HMPV  QLKTLTITTLYAASQNGPILKVNASAQGAAMSVLPKKFEVNATVALDEYS
APVC  ...........T....................A...S.D.S.S....D..
APVB  .....S...Q.TV.PE..V.Q...T.......A.....S.S.AA......
APVA  .....S...Q.T..PE..V.Q...A.......A.....A.S.A.......
HRSVA E.ANVN.LVKQISTPK..S.R.MINSRS.VLAQM.S..TIC.N.S...R.
HRSVB E.ASIN.LVKQISTPK..S.R.TINSRS.VLAQM.SN.IIS.N.S...R.
BRSV  E.INVN.LVRQISTLK..S..IMINSRS.VLAQM.S..TIS.N.S...R.
PVM   L.HDV.VICTQISTVH..MI..DL.SSN.GLATM.RQ.LI..II...DWG
                                                     150
HMPV  KLEFDKLTVCEVKTVYLTTMKPYGMVSKFVSSAKSVGKKTHDLIALCDFM
APVC  ...........L.A................N...A..............L
APVB  ..D.GV....D.RA.....L........I.TNMNT..R...........I
APVA  R...GT....D.RSI....L........IMTDVR...R...........I
HRSVA ..AY.VT.P..I.ACS..CL.SKN.LTTVKDLTMKTLNP...I....E.E
HRSVB ..AY.VT.P..I.ACS..CL.VKS.LTTVKDLTMKTFNP..EI....E.E
BRSV  ..AY.IT.P..I.ACS..CL.VKN.LTTVKDLTMKTFNP..EI....E.E
PVM   NMDYEVPVAFDK.SFCV.IL..KN.LYTVP.ITP-TNRP..E...V.S.H
                                                     200
HMPV  DLEKNTPVTIPAFIKSVSIKESESATVEAAISSEADQALTQAKIAPYAGL
APVC  ....GV......Y...................G.....I...R.......
APVB  .M.RGI......Y..A....D...........G.....I...R.......
APVA  .I..GV.I....Y..A....D...........G.....I...R.......
HRSVA NIVTSKK.I..TYLR.I.VRNKDLN.L.NITTT.FKN.I.N...I..S..
HRSVB NIMTSKR.I..TYLRPI.V.NKDLNSL.NIATT.FKN.I.N...I.....
BRSV  NIMTSKR.V..T.LR.INV.AKDLDSL.NIATT.FKN.I.N...I.....
PVM   NRVTLKSFN..V..RALY.RQQGLDS..Q....DV.H.I.T.RV......
                                                     250
HMPV  IMIMTMNNPKGIFKKLGAGTQVIVELGAYVQAESISKICKTWSHQGTRYV
APVC  ...................V................R..RN.........
APVB  .LL.A........R.............P......LG......N..R...I
APVA  .L.................M.......P......LG......N..R....
HRSVA LLVI.VTDN..A..YIKPQS.F..D....LEK...YYVTTN.K.TA..FA
HRSVB VLVI.VTDN..A..YIKPQS.F..D....LEK...YYVTTN.K.TA..FS
BRSV  VLVI.VTDN..A..YIKPQS.F..D....LEK...YYVTTN.K.TA.KFS
PVM   TLVINITST..A..L.K..S.ILA...P.LTQV.LHDVIMN.K.T..S.I
           258
HMPV  LKSR----
APVC  ....----
APVB  ....----
APVA  .R..----
HRSVA I.PMED--
HRSVB I.PLED--
BRSV  I.PIED--
PVM   ...SSTSG
```

Fig. 11

```
                     Signal peptide                                                                    100
HMPV   ---------MSWKVVIIFSLLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPS---LIKTELDLTKSALRELRTVSADQ
APVC   ---------......LLLV..A..TG..E.......Y..V.R...........................T....---..R...E...N..E..K......
APVB   ---------.YL.LLL.IY.VVGASGKIQ.T.S......V.R..K............N..I.N...I..N....---..S...S..QN..Q.........
APVA   ---------.DVRICLLLF.ISN.SSCIQ.T.N......V.R..K............N..I.N...I..N....---..D...V...N.....K......
HRSVA  MELLILKANAITTILTAVTFCFASGQNIT.EFYQST..AVSK....A.......S.I.I.LSNIKENK.NGTDAKVK...Q...KY.N.VT..QLLMQST
HRSVB  MELLIHRLSAIFLTLA.NA.YL.SSQNIT.EFYQST..AVSR..F.A.......S.I.I.LSNIKETK.NGTDTKVK...Q...KY.N.VT..QLLMQNT
BRSV   MATTAMRMII.IIFISTYVTH..LCQNIT.EFYQST..AVSR....A.......S.V.I.LSKIQKNV.KSTD.KVK...Q..ERYNN.VV..QSLMQNE
PVM    ----MIPGRIFLVLLV..NTKPIHPNT.T.K.Y.ST..VE.A..K.A.....HMT.MSIKLSQINIES.KSSN.---.LAH..AIYS..VD....L.SN-

                                           Fusion domain                              HRA              200
HMPV   LAREEQ----------------------IENPRQSRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELK
APVC   ..K.AR----------------------.MS..KA..............................G..A...G..R....................ND..
APVB   ITK.NR----------------------.LSH.KK............T........L........G..K...L..RS.............I.....ND..
APVA   V.K.SR----------------------LSS..RR.....................L........G..K......RN...................ND..
HRSVA  PPTNNRARRELPRFMNYTLNNAKKTNVTLSKK.KR..LG--FL...G--S.IAS...VS.VLH..G..NK..S..LS..K..VS.S...S..TSK.LD..
HRSVB  P.ANNRARREAPQYMNYTINTTKNLNVS.SKK.KR..LG--FL...G--S.IAS.I.VS.VLH..G..NK.....LS..K..VS.S...S..TSK.LD..
BRSV   P.SFSRAKRGIPELIHYTRNSTKKFYGLMGKK.KR..LG--FL..IG--S..AS...VS.VLH..G..NK.....LS..K..VS.S...S..TSK.LD..
PVM    --------------------------ALKSK-.KK..LG--LI..LG--.......L...VQ....IAL.RD.VRN......VS.T..MS...KV.DD..

                                                                                                       300
HMPV   DFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSS
APVC   ..I..K..P...R.....S.......G.Y................................V.........S...N...............I........
APVB   E.I..K..P...Q...N...IR..I..G.N..............S...S.V..........VK.INR....S...S...N...........I......GT
APVA   E.I..K..P...Q...N...I...I..G.N..............S...S.V.......D..V..INR....S...S...N...........I.....DGT
HRSVA  NYID.Q.LPIV..QS.S.SNIETVIE.Q.K.N.L.EIT.E..V...V.TPV.TYML.NS..LSLIND..ITND.K...SN.VQI..QQSYSIMSIIKEEV
HRSVB  NYINNQ.LPIV.CQS.R.SNIETVIE.Q.K.S.L.EIN.E..V...V.TPL.TYML.NS..LSLIND..ITND.K...SS.VQI..QQSYSIMSIIKEEV
BRSV   NYID.E.LPQV.NHD.R.SNIETVIE.Q.K.N.L.EIA.E..V.....TPL.TYML.NS..LSLIND..ITND.K...SS.VQI..QQSYSIMSV.KEEV
PVM    N.I..E.LPK..RVS..VH.ITAVIR.Q.L.K.L.E.S.E..S...L.HTV.SFML..R..TSI.GG.AV....KEI..SSK.IM..N.LAI.SS.NADT

                                                                                                       400
HMPV   VIYMVQLPIFGVIDTPCWIVKAAPSCSG--KKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCKVS
APVC   .V.I..............K.....I...--.D.............................E..V.S.............KE.E..R.....K......
APVB   .V...........E....R.V...I.RH--ERES............T.....A......D..V.D.Y...........SEVEQ..H....ST.......
APVA   .V...........E....R.V...I.RK--E......I.........T.....A.....KD..V.D.Y...........LEVEQ..Y....SK.......
HRSVA  LA.V...LY.........KLHTS.I.TTNT.E.SNI..T.T.R....D....VSFF.QAET.KVQSNR....MNSLTLPSEINI..VD.FNPK.I..IM
HRSVB  LA.V....Y.........KLHTS.I.TTNI.E.SNI..T.T.R....D....VSFF.QADT.KVQSNR....MNSLTLPSEVSI..TD.FNSK.I..IM
BRSV   IA.V....Y.........KLHTS.I.TTDN.E.SNI..T.T.R....D....VSFF.QTET.KVQSNR....MNSLTLPTDVNI..TD.FN.K.I..IM
PVM    LV.VI...L...M..I..VIRSSII.HN--IADK....A.A.N....H....LS.F.SPT..IHNGYA...LKSLT.PVT.R..S.MY....I..I.

                                                                                                       500
HMPV   TGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVF
APVC   ....................D.M.......K...RP.G.....S........................T...K....N...IE.......I......
APVB   .....V.....T...G..S..E.........K..........TH.P.NE...I.....I......V...RT...A..VNN.N.LL..............
APVA   .....V.....T...G..S..ES........K......G...TH.P.NE...I............V...RT...A..VNN.N.IL..............
HRSVA  .SKTDV.SSVITS...I.S..GKTK.TASNKNR....TFSN..D.VS.KGM...SVG..L.YVN.Q..KSLYV..E.IINFY..LV..S.E.DASIS..N
HRSVB  .SKTD..SSVITS...I.S..GKTK.TASNKNR....TFSN..D.VS.KGV...SVG..L.YVN.L..KNLYV..E.IINYY..LV..S.E.DASIS..N
BRSV   .SKTD..SSVITSI..I.S..GKTK.TASNKNR....TFSN..D.VS.KGV...SVG..L.YVN.L..KALY...E.IINYY..LV..S.E.DASIA..N
PVM    .SKTYV.TAV.TTM.C..S..GHN..TVIN.DK...RT.PD..H..S.KGV.R.QVG....Y...EV.KSI.VR.E.LVLKY..LS..D.K.D..IRD.E

               HRB                              Membrane anchor                          583
HMPV   ESIENSQALVDQSNRILSSAE----KGNTGFIIVIILIAVLGSTMILVSVFIIIKKTKKPTG---AP-PELSGVTNNGFIPHN
APVC   ..V.K..N.I....K..D.I.----...A..V...V..VL.MLAAVG.G..FVV..R.AAPK---F.-M.MN..N.K....--
APVB   ..VDK.KD.I.K..DL.DIEV----.S.I.AALA.TILV..SMLI.VGIAYYVV..R.AK.S---NGY.KTT.QS.M.Y.S--
APVA   ...DR..D.I.K..DL.GADA----.SKA.IA.A.VVLVI..IFFL.AVIYYCSRVR.TKPK---HDY.ATT.HSSMAYVS--
HRSVA  .K.NQ.L.FIRK.DEL.HNVN--AG.ST.NIM.TT.I.VIIVILLS.IA.GLLLYCKARS.P-VTLSKDQ...IN.IA.SN--
HRSVB  .K.NQ.L.FIRR.DEL.HNVN--TG.ST.NIM.TT.I.VIIVVLLS.IAIGLLLYCKA.N.P-VTLSKDQ...IN.IA.SK--
BRSV   AK.NQ.L.FIRR.DEL.H.VD--VG.ST.NVV.TT.I.VIVVVILM.IA.GLLFYCKT.S.P-IMLGKDQ...IN.LS.SK--
PVM    H..NQTRTFFKA.DQL.DLS.NREN.NLNKSY.LTT.LF.VMLII.MAVIGF.LY.VL.MIRDNKLKSKSTP.L.VLS-----
```

Fig. 12

A

```
             #       #     #                           50
HMPV   MSRKAPCKYEVRGKCNRGSECKFNHNYWSWPDRYLLIRSNYLLNQLLRNT
APVC   ....................................L.............
APVB   ..GRN..R..T..R.....S.T..........HV..V.A..M....V...
APVA   ...RN..R..I........S.T..........HV..V.A..M........
HRSVA  ...RN...F.I..H.LN.KR.H.S...FE..PHA..V.Q.FM..RI.KSM
HRSVB  ...RN...F.I..H.LN.RR.HYS...FE..PHA..V.Q.FM..KI.KSM
BRSV   ...RN.....I..H.LN.KK.H.S...FE..PHA..V.Q.FM..KI.KSM
PVM    ..VR-...F..Q.F.S..RN..YS.K..E..LKT.ML.Q..M..RIY.FL
                                                    # 100
HMPV   DRA-DGLSIISGAGREDRTQDFVLGSTNVVQGYIDDNQSITKAAACYSLH
APVC   ..S-....L......D...............N...N.EN....ST....Y
APVB   ..T-....L.................A....N..EG.AT...S......Y
APVA   ..T-....L.................A....N..EG.TT...S......Y
HRSVA  .KSI.T..E....AEL...EEYA..VVG.LES..GSINN...QS..VAMS
HRSVB  .KSI.T..E....AEL...EEYA..IVG.LES..GSINN...QS..VAMS
BRSV   ..NN.T..E....AEL...EEYA..VIG.LES.LGSINN...QS..VAMS
PVM    .TNT.AI.DV..FDAPQ..AEYA..TIG.LKS.LEKTNN...SI..G..I
                                                      150
HMPV   NIIKQLQEVEVRQARDNKLSDSKHVALHNLVLSYMEMS-KTPASLINNLK
APVC   ........TD........VD..................-...........
APVB   ........ND.KS...LMVD.P............ID..-.N..N...S..
APVA   ........ND.KTS..SM.E.P........I...VD..-.N......S..
HRSVA  KLLTE.NSDDIKKL...EELN.PKIRVY.T.I..I.SNR.NNKQT.HL..
HRSVB  KLLIEINSDDIKKL...EEPN.PKIRVY.T.I..I.SNR.NNKQT.HL..
BRSV   KLLAEINNDDIKRL.NKEVPT.PKIRIY.T.I..IDSNKRNTKQT.HL..
PVM    TVLQN.DVGL.I....SNTE.TNYLRSC.TI...IDKIL.K-RQI.HI..
                                                 195
HMPV   RLPREKLKKLAKLIIDLSAGAE--NDSSYALQDSESTNQVQ----
APVC   K..K...........E....V.--...TA.M...ANSD-------
APVB   ...K........I..Q....S.GE.AN.NT..KGD.S.-------
APVA   .............I.LQ....P.SD.A.GNT..KGD.N.-------
HRSVA  ...ADV...TI.NTL.IHKSITIN.PKESTVS.TNDHAKNNDTT-
HRSVB  ...ADV...TI.NTL.IHKSIIIS.PKESTVN.QNDQTKNNDITG
BRSV   ...ADV...TI.NT..IHNEINGN.QGDIIVNEQNE---------
PVM    ...VGV.CN.IQSV.SIEEKINSSMKTE-----------------
```

B

```
                                                       50
HMPV   --------MTLHMP-CKTVKALIKCS--------EHGPVFITIEVDDMIW
APVC   --------...QL.-..I.QT....G--------...LI.LKMKL...V.
APVB   --------.PIVI.-..R.T.V.R.N--------TL.VCLFKRTYEHN.I
APVA   --------.PVVI.-.RR.T.I...N--------AL.LCMVRKIY.YS.A
HRSVA  MTMPKIMILPDKY.-.SITSI..TSRCRVTMYNQKNTLY.NQNNPNNHMY
HRSVB  MTKPKIMILPDKY.-.SISSI..SSESMIATFNHKNILQ.NHNHL.NHQR
BRSV   MNNSNIIIFPEKY.-.SISSL...NENDVIVLSHQNVLDYLQFQYPCNMY
PVM    MQSDPICHLHRGEDKFFYENRM.RLPKYYPAILHKMYIIRVNRNLTYDGS
                                                    97
HMPV   THKDLKEA---L---SDGIVKSHTNIYNCYLENIEIIYVKAYLS----
APVC   .KNE.VDI---I---.TE...V.A..FK.R..D.......TF..----
APVB   NLG..I.E---V---ARM.IID.I.RKQ.NECRKDFEF.AV.T.YT--
APVA   SWS..I.E---V---ANMVLID.I.RKQ.VECRKDFEFIAI.T.YN--
HRSVA  SPNQTFNE---IHWT.QELIDTIQ.FLQHLGIIED.YTIYILV.----
HRSVB  LLNNIFDE---IHWTPKNLLDATQQFLQHLNIPED.YTIYILV.----
BRSV   SQNHMLDD---IYWT.QELIEDVLK.LHLSGIS.SKYVIYVLVL----
PVM    GPSTIID.GKSVVWNRVDVIACVKEALC.IEFSWNNQVIIDFDYSQAR
```

Fig. 13

A

50
MITLDVIKSDGSSKTCTHLKKIIKDHSGKVLIVLKLILALLTFLTVTITI
100
NYIKVENNLQICQSKTESDKKDSSSNTTSVTTKTTLNHDITQYFKSLIQR
150
YTNSAINSDTCWKINRNQCTNITTYKFLCFKSEDTKTNNCDKLTDLCRNK
183
PKPAVGVYHIVECHCIYTVKWKCYHYPTDETQS



Fig. 14

A

```
                                                  50
MEVKVENIRTIDMLKARVKNRVARSKCFKNASLVLIGITTLSIALNIYLI
                                                 100
INYKMQKNTSESEHHTSSSPMESSRETPTVPTDNSDTNSSPQHPTQQSTE
                                                 150
GSTLYFAASASSPETEPTSTPDTTNRPPFVDTHTTPPSASRTKTSPAVHT
                                                 200
KNNPRTSSRTHSPPRATTRTARRTTTLRTSSTRKRPSTASVQPDISATTH
                                    236
KNEEASPASPQTSASTTRIQRKSVEANTSTTYNQTS
```



Fig. 15

```
                  A                                   674
HMPV   NYIARASIVTDLSKFNQAFRYETTAICADVADELHGTQSLFCWLHLIVPM
APVA   .......................SV.....................T.SS
HRSVA  ...SKC..I..............SC..S..L.....V....F....AI.H
HRSVB  ...SKC..I..............SC..S..L.....V....S....TI.L
BRSV   ...SKC..I..............SC..S..L.....V....S....TI.F
HPIV2  FELSACF.T...A.YCLQW..Q.IIHF.RTLNRMY.VPH..E.I..RLIR
NDV    RRRVATF.T...Q.YCLNW..Q.IKLF.HAINQ.M.LPHF.E.I..RLMD
SV     YETLSCFLT...K.YCLNW.F.S..LFGQRCN.IF.FKTF.N.M.PVLEK
HPIV3  YETVSCFLT...K.YCLNW...S..LFGETCNQIF.LNK..N...PRLEG
MV     YETVS.F.T...K.YCLNW....ISLF.QRLN.IY.LP.F.Q...KRLET
NIPAH  FDTVS.FLT...K..CLNW...SM..F.ERL..IY.LPGF.N.M.KRLER
                                                 B     723
HMPV   TTMICAYRHAPPETKG-EYDIDKIEEQSGLYRYHMGGIEGWCQKLWTMEA
APVA   .....T......D.G.-I....Q.P.......F...........M.....
HRSVA  V.I..T......YIRDHIV.LNNVD..........................I..
HRSVB  V.I..T......FI.DHVVNLNEVD..........................I..
BRSV   A.V..T......YIRNHIT.LN.VD..........................I..
HPIV2  S.LYVGDPFN..AATD-AF.L..VLNGDIFIVSK-.....L...M...IS
NDV    ...FVGDPFN..SDPT-DC.LSRVPNDDIYIVSAR.....L.......IS
SV     C.IYVGDPYC.VADRM-HRQLQDHADSGIFIHNPR.....Y......LIS
HPIV3  S.IYVGDPYC..SD.E-HISLEDHPDSGFYVHNPR.....F......LIS
MV     SVLYVSDP.C..DLDA-HIPLY.VPNDQIFIK.P......Y......IST
NIPAH  SVIYV.DPNC..NIDK-HMELE.TP.DDIFIH.PK.....YS..T..IAT
                            C                         772
HMPV   ISLIDVVSVKTRCQMTSLLNGDNQSIDVSKFVKLSEG-LDEVKADYSLAV
APVA   .........RN.V.L...................R.TGA-QT.IQ......I
HRSVA  .....LI.L.GKFSI.A.I........I....R.M..-QTHAQ...L..L
HRSVB  .....LI.L.GKFSI.A.I........I....R.I..-QTHAQ...L..L
BRSV   .....LI.I.GKFSI.A.I........I...I..N..-QTHAQ...L..L
HPIV2  ..VIILS.AESKTRVM.MVQ....A.A.TTR.PR.LPSIQKKELA.AASK
NDV    .AAIQLAAARSH.RVACMVQ....V.A.TRE.RSDDSPEMVLTQLHQASD
SV     ..AIHLAA.RVGVRVSAMVQ....A.A.TSR.PVAQTYKQKKNHV.EEIT
HPIV3  ..AIHLAA.RIGVRV.AMVQ....A.A.TTR.PNNYDYRIKKEIV.KDV.
MV     .PY.YLAAYESGVRIA..VQ....T.A.T.R.PSTWPYNLKKREAARVTR
NIPAH  .PF.FLSAYE.NTRIAAIVQ...E..AITQK.HPNLPYKVKKEICAKQ.Q
                                                  D    822
HMPV   KMLKEIRDAYRNIGHKLKEGETYISRDLQFISKVIQSEGVMHPTPIKKIL
APVA   ...TAV....Y............V......M..T.......Y.AA...V.
HRSVA  NS..LLYKE.AG......GT.......M..M..T..HN..YY.AS...V.
HRSVB  NS..LLYKE.AG......GT.......M..M..T..HN..YY.AS...V.
BRSV   .S..LLYKE.AS......GT.......M..M..T..HN..YY.AS...V.
HPIV2  LFFERL.ANNYGL..Q..AQ..I..STFFIY..RVFYQ.RILTQAL.NAS
NDV    NFF..LIHVNHL...N..DR..IR.DTFFIY..R.FKD.AILSQVL.NSS
SV     RYFGAL.HVMFD...E..LN..I..SKMFVY..R.YYD.KIL.QCL.AIT
HPIV3  RFFDSL.EVMDDL..E..LN..I..SKMFIY..R.YYD.RIL.QAL.AIS
MV     DYFVIL.QRLHD...H..AN..IV.SHFFVY..G.YYD.LLVSQSL.S.A
NIPAH  LYFERL.MNL.AL..N..AT..I..TH.FIY..K.HYD.AVLSQAL.SMS
                             847
HMPV   RVGPWINTILDDIKTSAESIGSLCQ
APVA   ................M.A......
HRSVA  ............F.V.L......T.
HRSVB  ............F.V.L......T.
BRSV   ............F.V.M......T.
HPIV2  KLCLTADVLGECTQA.CSNSATTIM
NDV    KLVLVSGDLSENTVM.CAN.A.TVA
SV     .CVF.SE.LV.ENRSACSN.STSIA
HPIV3  .CVF.SE.VI.ETRSASSNLATSFA
MV     .CVF.SE..V.ETRAACSN.ATTMA
NIPAH  .CCF.SE.LV.ETRSACSN.STTIA
```

Fig. 16


A
APV B
91
APV A
100
hMPV
87
APV C
Metapneumovirus
PVM
57
bRSV
93
hRSV B
79
hRSV A
Pneumovirus
0.1
B
Nipah
100
Measles
Henipahvirus
Morbillivirus
100
Sendai
100
hPIV 3
Respirovirus
100
hPIV 2
100
NDV
Rubulavirus
Avulavirus
APV A
100
hMPV
Metapneumovirus
100
bRSV
100
hRSV A
100
hRSV B
Pneumovirus
0.1

A

Pos.,ORF	Stop	Non-coding sequence	Gene start	Start	Pos.,ORF
1,Le		ACGAGAAAAAAACGCGUAUAAAUUAGAUUCCAAAAAAAUAU	GGGACAAGUGAAA	AUG	55,N
1237,N	UAA	UUAAAAAAGU	GGGACAAGUCAAA	AUG	1263,P
2145,P	UAG	UUUAAUAAAAAUAAACAAU	GGGACAAGUAAAA	AUG	2180,M
2942,M	UAA	CAACCAAGCACCUUGGCCAAGAGCUACUAACCCUAUCUCAUAGAUCAUAAAGUCACCAUUCUAGUUAUAU AAAAAUCAAGUUAGAACAAGAAUUAAAUCAAUCAAGAAC	GGGACAAAUAAAA	AUG	3067,F
4684,F	UAG	UUAAUUAAAAAUAAAGUAAAUUAAAAUAAAUUAAAAUUAAAAAUAAAAAUUU	GGGACAAAUCAUA	AUG	4752,M2
5476,M2	UAG	UAAAAACACAUCAGAGU	GGGAUAAAUGACA	AUG	5509,SH
6058,SH	UAA	AUGUUAACACCAGAUUAGGAUCCAUCCAAGUCUGUUAGUUCAACAAUUUAGUUAUUUAAAAAUAUUUUGA AAACAAGUAAGUUUCUAUGAUACUUCAUAAUAAUAAGUAAUAAUUAAUUGCUUAAUCAUCAUCACAACAU UAUUCGAAACCAUAACUAUUCAAUUUAAAAAGUAAAAAACAAUAACAU	GGGACAAGUAGUU	AUG	6262,G
6970,G	UAA	CAAAAAAUACAAAAUAACUCUAAGAUAAACCAUGCAGACACCAACAAUGGAGAAGCCAAAAGACAAUUCA CAAUCUCCCCAAAAAGGCAACAACACCAUAUUAGCUCUGCCCAAAUCUCCCUGGAAAAAACACUCGCCCA UAUACCAAAAAUACCACAACCACCCCAAGAAAAAAACUGGGCAAAACAACACCCAA	GAGACAAAUAACA	AUG	7182,L
13197,L	UGA	AAAAUGAUAAAAAAUGAUAAAAAUAGGUGACAACUUCAUACUAUUCCAAAGUAAUCAUUUGAUUAUGCAAUU AUGUAAUAGUUAAUUAAAAACUAAAAAUCAAAAGUUAGAAACUAACAACUGUCAUUAAGUUUAUUAAAAA UAAGAAAUUAUAAUUGGAUGUAUACGGUUUUUUUCUCGU			13378,Tr

B

```
hMPV Le: 3′ UGCUCUUUUUUUGCGCAUAUUUAAUCUAAGGUUUUUUUAUACCCU
            ||||||||||||| |||||| ||   |||  ||     |||   |
hMPV Tr: 5′ ACGAGAAAAAAAC CGUAUACAUCCAAUUAUAAUUUCUUAUUUUU

hMPV Tr: 5′ ACGAGAAAAAAACCGUAUACAUCCAAUUAUAAUUUCUUAUUUUUA
            |||||||||||||||||| |||| |||| | |  | ||| ||||
APV  Tr: 5′ ACGAGAAAAAAACCGUAUUCAUCAAAUUUUUAGCUUUUAGUUUUU

hMPV Le: 3′ UGCUCUUUUUUUGCGCAUAUUUAAUCUAAGGUUUUUUUAU-ACCC
            ||||||||||||||| | | ||  || ||| | ||||||| ||||
APV  Le: 3′ UGCUCUUUUUUUGCGUA-AGUUCGUCCAAGAUCUUUUUAUUACCC
```

Fig. 17

Fig. 18a

Comparison of two prototypic hMPV isolates with APV-A and APV-C

DNA similarity matrices

N	00-1	99-1	APVC	APVA
00-1	1,000	0,862	0,757	0,660
99-1	---	1,000	0,757	0,663
APVC	---	---	1,000	0,656
APVA	---	---	---	1,000

P	00-1	99-1	APVC	APVA
00-1	1,000	0,811	0,677	0,588
99-1	---	1,000	0,674	0,593
APVC	---	---	1,000	0,584
APVA	---	---	---	1,000

M	00-1	99-1	APVC	APVA
00-1	1,000	0,865	0,766	0,695
99-1	---	1,000	0,773	0,707
APVC	---	---	1,000	0,705
APVA	---	---	---	1,000

F	00-1	99-1	APVC	APVA
00-1	1,000	0,838	0,706	0,662
99-1	---	1,000	0,716	0,655
APVC	---	---	1,000	0,685
APVA	---	---	---	1,000

M2-1	00-1	99-1	APVC	APVA
00-1	1,000	0,863	0,764	0,668
99-1	---	1,000	0,744	0,657
APVC	---	---	1,000	0,670
APVA	---	---	---	1,000

M2-2	00-1	99-1	APVC	APVA
00-1	1,000	0,861	0,648	0,486
99-1	---	1,000	0,675	0,486
APVC	---	---	1,000	0,463
APVA	---	---	---	1,000

SH	00-1	99-1	APVC	APVA
00-1	1,000	0,688	N.A.	0,421
99-1	---	1,000	N.A.	0,380
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

G	00-1	99-1	APVC	APVA
00-1	1,000	0,543	N.A.	0,262
99-1	---	1,000	N.A.	0,263
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

Fig. 18b

5'L	00-1	99-1	APVC	APVA
00-1	1,000	0,835	N.A.	0,596
99-1	---	1,000	N.A.	0,605
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

5'L: only the first 1500 nucleotides of 99-1 were available.
N.A.: sequence not available.

Protein similarity matrices

Fig. 19

N 00-1	99-1	APVC	APVA	
00-1	1,000	0,949	0,880	0,685
99-1	---	1,000	0,883	0,682
APVC	---	---	1,000	0,700
APVA	---	---	---	1,000

P 00-1	99-1	APVC	APVA	
00-1	1,000	0,860	0,683	0,552
99-1	---	1,000	0,676	0,549
APVC	---	---	1,000	0,528
APVA	---	---	---	1,000

M 00-1	99-1	APVC	APVA	
00-1	1,000	0,976	0,874	0,775
99-1	---	1,000	0,874	0,763
APVC	---	---	1,000	0,775
APVA	---	---	---	1,000

F 00-1	99-1	APVC	APVA	
00-1	1,000	0,938	0,810	0,677
99-1	---	1,000	0,803	0,674
APVC	---	---	1,000	0,719
APVA	---	---	---	1,000

M2-1	00-1	99-1	APVC	APVA
00-1	1,000	0,946	0,844	0,719
99-1	---	1,000	0,834	0,703
APVC	---	---	1,000	0,704
APVA	---	---	---	1,000

M2-2	00-1	99-1	APVC	APVA
00-1	1,000	0,901	0,563	0,246
99-1	---	1,000	0,577	0,232
APVC	---	---	1,000	0,191
APVA	---	---	---	1,000

SH	00-1	99-1	APVC	APVA
00-1	1,000	0,570	N.A.	0,178
99-1	---	1,000	N.A.	0,162
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

G 00-1	99-1	APVC	APVA	
00-1	1,000	0,326	N.A.	0,094
99-1	---	1,000	N.A.	0,107
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

5'L	00-1	99-1	APVC	APVA
00-1	1,000	0,921	N.A.	0,600
99-1	---	1,000	N.A.	0,594
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

5'L: only the first 500 amino acid residues of 99-1 were available.
N.A.: sequence not available.

Fig.20

Amino acid sequence alignment of two prototype hMPV isolates

Nucleoprotein (N)

```
                 10        20        30        40        50        60
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    MSLQGIHLSDLSYKHAILKESQYTIKRDVGTTTAVTPSSLQQEITLLCGEILYAKHADYK 60
99-1    MSLQGIHLSDLSYKHAILKESQYTIKRDVGTTTAVTPSSLQQEITLLCGEILYTKHTDYK 60

                 70        80        90       100       110       120
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    YAAEIGIQYISTALGSERVQQILRNSGSEVQVVLTRTYSLGKIKNNKGEDLQMLDIHGVE 120
99-1    YAAEIGIQYICTALGSERVQQILRNSGSEVQVVLTKTYSLGKGKNSKGEELQMLDIHGVE 120

                130       140       150       160       170       180
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    KSWVEEIDKEARKTMATLLKESSGNIPQNQRPSAPDTPIILLCVGALIFTKLASTIEVGL 180
99-1    KSWIEEIDKEARKTMVTLLKESSGNIPQNQRPSAPDTPIILLCVGALIFTKLASTIEVGL 180

                190       200       210       220       230       240
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    ETTVRRANRVLSDALKRYPRMDIPKIARSFYDLFEQKVYHRSLFIEYGKALGSSSTGSKA 240
99-1    ETTVRRANRVLSDALKRYPRIDIPKIARSFYELFEQKVYYRSLFIEYGKALGSSSTGSKA 240

                250       260       270       280       290       300
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    ESLFVNIFMQAYGAGQTMLRWGVIARSSNNIMLGHVSVQAELKQVTEVYDLVREMGPESG 300
99-1    ESLFVNIFMQAYGAGQTLLRWGVIARSSNNIMLGHVSVQSELKQVTEVYDLVREMGPESG 300

                310       320       330       340       350       360
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    LLHLRQSPKAGLLSLANCPNFASVVLGNASGLGIIGMYRGRVPNTELFSAAESYAKSLKE 360
99-1    LLHLRQSPKAGLLSLANCPNFASVVLGNASGLGIIGMYRGRVPNTELFSAAESYARSLKE 360

                370       380       390
        ....|....|....|....|....|....|....
00-1    SNKINFSSLGLTDEEKEAAEHFLNVSDDSQNDYE 394
99-1    SNKINFSSLGLTDEEKEAAEHFLNMSGDNQDDYE 394
```

Fig.21

Phosphoprotein (P)

```
              10        20        30        40        50        60
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  MSFPEGKDILFMGNEAAKLAEAFQKSLRKPGHKRSQSIIGEKVNTVSETLELPTISRPAK 60
99-1  MSFPEGKDILFMGNEAAKIAEAFQKSLKKSGHKRTQSIVGEKVNTISETLELPTISKPAR 60

              70        80        90       100       110       120
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  PTIPSEPKLAWTDKGGATKTEIKQAIKVMDPIEEEESTEKKVLPSSDGKTPAEKKLKPST 120
99-1  SSTLLEPKLAWADNSGITKITEKPATKTTDPVEEEEFNEKKVLPSSDGKTPAEKKSKFST 120

             130       140       150       160       170       180
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  NTKKKVSFTPNEPGKYTKLEKDALDLLSDNEEEDAESSILTFEERDTSSLSIEARLESIE 180
99-1  SVKKKVSFTSNEPGKYTKLEKDALDLLSDNEEEDAESSILTFEEKDTSSLSIEARLESIE 180

             190       200       210       220       230       240
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  EKLSMILGLLRTLNIATAGPTAARDGIRDAMIGVREELIADIIKEAKGKAAEMMEEEMSQ 240
99-1  EKLSMILGLLRTLNIATAGPTAARDGIRDAMIGIREELIAEIIKEAKGKAAEMMEEEMNQ 240

             250       260       270       280       290
      ....|....|....|....|....|....|....|....|....|....|....
00-1  RSKIGNGSVKLTEKAKELNKIVEDESTSGESEEEEEPKDTQDNSQEDDIYQLIM 294
99-1  RSKIGNGSVKLTEKAKELNKIVEDESTSGESEEEEEPKETQDNNQGEDIYQLIM 294
```

Fig.22

Matrix protein (M)

```
              10        20        30        40        50        60
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  MESYLVDTYQGIPYTAAVQVDLIEKDLLPASLTIWFPLFQANTPPAVLLDQLKTLTITTL 60
99-1  MESYLVDTYQGIPYTAAVQVDLVEKDLLPASLTIWFPLFQANTPPAVLLDQLKTLTITTL 60

              70        80        90       100       110       120
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  YAASQNGPILKVNASAQGAAMSVLPKKFEVNATVALDEYSKLEFDKLTVCEVKTVYLTTM 120
99-1  YAASQNGPILKVNASAQGAAMSVLPKKFEVNATVALDEYSKLDFDKLTVCDVKTVYLTTM 120

             130       140       150       160       170       180
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  KPYGMVSKFVSSAKSVGKKTHDLIALCDFMDLEKNTPVTIPAFIKSVSIKESESATVEAA 180
99-1  KPYGMVSKFVSSAKSVGKKTHDLIALCDFMDLEKNIPVTIPAFIKSVSIKESESATVEAA 180

             190       200       210       220       230       240
      ....|....|....|....|....|....|....|....|....|....|....|....|
00-1  ISSEADQALTQAKIAPYAGLIMIMTMNNPKGIFKKLGAGTQVIVELGAYVQAESISKICK 240
99-1  ISSEADQALTQAKIAPYAGLIMIMTMNNPKGIFKKLGAGTQVIVELGAYVQAESISRICK 240

             250
      ....|....|....
00-1  TWSHQGTRYVLKSR 254
99-1  SWSHQGTRYVLKSR 254
```

Fig.23

Fusion protein (F)

```
               10        20        30        40        50        60
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   MSWKVVIIFSLLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTC 60
99-1   MSWKVMIIISLLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTC 60

               70        80        90       100       110       120
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   ADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTA 120
99-1   TDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTA 120

              130       140       150       160       170       180
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   GVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKN 180
99-1   GIAIAKTIRLESEVNAIKGALKQTNEAVSTLGNGVRVLATAVRELKEFVSKNLTSAINRN 180

              190       200       210       220       230       240
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   KCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQ 240
99-1   KCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSYMPTSAGQ 240

              250       260       270       280       290       300
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   IKLMLENRAMVRRKGFGFLIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYA 300
99-1   IKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIIKAAPSCSEKNGNYA 300

              310       320       330       340       350       360
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   CLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYP 360
99-1   CLLREDQGWYCKNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSRECNINISTTNYP 360

              370       380       390       400       410       420
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   CKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTI 420
99-1   CKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNWVGIIKQLPKGCSYITNQDADTVTI 420

              430       440       450       460       470       480
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   DNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRI 480
99-1   DNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFESIENSQALVDQSNKI 480

              490       500       510       520       530
       ....|....|....|....|....|....|....|....|....|....|....|....
00-1   LSSAEKGNTGFIIVIILIAVLGSTMILVSVFIIIKKTKKPTGAPPELSGVTNNGFIPHN 539
99-1   LNSAEKGNTGFIIVVILVAVLGLTMISVSIIIIIKKTRKPTGAPPELNGVTNGGFIPHS 539
```

Fig.24

22K protein (M2-1)

```
                10        20        30        40        50        60
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    MSRKAPCKYEVRGKCNRGSECKFNHNYWSWPDRYLLIRSNYLLNQLLRNTDRADGLSIIS 60
99-1    MSRKAPCKYEVRGKCNRGSDCKFNHNYWSWPDRYLLLRSNYLLNQLLRNTDKADGLSIIS 60

                70        80        90       100       110       120
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    GAGREDRTQDFVLGSTNVVQGYIDDNQSITKAAACYSLHNIIKQLQEVEVRQARDNKLSD 120
99-1    GAGREDRTQDFVLGSTNVVQGYIDDNQGITKAAACYSLHNIIKQLQETEVRQARDNKLSD 120

               130       140       150       160       170       180
        ....|....|....|....|....|....|....|....|....|....|....|....|
00-1    SKHVALHNLVLSYMEMSKTPASLINNLKRLPREKLKKLAKLIIDLSAGAENDSSYALQDS 180
99-1    SKHVALHNLILSYMEMSKTPASLINNLKKLPREKLKKLARLIIDLSAGTDNDSSYALQDS 180


        ....|..
00-1    ESTNQVQ 187
99-1    ESTNQVQ 187
```

Fig.25

M2-2 protein (M2-2)

```
                 10        20        30        40        50        60
         ....|....|....|....|....|....|....|....|....|....|....|....|
00-1     MTLHMPCKTVKALIKCSEHGPVFITIEVDDMIWTHKDLKEALSDGIVKSHTNIYNCYLEN 60
99-1     MTLHMPCKTVKALIKCSKHGPKFITIEADDMIWTHKELKETLSDGIVKSHTNIYSCYLEN 60

                 70
         ....|....|.
00-1     IEIIYVKAYLS 71
99-1     IEIIYVKTYLS 71
```

Fig.26

Short hydrophobic protein (SH)

```
                10        20        30        40        50        60
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   MITLDVIKSDGSSKTCTHLKKIIKDHSGKVLIVLKLILALLTFLTVTITINYIKVENNLQ 60
99-1   MKTLDVIKSDGSSETCNQLKKIIKKHSGKVLIALKLILALLTFFTATITVNYIKVENNLQ 60

                70        80        90       100       110       120
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   ICQSKTESDKKDSSSNTTSVTTKTTLNHDITQYFKSLIQRYTNSAIN-SDTCWKINRNQC 119
99-1   ACQPKNESDKKVTKPNTTSTTIRPTPDPTVVHHLKRLIQRHTNSVTKDSDTCWRIHKNQR 120

               130       140       150       160       170       180
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   TNITTYKFLCFKSEDTKTNNCDKLTDLCRNKPKPAVGVYHIVECHCIYTVKWKCYHYPTD 179
99-1   TNIKIYKFLCSGFTNSKGTDCEEPTALCDKKLKTIVEKHRKAECHCLHTTEWGCLHP--- 177


       ....
00-1   ETQS 183
99-1   ---- 177
```

Fig.27

Attachment glycoprotein (G)

```
                 10        20        30        40        50        60
         ....|....|....|....|....|....|....|....|....|....|....|....|
00-1     MEVKVENIRTIDMLKARVKNRVARSKCFKNASLVLIGITTLSIALNIYLIINYKMQKNTS  60
99-1     MEVRVENIRAIDMFKAKIKNRIRSSRCYRNATLILIGLTALSMALNIFLIIDHATLRNMI  60

                 70        80        90       100       110       120
         ....|....|....|....|....|....|....|....|....|....|....|....|
00-1     ESEHHTSSSPMESSRETPTVPTDNSDTNSSPQHPTQQSTEGSTLYFAASASSPETEPTST  120
99-1     KTENCANMPSAEPSKKTPMTSTAGPNTKPNPQQATQWTTENSTSPVATPEGHPYTGTTQT  120

                130       140       150       160       170       180
         ....|....|....|....|....|....|....|....|....|....|....|....|
00-1     PDTTNRPPFVDTHTTPPSASRTKTSPAVHTKNNPRTSSRTHSPPRATTRTARRTTTLRTS  180
99-1     SDTTAPQQTTDKHTAPLKSTNEQITQTTTEKKTIRATTQKREKGKENTNQTTSTAATQTT  180

                190       200       210       220       230
         ....|....|....|....|....|....|....|....|....|....|....|.
00-1     STRKRPSTASVQPDISATTHKNEEASPASPQTSASTTRIQRKSVEANTSTTYNQTS  236
99-1     NTTNQIRNASET-----ITTSDRPRTDTTTQSSEQTTRATDPSSPPHHA-------  224
```

Fig.28

N-terminus of polymerase protein (L)

```
                10        20        30        40        50        60
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   MDPLNESTVNVYLPDSYLKGVISFSETNAIGSCLLKRPYLKNDNTAKVAIENPVIEHVRL 60
99-1   MDPFCESTVNVYLPDSYLKGVISFSETNAIGSCLLKRPYLKNDNTAKVAVENPVVEHVRL 60

                70        80        90       100       110       120
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   KNAVNSKMKISDYKIVEPVNMQHEIMKNVHSCELTLLKQFLTRSKNISTLKLNMICDWLQ 120
99-1   RNAVMTKMKISDYKVVEPVNMQHEIMKNIHSCELTLLKQFLTRSKNISSLKLNMICDWLQ 120

               130       140       150       160       170       180
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   LKSTSDDTSILSFIDVEFIPSWVSNWFSNWYNLNKLILEFRKEEVIRTGSILCRSLGKLV 180
99-1   LKSTSDNTSILNFIDVEFIPVWVSNWFSNWYNLNKLILEFRREEVIRTGSILCRSLGKLV 180

               190       200       210       220       230       240
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   FVVSSYGCIVKSNKSKRVSFFTYNQLLTWKDVMLSRFNANFCIWVSNSLNENQEGLGLRS 240
99-1   FIVSSYGCVVKSNKSKRVSFFTYNQLLTWKDVMLSRFNANFCIWVSNNLNKNQEGLGLRS 240

               250       260       270       280       290       300
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   NLQGILTNKLYETVDYMLSLCCNEGFSLVKEFEGFIMSEILRITEHAQFSTRFRNTLLNG 300
99-1   NLQGMLTNKLYETVDYMLSLCCNEGFSLVKEFEGFIMSEILKITEHAQFSTRFRNTLLNG 300

               310       320       330       340       350       360
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   LTDQLTKLKNKNRLRVHGTVLENNDYPMYEVVLKLLGDTLRCIKLLINKNLENAAELYYI 360
99-1   LTEQLSVLKAKNRSRVLGTILENNNYPMYEVVLKLLGDTLKSIKLLINKNLENAAELYYI 360

               370       380       390       400       410       420
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   FRIFGHPMVDERDAMDAVKLNNEITKILRWESLTELRGAFILRIIKGFVDNNKRWPKIKN 420
99-1   FRIFGHPMVDEREAMDAVKLNNEITKILKLESLTELRGAFILRIIKGFVDNNKRWPKIKN 420

               430       440       450       460       470       480
       ....|....|....|....|....|....|....|....|....|....|....|....|
00-1   LKVLSKRWTMYFKAKSYPSQLELSEQDFLELAAIQFEQEFSVPEKTNLEMVLNDKAISPP 480
99-1   LKVLSKRWAMYFKAKSYPSQLELSVQDFLELAAVQFEQEFSVPEKTNLEMVLNDKAISPP 480

               490
       ....|....|....|....
00-1   KRLIWSVYPKNYLPEKIKN 499
99-1   KKLIWSVYPKNYLPETIKN 499
```

Fig. 29

+ = positive; - = negative; T = throatswabs; NO = nose swab; N = not done; ? = not sure; D = dead; 0 to 12: days post infection. 2e infection is only tested on nose swabs.

nr	1^e infection	swab	0	1	2	3	4	5	8	10	11	12	2^e infection	0	1	2	3	4	5
1	00-1	T	-	+	+	+	-	+	+	+	-	-	99-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	+	-	-		-	-	-	-	-	-
2	00-1	T	-	+	+	+	+	+	-	-	-	D		N	N	N	N	N	N
		NO		+	+	+	+	+	N	+	-	D		-	-	-	-	-	-
3	00-1	T	-	-	?	-	-	-	-	-	-	N	99-1	N	N	?	N	N	N
		NO		+	?	?		-	N	-	-	-		-	-	?	+	+	-
4	00-1	T	-	+	+	+	+	+	-	?	-	N	00-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	?	-	-		-	-	-	+	-	-
5	00-1	T	-	?	+	+	+	+	+	+	-	N	00-1	N	N	N	N	N	N
		NO		+	+	+	+	+	N	+	-	-		-	-	-	-	-	-
6	00-1	T	-	-	+	+	+	+	-	+	-	N	00-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	+	-	?		-	-	-	-	-	-
7	99-1	T	-	-	-	+	+	-	+	D	-	-		N	N	N	N	N	N
		NO	-	-	--	+	+	+	N	D	-	-		-	-	-	-	-	-
8	99-1	T	-	-	+	+	-	-	-	-	-	N	00-1	N	N	N	N	N	N
		NO	-	?	-	+	+	?	N	-	-	--		-	-	+	+	+	+
9	99-1	T	-	-	-	-	-	-	-	-	-	N	00-1	N	N	N	N	N	N
		NO	-	-	-	-	+	+	N	-	-	--		-	?	+	+	-	-
10	99-1	T	-	-	-	+	+	-	-	-	-	N	99-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	-	-	--		-	-	-	-	-	-
11	99-1	T	-	-	+	+	+	-	-	-	-	N	99-1	N	N	N	N	N	N
		NO	-	+	?	+	+	+	N	-	-	-		-	-	-	+	-	-
12	99-1	T	-	-	+	+	?	-	-	-	-	N	99-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	-	-	-		-	-	-	-	-	-

Fig. 30A


00-1
99-1
guinea pig 1 (00-1/99-1)
guinea pig 3 (00-1/99-1)
guinea pig 4 (00-1/00-1)
guinea pig 5 (00-1/00-1)
guinea pig 6 (00-1/00-1)
O.D. 450 nm
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
52
70
80
90
110
126
160
days post primary infection

Fig. 30B


00-1
99-1
guinea pig 8 (99-1/00-1)
guinea pig 9 (99-1/00-1)
guinea pig 10 (99-1/99-1)
guinea pig 11 (99-1/99-1)
O.D. 450 nm
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
52
70
80
90
110
126
160
days post primary infection

Fig. 31


Specificity ELISA
◆99-1 challenge ●00-1 challenge
3.0
2.5
2.0
1.5
1.0
0.5
0.0
OD tegen 99-1
0.0
0.5
1.0
1.5
2.0
2.5
3.0
OD tegen 00-1


mean IgG respons of 00-1/99-1 infected guinea pigs
against 00-1
against 99-1
O.D. 450 nm
3.0
2.5
2.0
1.5
1.0
0.5
0.0
52
70
80
90
110
126
160
days post primary infection
Mean IgG respons of 99-1/00-1 infected guinea pigs
against 00-1
against 99-1
O.D. 450 nm
days post primary infection
mean IgG respons of 00-1/00-1 infected guinea pigs
against 00-1
against 99-1
O.D. 450 nm
days post primary infection
mean IgG respons of 99-1/99-1 infected guinea pigs
against 00-1
against 99-1
O.D. 450 nm
days post primary infection

Fig. 32

Fig. 33


mean reaction in APV inhibition test
of hMPV infected guinea pigs
% inhibition
100
90
80
70
60
50
40
30
20
10
0
0
70
80
90
126
days post primary infection
00-1/99-1
00-1/00-1
99-1/00-1
99-1/99-1

Fig. 34

	Against 00-1	Against 99-1	Against APV-C
1 infection with 00-1			
2 infections with 00-1			
1infection with 99-1			
2 infections with 00-1			

Fig. 35

+ = positive; - = negative; N = not done; ? = not sure; 0 to 10: days post infection

nr	1st infection	0	2	3	4	5	6	7	8	9	11	2nd infection	0	1	2	3	4	5	7	10
3	00-1	-	-	-	+	+	+	+	+	N	-		-	+	+	+	+	-	?	-
6	00-1	-	+	+	+	+	+	+	-	-	-		-	+	+	+	+	+	-	-



Fig. 36A



Fig. 36B

Fig. 37


Correlation between APV and hMPV ELISA for the detection of hMPV IgG antibodies in human sera
y = 0.7507x + 0.1759
R2 = 0.7953
APV IgG ratio
hMPV IgG ratio
0.0
1.0
2.0
3.0
4.0
5.0
6.0